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 The brain is the most well protected organ in the body. Externally, the brain is 
protected by the bony skull, whereas it is internally protected from blood borne, 
potentially toxic substituents by the blood-brain barrier (BBB). The presence of a BBB 
has been known since the 1880s when Paul Ehrlich demonstrated its presence through 
the use of a vascular dye. Several decades later, it was Spatz,1 who proposed a cerebral 
vascular system resembling the contemporary model of the BBB. It was not until the 
1960s that Reese and Karnovsky2 and Brightman et al.3 verified this BBB model by 
localizing tight junctions in the endothelial cells, with the use of electron microscopy. 
Later, the uniqueness of the BBB tight junctions and physiology, relating to capillary 
networks of peripheral organs were addressed by Stuart and Wiley.4 They showed that 
embryonic quail brain tissue retained its BBB properties when transplanted into 
embryonic chick gut tissue. Conversely, capillaries of transplanted quail gut 
transplanted into embryonic chick brain were leaky to tryptan blue and did not 
maintain BBB characteristics. These elegant experiments supported the belief that the 
protective properties of the BBB lie within the endothelial cells and the surrounding 
tissue. More recent data have emphasized the characteristics of the BBB as a functional 
barrier.5 A major aspect of this functional barrier is the way the transport of molecules 
is performed in tight control by protein pumps located at the luminal side of the 
capillary wall. Influx is regulated for all molecules, except small, lipophilic and 
uncharged molecules can freely pass the BBB. The efflux pump P-glycoprotein (P-gp) is 
however capable of extruding many of these molecules. The physiological role of P-gp 
presumably involves defence of tissues against xenobiotics or (endogenous) toxic 
compounds. In the last decades, the role of the BBB and its components have received 
increased attention in psychopathological conditions.  
Chapter 2 gives a general review of the blood-brain barrier, including the main 
components of the BBB (i.e. endothelial cells, tight junctions, surrounding cells and 
neurons).  Briefly the main function of separate components are explained and a 
concise description of the three main endogenous transport systems is given. One of 
these systems is the group of efflux transporters, of which P-glycoprotein (P-gp) is one 
of the major efflux proteins, which is shortly introduced. In short, we reflect on the 
altered BBB characteristics in neuropathological conditions.  
In chapter 3 the localization of P-gp at the BBB and consecutively its function, 
structure and transport activity are described. We focus on the relevance of P-gp in 
relation to drug disposition of antidepressants and antipsychotics. We discuss the 
tentative contribution of P-gp modulation (eg. P-gp as susceptibility factor) in affective 
and psychotic disorders and the possible influence of variarion in the coding gene, 
ABCB1 (ATP Binding Cassette family, member B1). Other transporters are also 
mentioned briefly.  
Chapter 4 describes the results of a [11C]-verapamil PET (positron emission 
tomography) study in (medicated) patients with a major depressive disorder (MDD).
  The same protocol was used to assess the [11C]-verapamil in patients with 
schizophrenia, described in Chapter 5. Chapters 6 and 7 are a description of two studies 
using the data of the NESDA cohort (NEtherlands Study on Depression and Anxiety). 
The effect of variations of the encoding gene for P-gp, ABCB1, on different predictors 
of familial aggregation in depression is discussed in chapter 6. This chapter addresses 
the possible role of ABCB1 gene variants as susceptibility factor in MDD. In chapter 7 
the association between ABCB1 gene variants and the incidence and severity of 
reported side effects on antidepressants is discussed. Chapter 8  is a description of an 
animal PET study, which is a continuation of the two human studies (chapters 4 and 5) 
in which we found a regional increase in P-gp activity. The study was set up to 
differentiate between the effects of antidepressant treatment and disease. The effect of 
chronic stress on male Wistar rats (as a model for depression) was compared to the 
effect of chronic administration of venlafaxine, an antidepressant. The effects were 
measured in vivo using [11C]-verapamil as PET tracer. After the PET the rat brains were 
collected for western blot analysis and in vitro immunohistochemistry. In the 
following chapter (chapter 9) we describe the regional analysis of the effects found in 
the animal studies. A reanalysis is done for the PET scans, in order to determine 
whether the effects are global or region specific, the latter possibly indicating a disease 
specific locus. The results of the in vitro studies has not been finished yet, but may 
denote regional or global changes in protein expression. The future perspectives, 
relating to further research on the various roles of P-gp may play in psychiatry, are 
outlined, including its role in drug disposition and a protective role as part of the BBB.    
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 Introduction  
 
The central nervous system requires a perfectly regulated environment, for optimal 
activity. The main contribution to this homeostasis is accomplished by the BBB, by 
protecting and isolating the nervous tissue from too strong fluctuations in nutrients, 
hormones, metabolites, and other solutes. The microenvironment within the brain is 
precisely controlled by the BBB, and neuronal transmission is secured in this way.1 It 
also protects against the direct influence of potentially harmful endogenous or 
exogenous substances. The BBB has to be a stable structure to exert its protective 
function, but on the other hand the BBB requires the ability for plastic changes,2 in 
order to adapt to fast changing conditions. Several areas, such as the pineal body and 
the pituitary, both small endocrine glands in the brain, are not ”behind” the BBB, but 
secrete their hormones directly into the systemic circulation.  
 
The protective function of the BBB is exerted in two ways. Until recently the BBB was 
largely viewed as an anatomical barrier, preventing the passive diffusion of solutes from 
blood to the brain. In addition to being a physical barrier, the BBB is a complex 
transport and metabolic barrier due to its highly reactive and dynamic endothelium. 
The major components of the anatomical barrier are the specialized non-fenestrated 
tightly-joined endothelial cells with tight junctions (see figure 2.1).1,3,4 In the following 
paragraphs we will discuss these main components of the BBB.   
 
 
Components of the BBB 
 
Endothelial cells  
Brain endothelial cells (EC) are unlike other endothelial cells in the body. Compared to 
the leaky capillaries formed by mesenteric endothelium, the brain endothelium is 50-
100 times tighter, as indicated by the transendothelial electric resistance (TEER).5 They 
differ phenotypically by a lack of fenestrations and the presence of tight junctions. The 
rate of pinocytosis is minimal and  free membrane diffusion applies mainly to small 
lipophilic molecules like ethanol or nicotine.6 The ECs are surrounded by a basal  
lamina, which further restricts the microvascular integrity.7 ECs are rich in 
mitochondria, necessary for their high metabolic demands. Specific enzymes expressed 
by ECs  (monoamine oxidases, epoxy hydrolase, endopeptidases, etc.) are important 
elements, constituting the so-called metabolic barrier, and participate in the regulation 
of brain penetration of drugs and their metabolism.8-11  ECs have an extensive transport 
system on their surface, which is carrier mediated or receptor mediated. 
 Tight junctions 
Tight junctions are the closely associated areas of two cells whose membranes join 
together forming a virtually impermeable barrier to fluid. This is accomplished by their 
structure, as it is composed of a branching network of sealing strands, a complex of 
transmembrane (junctional adhesion molecule-1, occludin, and claudins) and 
cytoplasmic proteins.1,12 Each strand acts independently from the others. Tight 
junctions prevent the passage of molecules and ions through the space between cells, 
the so called paracellular flux. In order to pass the blood-brain barrier molecules must 
enter the endothelial cells. Together with the endothelial cells, the tight junctions play 
the most substantial role in maintaining the BBB.13  
 
Astrocytes, microglia and pericytes 
Astrocytes, microglia and pericytes surround the endothelial cells, and form the 
“second line of defence” in the BBB. Astrocytes are star shaped glia cells, that perform 
many functions, including the biochemical support of endothelial cells. Their end-feet, 
encircling the endothelial cells aid in the maintenance of the blood-brain barrier, as 
they regulate the homeostasis of brain water and electrolytes.1,14 In addition, they 
interconnect endothelial cells with surrounding neurons. Astrocytes secrete proteins 
that can have an opposite effect on neurons and endothelial cells. For example, 
thrombospondin, an astrocyte-derived protein stimulates neurogenesis on the one 
hand, while it counteracts the effects of angiogenesis.15 Current in vitro cellular models 
for the study of BBB function often incorporate astrocytes with endothelial cells. 
Studies have shown that when astrocytes are removed from an in vitro BBB model, an 
increased permeability is observed.16 Many transporters (see below) are under the 
control of astrocytes.17 In pathological conditions, astrocytes mediate the immune 
response, they synthesize proinflammatory cytokines and chemotactic factors, that 
eventually trigger the breakdown of the BBB.12 The pericyte, another foremost cell 
type in the CNS, intimately embraces the brain endothelial capillary. Less is known 
about their role at the BBB, although they seem to stabilize the formation of capillary-
like structures when they are added to a co-culture of astrocytes and endothelial cells.18  
Microglia are omnipresent throughout the brain parenchyma. They are the immune 
effectors in the CNS, as they can release a large number of immunoregulatory, 
inflammatory, and cytotoxic mediators.19 They surround the brain capillaries and stay 
in a resting state until they are activated, which can be induced by a variety of 
stimuli.20,21 Figure 1 shows the main components of the BBB. 
 neurons  
Neurons lie in close proximity of the brain capillaries and their needs, including 
protection and the unrestricted provision of nutrients, are optimally met. Neuronal 
tissue needs an abundant supply of oxygen. At rest, 80–92% of its ATP comes from 
oxidative metabolism of glucose.22 Given the dynamic nature of neural activity and the 
considerable metabolic needs of nervous tissue, the microcirculation of the brain must 
be highly responsive to the tissue it supplies. Iadecola found that blood flow was 
increased in response to local neuronal activation and proposed a role for nitric oxide as 
a messenger between blood and neuronal tissue.23  This "metabolic coupling" of 
regional brain activity to blood flow is the basis of functional neuroimaging.24 However, 
data from positron emission tomography (PET) and functional MRI studies indicate 
that during short-term functional activation, cerebral blood flow and cerebral 
metabolism (oxygen consumption) are not directly linked.22,25  
 
 
Transport across the BBB 
 
There are two tightly controlled ways of transport for molecules and cells across the 
BBB (see figure 2.2). The paracellular route, or junctional route, is restricted by the 
interendothelial tight junctions. Tight junctions not only restrict paracellular flux, but 
also maintain polarity of enzymes and receptors on luminal (blood) and abluminal 
(brain) membrane domains.26,27 Due to the presence of tight junctions, only lipid-
soluble substances or those transported through an active mechanism can cross the 
BBB.3,28  
The transendothelial route further restricts the passage of molecules by three distinct 
transport systems. Small lipid-soluble molecules can penetrate the brain EC through 
diffusion, unless their molecular weight exceeds 400-600  Da.29 All other transport to 
the brain is via endogenous catalyzed transport systems on the capillary membrane. As 
we will describe below, three main transport systems function at the BBB: (1) carrier 
mediated transport, which relies on a molecular carrier present on both the luminal 
side and the abluminal side of the BBB. (2) receptor-mediated transport for endogenous 
large-molecule peptides such as insulin30 or transferrin31 and (3) active efflux 
transporters such as P-glycoprotein and many other active efflux transport systems 
within the BBB (see figure 2.2).  
 
Carrier mediated transport 
Carrier mediated transport is a highly selective form of transport for small molecules 
such as ions, glucose and amino acids. Examples of carrier mediated transport systems 
include the GLUT1 glucose transporter, the OAT (organic anion transporter) and 
organic anion transporting polypeptide family (OATP), the monocarboxylate transport 
 family and the LAT1 (large neutral amino-acid transporter) 32. This form of BBB 
transport is a saturable process which can be unidirectional or bidirectional. Carrier 
mediated channels can be gated and can function ion and energy independent, like the 
LAT1.33 The membrane spanning pores are highly stereospecific. The substrate forms a 
complex with the carrier in order to be translocated to the opposite side of the 
membrane.34 L-DOPA is such a drug, that utilizes the LAT1 to enter the brain. Once 
transported through the BBB, L-DOPA is reformulated to dopamine.35 Another 
example is valproic acid, that is delivered to the brain via a medium-fatty chain 
transporter.36 Uptake of valproic acid was reduced in the presence of medium-chain 
fatty acids, but not short-chain fatty acids, indicating that valproic acid is taken up by a 
transport system for medium-chain fatty acids. The monocarboxylate transport family 
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Receptor mediated transport 
Another main transport mechanism at the BBB is receptor-mediated transport, which 
involves a vesicular trafficking system of the endothelial cells (fig. 2). The influx of 
several brain nutrients like leptin37 and insulin38 occurs by this form of transport. 
Circulating molecules are bound to a specific receptor at the plasma membrane, to form 
a receptor-ligand complex. When the ligand is bound to the receptor, the process of 
invagination is initiated. Dependent on subsequent intracellular processes, the vesicles 
are either sent to the basolateral side of the cell, where they are released, or the 
 complex is dissociated from the ligand in the cell. A similar transport system is called 
‘absorptive-mediated transcytosis’ which does not require  specific binding to a 
receptor. Instead, binding is non-specific, for example to negative charges on the 
plasma membrane.  The receptor mediated transcytosis offers a promise as drug vector 
for drug delivery into the brain.39 
 
Efflux transport 
Uncharged, small lipophilic compounds enter the brain much better than other 
molecules, because they can diffuse passively across the endothelial cells. However, an 
ATP-driven efflux system exists at the luminal wall of the capillary wall, that can 
extrude a variety of structurally diverse drugs, drug conjugates and metabolites, and 
other compounds from the cell. These efflux proteins involved belong to the 
superfamily of ABC (ATP Binding Cassette) transporters, an extensive and functionally 
highly diverse family of  membrane transporters. Export of these compounds occurs in 
an active, ATP-dependent manner, and can take place against a considerable 
concentration gradient. 40,41 Thus far, 49 human ABC transporter genes have been 
identified.42 They are classified into eight subfamilies (ABCA-ABCH) 43, P-glycoprotein 
(P-gp, ABCB1), multidrug resistance protein ABCC subfamily, (formerly denoted as 
MRP) ABCC4 and ABCC5 (and possibly ABCC1 and -2, see below)42,44-46 and the breast 
cancer related protein (BCRP, ABCG2) have been localized in the apical membrane of 
the brain endothelial cell and have a role in efflux at the BBB. Of these, P-gp is the best 
studied transport protein. Its most striking property is transport of a wide range of 
structurally different substrates, including many CNS drugs. As a consequence, the net 
penetration of substrate drugs and other substrate compounds from the blood into the 
brain tissue can be dramatically decreased. Various members of the ABCC family show 
considerable differences in their tissue distribution, substrate specificity, and proposed 
physiological function. These proteins play a role in drug disposition and excretion and 
thus are implicated in drug toxicity and drug interactions. ABCC primarily transports 
anionic compounds, such as glutathione S- conjugates and oxidized glutathione.47 
Furthermore, ABCC transport appears to be dependent upon intracellular glutathione.48  
 
Alteration of BBB permeability in neurodegenerative disorders 
Altered BBB integrity is an early event in many neuroinflammatory conditions, 
including meningitis, multiple sclerosis, epilepsy and neuropsychiatric disorders.2,49-54 
In contrast, Bartels et al. suggested BBB breakdown to be a late event in Parkinson’s 
and related diseases.55 Alteration in BBB permeability occurs secondary to cell damage 
in trauma, ischemia and stress. An inflammatory response results, with a release of 
proinflammatory cytokines such as TNF-α (tumor necrosis factor), IL-1β (interleukine-
1β), IL-6.51,56,57 These three appear to be the main cytokines involved in the regulation 
of the acute phase response, by up-regulating cell adhesion molecules, activating T-
 cells and B-cells and stimulating the release of acute phase proteins. These cytokines 
and toxic factors such as nitric oxide promote neurodegeneration and may also activate 
astrocytes which will further affect the integrity of the BBB. Features of BBB 
disruption include increased vesicular transport across cells, separation of tight 
junctions, swelling of astrocytes, activation of microglia cells and disintegration of the 
capillary basement membrane. Cytokines represent an important communication 
pathway for the brain and immune system, they are also intimately involved in the 
stress response. For example, proinflammatory cytokine production in the brain is 
upregulated following exposure to physiological or psychological stressors.58 In 
response to stress, proinflammatory cytokines have been shown to modulate transport 
systems at the BBB, e.g. the voltage gated K+ channels,59 lactoferrin transport60 and the 
efflux pump P-gp.61-63 
 
 
Figure 2.2    
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 Abstract 
 
A major component in the protection of the brain against blood-borne toxic influences 
is the multispecific efflux pump P-glycoprotein. This pump, a 170 kD protein, located at 
the luminal side of the capillary endothelial cells, has a large capacity and is capable of 
extruding a wide array of structurally divergent substrates. The brain uptake of the 
majority of antidepressants and  antipsychotics, as well as many other psychotropic 
drugs and endogenous compounds is hampered by the activity of P-glycoprotein. In this 
review we discuss the current state of knowledge concerning the role of P-glycoprotein 
on pharmacokinetics of  psychiatric drugs and the impact of modulation of P-
glycoprotein on major psychiatric disorders. Relevant issues in reference to the function 
of P-glycoprotein and other efflux pumps in the blood-brain barrier related to mood 
disorders and schizophrenia are addressed, such as a possible role of P-glycoprotein as a 
susceptibility factor in depressive disorders and psychotic disorders.  
 
   
 Introduction 
 
The central nervous system (CNS) requires a perfectly regulated environment, for 
optimal activity. The main contribution to this homeostasis is accomplished by the 
blood-brain barrier (BBB), by protecting and isolating the nervous tissue from too 
strong fluctuations in nutrients, hormones, metabolites, and other solutes. Due to the 
presence of tight junctions, preventing the passage of molecules and ions through the 
space between cells, all substances must pass through the endothelial cell before 





Model of substrate transport by P-gp. (A) Substrate (magenta) partitions into the 
bilayer from outside of the cell to the inner leaflet and enters the internal drug-binding 
pocket through an open portal. The residues in the drug binding pocket (cyan 
spheres) interact with a substrate in the inward facing conformation. (B) ATP (yellow) 
binds to the nucleotide binding domains causing a large conformational change 
presenting the substrate and drug-binding site(s) to the extracellular space. In this 
model of P-gp, exit of the substrate to the inner leaflet is sterically occluded providing 
unidirectional transport to the outside. Reprinted from Aller et al. with permission12 
 This transendothelial route  further restricts the passage of molecules by distinct and 
highly selective transport systems, present on the luminal side of the endothelial cell. 
Only small lipid-soluble molecules can penetrate the endothelial cell through diffusion, 
unless their molecular weight exceeds 400-600 Da.2 
During the last decade it has become clear that multispecific, xenobiotic transporters 
play an important role at the blood-brain barrier (BBB). Of all efflux pumps discovered 
at the BBB so far, P-gp is the best described. It has been shown that P-gp exerts an 
important influence on the penetration of psychoactive drugs at the BBB.3,4 P-gp is 
found at the luminal side of the endothelial cells, where it extrudes hydrophobic 
compounds from the cell. It was discovered in 1976 in drug-resistant ovary cells from 
Chinese hamsters.5 Human P-gp is encoded by the multidrug resistance gene (MDR1), 
which is now denoted as ABCB1 (ATP Binding Cassette gene B1). P-gp contains 1280 
amino acids and has a molecular weight of  174 kD.6 
 
Localization and function of P-gp 
Cerebral P-gp is not only present at the BBB, but also at the blood-CSF barrier.7 Apart 
from the CNS, P-gp is present in kidneys, gut and other organs that have an epithelial 
lining. Interestingly, while in normal conditions P-gp is not found in neurons, 
neuronal P-gp expression was reported in pathological conditions, such as refactory 
epilepsy, cortical dysplasia and glioneuronal tumors.8-10 The physiological function of 
ABCB1 has not been unambiguously identified yet,6,11 but it involves the protection of 
the brain from compounds that have gained access to the circulation. The fact that it is 
being expressed in damaged neuronal tissue as well as in malignancies, affirm such a 
function.8,9 It needs to be considered that xenobiotic or drug concentrations in the 
brain might also be affected by intestinal P-gp limiting oral bioavailability.   
 
 Its imposing ability to transport hundreds of structurally divergent drugs, natural 
products and peptides, render this protein a fascinating molecule. P-gp is composed of 
two transmembrane bound domains, each consisting of 6 transmembrane helices and 
two nucleotide binding sites, that hydrolyze ATP, enabling substrate transport (see 
figure 1).12 P-gp substrates are known to partition into the lipid bilayers and 
accumulate to high concentrations. In the inner leaflet of the lipid bilayer the 
compounds can then get in contact with the drug binding pocket of the transporter.11,12 
Initiated by ATP binding a conformational change of the transporter molecule then 
brings the drug binding site to the outer leaflet or extracellular surface, thereby 
promoting unidirectional transport to the extracellular space. 
 
In vivo imaging of P-gp at the BBB 
In the last decade considerable effort has been put into gaining further insight into the 
role of P-gp under pathophysiological conditions. Different substrates of P-gp have 
 been radiolabeled and imaged using single-photon emission computed tomography 
(SPECT) and positron emission tomography (PET).13  
 
A P-gp tracer that meets the criteria of a useful ligand is a selective substrate for P-gp, 
produces a good signal after P-gp blockade and generates few radiolabeled metabolites 
that contribute to the PET signal. The principle of PET imaging of P-gp activity 
amounts to measure the difference in cerebral uptake of a radiolabeled P-gp substrate 
(i.e. radioligand) under two different conditions, for example major depressive disorder 
vs. healthy control, or before and after drug inhibition. The function of P-gp can be 
quantified by calculating the distribution volume (VT) of the ligand, which inversely 
reflects P-gp function.14 VT is an estimate of the brain tissue-blood partition coefficient 
of activity of the radiotracer at equilibrium and is defined as the influx rate constant K1 
over the efflux rate constant k2. Several radiolabeled P-gp substrates are available for 
PET, such as [11C]-verapamil and [11C]-carvedilol, [11C]-loperamide and [11C]-
desmethyl-loperamide.15-17 Of these, the in vivo studies with [11C]-verapamil 
outnumber all other ligands and it is the only tracer used in clinical studies. The (R)-
enantiomer of [11C]-verapamil can be considered superior to the racemic mixture.14,15,19 
Although the feasibility of in vivo measurement of P-gp function by [11C]-verapamil-
PET (VPM-PET) has been confirmed by several research groups,14,18,19 it is not an ideal 
tracer, because its brain uptake is low. The production of several metabolites of the 
parent compound [11C]-verapamil does not appear to be a problem, since the main 
metabolite is also a P-gp substrate.14 Several strategies have been launched in search of 
an optimal tracer, that is capable of detecting subtle changes in function (in particular 
increased P-gp activity). The development of a radiotracer that is not a substrate but 
works as a pure inhibitor, could bypass this problem, but so far the results of this 
strategy are ambiguous, possibly due to the fact that these inhibitors have affinity as a 
substrate too.20 Several new imaging strategies may still hold the unfulfilled promise of 
a method to study drug interactions with P-gp. For example, radiolabeling of a new 
drug candidate after administration of an inhibitor, or a double PET scan to evaluate 
the effect of a P-gp modulator. Another strategy that could work is the co 
administration of a P-gp inhibitor, that can increase the baseline signal.21 
 
Relevance of P-gp in relation to antidepressants, mood stabilizers and antipsychotics 
Different in vitro approaches and in vivo models (ABCB1ab (-/-) knock-out mice)  have 
been used to assess the impact of P-gp on pharmacokinetics of psychiatric drugs. In 
vitro data have indicated that most antidepressants and antipsychotics have affinity for 
P-g (table 3.1).22-26 Many of the in vitro data are contrary, which is inherent to the 
different methods and materials used. 
 
 Most research focusing on the inhibitory effects of antidepressants and antipsychotics 
has been done with various cell lines expressing (recombinant) human P-gp. As a 
measure of the P-gp-inhibitory potency of the drug a prototypic P-gp substrate, such as 
calcein-AM or Rhodamine123, was often used. The concentration needed to displace 
50% of the prototypic compound (called IC50 or EC50) was used as measure of the 
inhibitory effect on P-gp activity.  
 
For most compounds, the ability to inhibit P-gp has been compared to a typical 
comparator, such as verapamil or cyclosporine A. (tables 3.1-3.3). It must be considered 
that these inhibitors significantly differ in their potency to affect P-gp transport 
function.27 For example, haloperidol appeared to be a weak inhibitor compared to 
PSC833,28 whereas it proved to be a much stronger inhibitor in comparison to 
verapamil and ivermectin.29 
 
Some antidepressants have only shown inhibition without demonstrated substrate 
affinity (i.e. desipramine, imipramine, reboxetine).24,25 Besides, the translation of in 
vitro results to the human case could be complicated by differences in substrate 
specificity for P-gp across species.30 A more reliable method of studying affinity for P-
gp is based on studies in knock-out mice, which lack the ABCB1ab genes encoding P-
gp. Affinity for P-gp has been demonstrated in knock-out mice for most of the 
common antidepressants23,31-35 and antipsychotics (tables 3.1-3.2).31,36-41 
Despite the differences in the experimental set-up that partly explain the controversies 
regarding the interaction between P-gp and antidepressants and antipsychotics, it is 
feasible to say that the majority of the antidepressants and antipsychotics have shown 
(mostly weak) affinity as a P-gp substrate and that most have a weak inhibitory effect 
on P-gp in vitro. Some authors have argued that the inhibitory effect of antidepressants 
on P-gp is clinically irrelevant,25,26,34 since the drug concentrations used in most studies, 
necessary for P-gp inhibition were far above the therapeutic dose range. On the other 
hand, others have suggested that some antidepressants may be strong inhibitors in 
vivo.23,42,43 For antipsychotics comparable differences between the individual drugs have 
been described.   
 
The impact of cerebral P-gp in man for the bioavailability of psychoactive drugs cannot 
be satisfactorily deducted from the in vitro data. It needs to be considered that 
antidepressants and antipsychotics can generally access the brain and therefore can not 
be high affinity substrates of P-gp like compounds that do not exhibit any relevant 
brain penetration based on its interaction with P-gp. Moreover, CNS active drugs are in 
general characterized by a fairly high lipophilicity. Recent data demonstrated that it 
can be more difficult to detect an interaction with P-pg, when drugs pass membranes 
efficaciously by rapid diffusion due to their lipophilic characteristics.44 
  
Most of the antidepressants and antipsychotics, as well as several mood stabilizers 
demonstrated a significantly greater, albeit small brain/plasma ratio in ABCB1a 
knockout mice compared to wild type mice (mean = 1.8 for antidepressants; 4.9 for 
antipsychotics) (see table 3.1-3.3). The value of the studies using the knock-out mouse 
model is limited by the fact that a one dose model is mostly used, representing only the 
acute modulatory effect on P-gp. There are only two reports on long term treatment on 
P-gp activity in vivo.45,46 For amitriptyline, it was demonstrated that the brain uptake in 
WT and KO mice was equal for the parent compound (amitriptyline), whereas a much 
higher cerebral concentration was measured for its metabolites in the knock-out mice. 
It was suggested that chronic administration of amitriptyline induces up-regulation of 
the P-gp pump, thus inhibiting its own access to the brain. In an elaborative study they 
refined their results and demonstrated that 4 hours after a single dosis of amitriptyline 
the initial differences (present at one hour post injection) in cerebral uptake had 
disappeared, in contrast to the metabolites, pleading against an up-regulatory 
mechanism.47 Differences in cerebral uptake between the parent compound 
(amitriptyline) and its metabolites can also be explained by a differential affinity of P-
gp for the respective molecules. Miura et al. demonstrated that small molecular changes 
can turn a strong P-gp substrate into a weak one.48 Another notion is that the effect of a 
non-substrate on P-gp activity can apparently vary over time.23   
 
In spite of the findings of the preclinical work on the role of P-gp in the uptake of 
drugs used for the major psychiatric disorders, there are arguments pleading against a 
significant role for P-gp. For example, antipsychotic drugs like risperidone and 
haloperidol may significantly differ in their interaction with P-gp, but have a 
comparable clinical efficacy. Because direct evidence for a major role of P-gp in 
pharmacokinetics has been lacking, CNS side effects of drugs with potential P-gp 
inhibiting effects may erroneously have been attributed to other causes. Cytochrome 
P450 3A4, a major drug metabolizing enzyme, shows a striking overlap in substrate 
specificity with P-gp.49,50 Several CNS effects have been ascribed to interactions 
between drugs concurrently inhibiting Cyp3A4, without notice of a potential 
concomitant P-gp inhibiting effect of these drugs in vitro.51-53  
Cortisol is a substrate of P-gp as well. Its uptake into the brain is thwarted by P-gp.54,55 
It has been well established that depression coincides with dysregulation of the HPA 
axis, characterized by negative feedback inhibition and elevated cortisol levels.56 As 
some of the in vitro data have suggested that P-gp is inhibited by the action of 
antidepressants,57 it has been hypothesized that antidepressants exert their 
antidepressant effect partly by the inhibition of P-gp, leading to an intracerebral 
cortisol increase and normalization of the HPA axis. However, antidepressants appear 
to have an insignificant effect on plasma cortisol levels.58 Besides, cortisol entry to the 
 brain is not regulated by P-gp only, as Mason et al. found in mice.59 Concluding, data 
supporting the hypothesis that P-gp inhibition plays a role in normalisation of a 
hyperactive HPA-axis, are lacking.  
 
Mood stabilizers belong to different drug classes. Lithium is the drug of first choice in 
the treatment of bipolar disorders. Although lithium itself is not a substrate of P-gp, 
lithium shares many properties with magnesium (Mg2+), such as a synergistic effect on 
the Na/K ATP-ase.60 Mg2+ appears to play a key role in P-gp mediated efflux through 
ATP hydrolysis.61 It may thus be conceived that lithium has a similar impact on the 
function of P-gp. Other drugs registered as mood stabilizers include the anti-epileptic 
drugs carbamazapine, valproic acid and lamotrigine. These agents appear to have no or 
at most a weak affinity for P-gp (see table 3.3). Reports on the effect of different 
antiepileptic drugs on P-gp expression in brain capillary cell lines have been 
equivocal.62-64 
 
Modulation of P-gp at the BBB by stress (in vitro studies) 
An understanding of the physiological regulation of P-gp is key to therapeutic 
strategies in the treatment of psychiatric disorders, since most of the drugs used for 
depression and psychosis seem to be P-gp substrates. Stress is the hallmark of many 
psychiatric diseases, including depression and psychosis, and it appears that all sorts of 
stress responses evoked by a variety of environmental stimuli, such as cytotoxic agents, 
heat shock, irradiation, genotoxic stress and inflammation are able to influence either 
the expression or the activity of P-gp.65 P-gp is regulated at various levels of expression 
including DNA, mRNA and protein. 
 
There is increasing evidence for the role of cytokines in the pathogenesis of 
depression.66 Proinflammatory cytokines are produced by different immune cells upon 
presentation of an antigen and their secretion is believed to be the prime event in the 
subsequent neurophysiological responses taking place during immune stimulation. 
Several animal models are applied,65,67 and although results of the in vivo studies are 
somewhat conflicting, most demonstrated that P-gp expression and activity can be 
involved in different ways during an inflammatory episode, the degree and direction of 
the change in P-gp activity depending on the model and the inflammatory mediator 
used.67,68 
 
Several in vitro studies have tried to extricate the signalling pathways of the involved 
cytokines and other chemotactic compounds leading to a functional change of P-gp at 
the BBB. Hartz and colleagues define a pathway through which P-gp is acutely 
modulated. They describe a sequence of events, starting with TNFα (tumor necrosis 
factor), releasing endotheline-1, that in turn activates nitric oxide synthase and then 
 protein C kinase, ultimately reducing P-gp transport.69,70 The same group showed that 
this regulation is biphasic: after an initial rapid decrease of P-gp activity following 
exposure to TNF and endotheline-1, an increase in transport activity was found at 6 
hours post exposure. Similar data are presented by others. For example, the results by 
Tan and colleagues showing an increase in P-gp expression following BBB breakdown 
by activated T-cells, suggest both a role in immune cell mediated cytotoxicity and a 
counterregulatory role in promoting cell survival and maintaining BBB integrity. They 
hypothesize that the latter role may be relevant in later stages of the inflammation.71 In 
vivo studies focusing on such a biphasic response in cytokine regulation and in P-gp 
activity in depressive or psychotic disorders are warranted and can be best worked out 
in animal models.  
 
Depressive disorder, schizophrenia and stress-related disorders and P-gp 
A few studies have focused on BBB characteristics in relation to psychological stress. 
Rats subjected to perinatal stress had an increased permeability as measured by the 
uptake of Evans blue.72 Acute stress (e.g. immobilization stress or forced swim) 
increases BBB permeability likewise.73-75 In respect to the effect of chronic stress on 
BBB function, studies are lacking, but in major depressive disorder (MDD) BBB 
dysfunction has been suggested as potential mechanism.76  
 
If P-gp is a susceptibility factor in stress related disorders, animal models could be used 
to demonstrate their modulatory role in stress. To date, evidence is sparse. In one 
study, describing the anxiolytic-like effect of tariquidar (a P-gp inhibitor) in mice 
sensitized by a mild stressor, it was suggested that P-gp inhibition led to an increase of 
corticosteroids, which, in turn would enhance the negative feedback control of the 
HPA axis.77  
 
In two PET studies with [11C]-verapamil, an increased function of P-gp at the BBB in 
temporal and frontal areas was found both in a group of medicated patients with MDD 
and schizophrenia.78,79 Caution in the interpretation of the results of both studies is 
justified, since the findings were complicated by the use of either antidepressants or 
antipsychotics. The increase in P-gp function might be a result of the disorder itself or 
a result of antidepressant treatment. A sequel to these studies was set up to disentangle 
the possible contribution of antidepressant therapy and MDD. Rats were either 
subjected to chronic stress or to a continuously administered antidepressant. Using 
[11C]-verapamil PET as a measure of P-gp activity, an indication was found for 
decreased P-gp activity in the stressed rats, whereas venlafaxine appeared to have an 
opposite effect on P-gp activity.80 A confirmation study correlating the in vivo results 
from both studies to P-gp expression at protein and mRNA level is under way. 
Although the in vivo imaging study may provide an indication for a susceptibility role 
 of P-glycoprotein in depressive disorders, in the light of the limited evidence so far, it is 
impossible to interpret the findings without great restrictions.  
 
The role of ageing and neurodegeneration in P-gp functionality 
Although the status of both MDD and schizophrenia as neurodegenerative disorders is 
tenuous, both disorders have neurodegenerative features. In depression, it has been 
hypothesized that neuroinflammation ultimately leads to neurodegeneration.81 The 
coincidence of structural brain changes and decreased regional blood flow has been 
well established in MDD as well as in schizophrenia. Loss of the integrity of the blood-
brain barrier is a cardinal phenomenon in many neurodegenerative disorders including 
Alzheimer dementia. In the PET studies on Parkinson’s disease a role for P-gp in 
neurodegeneration has been suggested, but this is based on small differences in tracer 
uptake between patients and control group.82  
 
The decline in function of P-gp in old age, which has been indicated by [11C]-
verapamil-PET studies will certainly accentuate the problems encountered in 
pharmacotherapy in the elderly.83,84 The decreased P-gp activity might be linked to the 
pathology in late-life depression, such as the cognitive changes, but a major role in the 
etiology of MDD at old age is refuted by the fact that the incidence of MDD declines 
with age.85 
 
Polymorphisms of P-gp and their effect on function.  
Since the first report on a polymorphism in the ABCB1 gene, the quest for more 
variations in the DNA sequence explaining phenotypical differences has not stopped. 
Substantial progress has been made in identifying single nucleotide polymorphisms 
(SNPs) in the entire ABCB1 gene. Reports in the literature have particularly focused on 
C3435T (non-coding exon 26), after an initial report on altered duodenal P-gp 
expression and functionality associated with the TT variant,86 but later on the SNPs 
G2677T/A and C1236T have generated interest as well.   
Studies within the field of psychiatry have particularly focused on treatment response 
to antidepressants or antipsychotics. Other studies refer to side effects and two studies 
pertain to the occurrence of ABCB1 polymorphisms in mood disorders and 
schizophrenia. In two studies, the diagnosis of depression was found to be associated 
with a haplotype of 13 ABCB1 polymorphisms.87 In the other study, mood disorders 
were associated with the haplotype of 129-2677-3435 (T-A-C) and with a lower 
frequency of ABCB1 alleles at -1517, -41 and -129 and a higher frequency of 2677A.88 
In this study no association was found between ABCB1 and schizophrenia. 
  
Most studies on the genetic effects of the SNPs C3435T, G2677T/A and C1236T or 
ABCB1 haplotypes showed little or no effect on treatment response (table 3.4A). A 
 strong effect of a single transporter gene on a phenotypic response in complex disorders 
like MDD and schizophrenia is not amenable. A few reports on antipsychotic or 
antidepressant related side effects associated with polymorphisms have been published, 
and a few groups have communicated on the effect of ABCB1 polymorphisms and 
plasma concentrations of antipsychotics or antidepressants (table 3.4B). For risperidone, 
displaying high substrate affinity for P-gp, only modest genetic effects were reported in 
side effects (weight gain) and in treatment response.89,90     
 
The contradictions in observations for the major polymorphisms of ABCB1, are partly 
accountable to differences in methodology and to ethnic differences between study 
groups. In most studies the sample size is too small to draw firm conclusions.  
 
Thus, none of the SNPs of ABCB1, nor any of the haplotypes, can definitely be 
connected to phenotypical variation, but instead some may serve as biological marker 
for pin pointing a disease. In the near future it is to be expected that analysis of SNP 
patterns in large patient cohorts with identical phenotypic features will identify SNP 
profiles that characterize susceptibility factors. Genome wide association studies 
(GWAS) are the type of study designed to identify such a genetic variation. This 
strategy may be best worked out in a subset of patients with severe, recurrent and early 
onset form of depression, since this group of patients has shown an elevated genetic 
contribution.91          
 
Non-P-gp mediated efflux transport at the BBB 
Other members of the ABC family that are expressed in the BBB, include multidrug 
resistance proteins (MRP1, -2, -4 and -5) (ABCC genes) and breast cancer related 
protein (BCRP/ABCG2 gene).92,93 The exact location of some of the MRPs within the 
BBB is still debated.93  The reasons for this uncertainty are the differences in transporter 
profiles between species as well as inferior antibody specificity. The predominant 
location of MRP1 is probably the basolateral membrane.94 Among the non-P-gp efflux 
transporters MRP1 and BCRP have the highest expression in the human BBB, which 
however is much lower (around 20-fold) than that of P-gp.95 
 
The MRPs transport anionic compounds, including sulphate, glucuronide, and 
glutathione (GSH) conjugates.96 Three typical antipsychotics (thioridazine, 
chlorprotixene and flupentixol), all carrying a sulphur atom, were found to inhibit 
MRP2 in vitro.96 Of the few reports on involvement of MRP1 or MRP2 in the transport 
of an antidepressant no significant inhibition was found.97 BCRP appears to be involved 
in the efflux of antipsychotics. For the major antipsychotics Wang et al. demonstrated a 
similar profile of inhibition to that of P-gp,28 albeit that for most antipsychotics at least 
a 5-fold higher concentration was needed to inhibit BCRP (compared to P-gp).98 For 
 the antidepressants maprotiline and desipramine no significant inhibition of BCRP was 
reported.99   
 
Concluding, the clinical relevance of the MRPs in conferring resistance to the major 
psychiatric drugs at the BBB is probably negligible in comparison to P-gp, given the 
lower substrate affinity and the much lower expression in the BBB. BCRP might exert a 
more significant role at the BBB and is probably more subsidiary to P-gp function than 
the MRPs.99 Nevertheless, the impact of BCRP in drug disposition at the BBB in vivo is 
still uncertain.100  
 
Concluding remarks and future directions  
In conclusion, the role that P-gp plays in depressive and psychotic disorders, is far from 
clear. Most antidepressant and antipsychotic drugs have a weak to moderate affinity as 
a substrate for P-gp, and some may have inhibitory properties as well, which may be 
relevant in drug-drug interactions. P-gp may be involved in a depressive or psychotic 
episode as well, since evidence exists for a (temporarily) decrease in activity and 
expression during a neuroinflammatory event, which characterizes the 
pathophysiology of these disorders.  
 
Given the importance of P-glycoprotein in drug transport at the BBB and its 
involvement in neuroinflammation, it is comprehensible that the protein is of great 
interest in the field of neuroscience. At this time, the understanding of the precise role 
in neuropsychiatric disorders and drug disposition is incomplete, but new 
developments in neuroimaging, pharmacogenetics and molecular biology are in full 
progress and it will be only a matter of time to accomplish this. As outlined above, an 
important step forward in the identification of genetic variants has been made, albeit 
the complex regulatory pathways involved in P-gp modulation require further 
considerations in pharmacogenetic studies. Studies with larger sample size will be 
needed to detect modest effects. Progress in PET imaging largely depends on 
development of new tracers that approach the unmet needs of an ideal tracer.   
 
 Table 3.1 
 













amitriptyline ++  weak 
24,25,33,45
 
bupropion  0 no 
43
 





clomipramine   no  
25
 
desipramine   weak-moderate 
24,25
 
doxepin +  weak 
24; 35
 
duloxetine   moderate 
102
 
fluoxetine 0/+  no 
25,26,31,33
 
fluvoxamine + 0 weak 
26,29,31,33,103
 
imipramine   weak-moderate 
24,25
 
maprotiline   weak 
24
 
mirtazapine 0  weak 
25,35
 
nefazodone  0 good 
23
 
nortriptyline +  weak  
25,31-33
 
paroxetine + ++ moderate 
29,31,101,103
 
reboxetine   weak 
25,26
 





trazodone 0 0 no 
23,31
 
trimipramine +   
34
 





Legend (table 3.1-3.3) 
substrate affinity in vivo denotes the ratio between in vivo brain uptake in ABCB1a -/- 
knock-out vs. wild type (KO-WT) mice: 0: no significant change; +: 1-3; ++: 3-10; 
+++:>10.  
substrate affinity (in vitro):  transport capacity compared to a prototypical P-gp 
substrate (mostly expressed as IC50 or EC50, see text): 0: 0-5% ; +: 5-25%; ++: 25-75%; 
+++: >75% 
Inhibition: good = comparable to comparator inhibitor* (at least 75%) ; moderate: 25-
75% inhibition of comparator; weak: 5-25% inhibition ; no: < 5 % inhibition or non 
definable ; *: inhibition (in vitro) is related to a typical comparator inhibitor, either 
verapamil, ivermectin, cyclosporine, or PSC833; α P-gp inhibition compared to PSC833 ; 
∂significant increase in lamotrigine brain/plasma ratio after administration of a P-gp 
inhibitor (verapamil) 
 Table 3.2 
 













amisulpiride 0 + Weak 
29
 
aripiprazole ++ ++  
39,46,105
 
chlorpromazine + +/++ Weak 
25,28,31,106
 
clozapine 0/+ 0/+ Weak 
22,25,28,29,31,38,106
 
fluphenazine + ++ Moderate 
24,29,107
 
flupentixol  + Good 
29
 
haloperidol 0/+ 0/+ weak
α
-good 
25,29; 28,106,108; 24,31,37,38 







paliperidone +++ ++ No 
28,31,36,36,37,41
 
perospirone   Good 
109
 
perphenazine   Good 
29
 
































 0/+ no-weak 
31, 44, 112,115-117
 
lithiumcarbonate     

























amitriptyline  G2677T/A rs2032583 50 % change in HAMD response after 3 weeks 
119
 n.s. 




(C/T) intron 22 rs2032583 132 




MDD UTR rs17064 % change in HAMD-21 score after 8 weeks n.s.  
desipramine 
 haplotype block 1 
272 
 




(C/T) intron 22 rs2032583 0.024 
Intron 4 rs2235015 n.s. MDD 
(A/G) intron 21 rs2235040 




G2677T/A rs2032583 0.01 
C3435T rs1045642 n.s. 









MDD G2677T/A rs2032582 n.s. 
paroxetine 
 
 C3435T rs1045642 




(A/C) (intron 22) rs10280101 238 n.s. 
(A/G) (intron 22) rs7787082 237 n.s. 
(C/T) intron 22 rs2032583 238 n.s. 
duloxetine MDD 
(A/G) intron 21 rs2235040 239 




C1236T rs1128503 n.s. 
G2677T rs2032582 n.s. citalopram MDD 
C3435T rs1045642 
652 
response (395) vs. non-response (257) on (different doses) 





C1236T rs1128503 n.s. 
C3435T rs1045642 0.045 
haplotype block 1 (intron26-27) 0.003 
escitalopram MDD 
haplotype block 2 (incl. exon13)  




MDD G1236A rs1128503 n.s. 
 (T/C) rs10276036 n.s 
 (T/A) rs2235020 n.s 
 (C/G) rs2214103 
142 % change in HAMD-21 score after 8 weeks  
n.s. 
 haplotype block 1 272 remission versus non-remission after 8 weeks 0.03 
fluoxetine 
 haplotype block 2 272 remission versus non-remission after 8 weeks  0.04 
fluoxetine or 
desipramine 




nortriptyline MDD C3435T rs1045642 160 MADRAS score after 6 weeks 
127
 n.s. 
C3435T rs1045642 n.s. 









G2677T rs2032582 54 n.s. 
S 
C3435T rs1045642 58 




C1236T rs1128503 0.021 
































amitriptyline MDD G2677T/A rs2032582 50 C/D ratio 
119
 n.s. 
C3435T rs1045642 0.046 
clozapine S 
G2677T/A rs2032582 




fluvoxamine MDD C3435T rs1045642 62 higher C/D ratio in T-genotypes 
131
 0.026 
S C3435T rs1045642 41 weight gain related to olanzapine concentration 
128
 n.s. 
C3435T rs1045642 n.s. 
S 
G2677T/A rs2032582 












C3435T rs1045642 0.015 
G2677T rs2032582 0.031 S 
Haplotype 3435T-2677T 






















Legend (table 3.4A and 3.4B) 
a DSM diagnosis: diagnostic statistical manual; MDD = Major depressive disorder; S= schizophrenia; brs-id = reference seauence identity; 
cn = number; dHAMD(-21) = Hamilton Depression Rating Scale (-21 item version); eMADRAS = Montgomery Asberg Rating Scale; fBPRS 
= Brief Psychiatric Rating Scale; gCIT = citalopram ; h C/D = concentration-to-dose; iPANSS = positive and negative symptom scale ; 
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The etiology of depressive disorder remains unknown, although genetic susceptibility 
and exposure to neurotoxins are currently being discussed as possible contributors to 
this disorder. In normal circumstances, the brain is protected against blood borne toxic 
influences by the blood-brain barrier, which includes the molecular efflux pump P-
glycoprotein (P-gp) in the vessel wall of brain capillaries. We hypothesised that P-gp 
function in the blood-brain barrier is changed in patients with major depression. 
Positron-emission tomography was used to measure brain uptake of [11C]-verapamil, 
which is normally expelled from the brain by P-gp. Cerebral volume of distribution 
(VT) of [11C]verapamil was used as measure of P-gp function. Both region of interest 
(ROI) analysis and voxel analysis using statistical parametric mapping (SPM2) were 
performed to assess regional brain P-gp function. We found that patients with a major 
depressive episode, using antidepressants, compared to healthy controls showed a 
significant decrease of [11C]-verapamil uptake in different areas throughout the brain, 
in particular in frontal and temporal regions. The decreased [11C]-verapamil-uptake 
correlates with an increased function of the P-gp protein and may be related to chronic 
use of psychotropic drugs. Our results may explain why treatment resistant depression 




A large body of evidence gathered during the past decades indicates that brain 
monoaminergic systems play a key role in the pathogenesis of affective disorders. 
However, not all symptoms of depression can be related to dysfunctions in 
monoaminergic systems. For instance, it is now known that stressful events paving the 
way to affective disorders, lead to changes in neuroplasticity, impair neurogenesis and 
may lead to a neuroinflammatory response in the brain.1 As such, it has been suggested 
that a dysfunction of the blood-brain barrier (BBB) and blood-cerebrospinal fluid 
barrier may contribute to the pathophysiology of major depressive disorder. Hampel 
and colleagues reported that serum/cerebrospinal fluid ratios of several inflammatory 
proteins (used as an indirect measure of BBB function) were altered in depression.2,3 
Several endogenous substances, such as cortisol, are found in the brain parenchyma in 
concentrations in subjects with a major depressive disorder. 
 
The BBB is formed by the brain capillary non-fenestrated polarized endothelial cells 
that have high-resistance tight junctions. Besides low passive permeability, the brain is 
protected from potentially harmful endogenous and exogenous substances by efflux 
transporter proteins, located in the brain capillary wall.  
P-glycoprotein (P-gp), a product of the MDR-1 gene, now denoted as ABCB1, in 
humans and the MDR-1a and MDR-1b genes in mice, is a major drug efflux 
transporter, involved in the efflux of a wide variety of lipophilic drugs and endogenous 
substances.4 Attenuation of P-gp function, for example through use of pharmacologic 
inhibitors, results in substantial changes in the pharmacokinetics and 
pharmacodynamics of various substrates.5-7  
 
Nuclear medicine imaging techniques such as PET (Positron Emission Tomography) 
have been evaluated as non-invasive techniques for the evaluation of the BBB, allowing 
study of the P-gp pump.8 Using several experimental designs, the applicability of [11C]-
verapamil as PET-tracer has been extensively studied9-11 and has been found to be a 
suitable methodology for the in vivo assessment of P-gp functionality in humans, and 
allows the quantification of BBB-P-gp function in neurodegenerative diseases.8,10-12 
 
The protective role of P-gp may be negatively influenced in neurodegenerative 
diseases. Animal models of neuroinflammation have demonstrated that P-gp is 
downregulated by proinflammatory cytokines.13-15 In a recent PET study using [11C]-
verapamil it was found that the function of BBB P-gp was diminished in later stages of 
Parkinson’s disease, whereas de novo patients with Parkinson showed a regional 
upregulation of P-gp in frontal regions.16 In another [11C]-verapamil PET study in 
patients with schizophrenia it was shown that P-gp function was locally increased.17 
  
The authors state that P-gp induction may be a factor of importance in drug resistance 
in schizophrenia.  P-gp function is possibly under the influence of genetic 
polymorphisms.18 
 
To date, no detailed evidence is available for a dysfunction of the Blood-Brain Barrier 
through P-glycoprotein modulation in major depressive disorder. It is not known 
whether P-gp function or expression is altered during a depressive episode.  
 
In this exploratory study we hypothesized that P-glycoprotein function would be 
altered in limbic areas (hippocampus, amygdala) as well in frontotemporal areas (incl. 
anterior cingulate cortex) since these areas are known to play a role in depression.19,20   
 
We performed positron emission tomography (PET) brain imaging of P-gp with [11C]-
verapamil as radiotracer in depressed patients and healthy controls. We further  
hypothesized that this altered functional activity of P-gp could be connected to a 
genetic polymorphism of the ABCB1 gene. To assess these hypothesized changes in P-
gp function, PET brain imaging with [11C]-verapamil as radiotracer was performed in 
depressed patients and healthy controls. The distribution volume of [11C]-verapamil 






Fourteen patients suffering from depression were recruited and participated in the 
study. All underwent a Mini International Neuropsychiatric Interview, (M.I.N.I. plus 
5.0.0., Dutch Version, 2000) for DSM-IV and fulfilled the criteria for a major depressive 
episode.21 Inclusion criteria for subjects with a major depressive episode were 1) age 40-
80 years; 2) fulfilment of the DSM-IV criteria for major depressive episode; and 3) 
capacity to give informed consent. The age range 40-80 years was chosen, because we 
expected to find larger differences at a later age in particular, since P-gp function 
declines with aging.22 Moreover, the control group was also used in another study. 
Exclusion criteria were 1) use of known P-gp modulating agents (cardiovascular drugs, 
antimalarial drugs, cyclosporine A, phenothiazines, hormones (eg. tamoxifen), certain 
antibiotics such as cefoperazone, ceftriaxone, erythromycine);23 2) any somatic disease 
of kidney, liver, heart or brain; 3) history of traumatic brain damage; 4) 
electroconvulsive treatment in the past three months; 5) abnormalities at clinical (incl. 
neurological) and laboratory examination; 6) pregnancy. This research was approved by 
the Ethics Committee of the University Medical Centre Groningen, and all subjects 
gave written informed consent according to the Declaration of Helsinki. All patients 
  
had a minimum score of at least 19 on the 17-item Hamilton Depression Rating Scale at 
the time of the PET study.24 All patients had a physical examination and laboratory 
evaluation. All were in good physical health and none had meaningful laboratory 
abnormalities. The healthy controls as well as their first degree relatives were required 
to have no history of any psychiatric disease, nor in their first degree relatives. The 
other inclusion and exclusion criteria for healthy controls were similar to the patients. 
Before the scan, blood was drawn from the venous canula for genotyping. Three 
common MDR1 single nucleotide polymorphisms were detected using a PCR analysis. 
 
Radiochemistry 
Racemic [11C]-verapamil was produced as previously described.25 The injected 
radioactivity of [11C]-verapamil was comparable for the control group and subjects with 
a major depressive episode (see Results section). Specific activity for all subjects was at 
least 16 GBq/µmol. Following radiotracer injection, subjects underwent a dynamic PET 
acquisition protocol as described previously.12   
 
PET procedure 
All scans were performed with the use of an ECAT EXACT HR+ position camera 
(Siemens/CTI, Knoxville, TN). After the radiotracer injection of [11C]-verapamil serial 
dynamic PET scanning was done at escalating time frames and serial arterial blood 
sampling for [11C]-verapamil took place during the scan in order to define the input 
function. The samples of all subjects were collected with an automated sampling 
system, together with 6 manually drawn samples per subject. These samples (collected 
at intervals of 10 minutes) were further processed to measure the radioactivity in 
plasma and blood. In this way the contribution of the injected activity to the signal 
could be calculated. No metabolite analysis was done. Images were reconstructed in 
brain mode using an iterative reconstruction (Ordered Subsets - Expectation 
Maximization) with 4 iterations and 16 subsets and a Gaussian filter of 4 mm. The scans 
were performed in 3D mode. 
 
Data analysis 
The PET data were analyzed with both a voxel-wise group analysis using statistical 
parametric mapping (SPM2) and a ROI  (regions of interest)-based approach. Results 
from both methods were used and compared. 
 
First, all images were stereotaxically normalized to MNI space using SPM2 and a [11C]-
verapamil template image that could be used from earlier studies of our group.12,22 The 
resulting images were analysed with SPM2 as described below. For the ROI analysis the 
following ROIs, based on the literature as cited above, were selected for 
analysis: prefrontal cortex, anterior cingulate cortex, temporal lobes, amygdala and 
  
hippocampus. Therefore, predefined ROIs from the Anatomical Automated Labeling 
package26 were used to select the appropriate voxels and calculate the corresponding 
time-activity curves using in-house developed software. In addition, a whole brain ROI 
was manually drawn using Clinical Applications Programming Package software 
(CAPP; CTI/Siemens PET Systems, Knoxville, USA).  
 
A graphical analysis according to Logan for quantification of the dynamic PET data was 
done with plasma data as input. The Logan plot was started at 5 minutes. With this 
method the distribution volume (VT) was estimated. Because the slope (i.e.VT effect) 
obtained in the graphical approach may be biased in the presence of noisy data,27 we 
verified the VT in a kinetic analysis (i.e. single tissue compartment model). The influx 
rate constant (K1) and efflux k2 were derived from this model and on all parameters (i.e. 
VT, K1 and k2) the group means (patient group vs. control group) were compared  with 
each other, using parametric tests. Analysis of covariance was performed in order to 
find relevant (clinical) predictors (age, length of present episode, number of previous 
episodes, severity of symptoms) of VT or K1. To exclude a possible confounding effect of 
subjects without a strict DSM-IV diagnosis (i.e. Diagnostic Statistical Manual, 4th ed.) of 
Major Depressive Disorder (MDD), a subanalysis was also done for the group with 
MDD only (n=10).     
 
Data were then analyzed with SPM2 (Statistical Parametric Mapping, 2002). To adjust 
for differences in individual neuroanatomy and to improve the signal-to-noise ratio, a 
12-mm full-width at half-maximum Gaussian smoothing filter was applied to all images. 
We first compared the groups by looking at absolute differences in VT, using t-test and 
ANCOVA with cofactors (MDR1 allelic variation, age, length of present episode, 
number of previous trials, severity of symptoms, injected activity of [11C]-verapamil). 
Clusters of 8 or more voxels at a threshold of PFDR<0.05 (false discovery rate) were 
considered to be significant. Coordinates were transformed into Talairach space 





The mean injected [11C]-verapamil dose was not different for the two groups (control 
group: mean = 317 MBq, SD = 119; group with depression: mean = 279 MBq; SD = 179; 
t-test: t=-0.344; d.f.=24; p=0.734). Table 4.1 shows the demographic characteristics and 
medication use of the patient group. Twelve patients had had a previous depressive 
episode, three patients had a bipolar type I disorder, the current episode being 
depressive.  
  
Three subjects had a depressive episode with psychotic features. One patient was 
excluded from the analysis because the VT was considered an outlier since the 
difference to the group mean was 4.6 times the standard deviation of the group, for 
unknown reasons. The patient group (6 female/7 males, mean age 54.1 years ± 7.6) was 
compared to a sex matched comparison group (6 female and 7 male subjects; mean age 
56.3 ± 14.3 years). Patients had a mean score of 25.8 (± 4.8) on the 17-item HAM-D 
(range 19-37). Nine patients were currently depressed for more than 12 weeks. 
Interestingly, 7 of this group could be considered to be treatment resistant, using 
criteria of Dunner).28 Comorbid disorders included post traumatic stress disorder 
(PTSD) (n=1) and panic disorder (n = 1). All subjects used an antidepressant or a mood 
stabilizer at the time of scanning. 
We determined three common MDR1 single nucleotide polymorphisms (SNP) (-129 T 
>C (exon 1), 2677 G> T/A (exon 21) and 3435 C> T (exon 26)) in our patient group. For 
the SNP 3435 on exon 26 the allele frequencies in the patient group were CC 23%; CT 
38% and TT 39%. The allele frequencies of SNP 3435 in our subjects were not different 
from the frequency in the population.29  
The mean brain time activity curves (after correction for weight and injected dose) for 
the whole brain of patient group and control group were compared and the area below 
the curve was calculated. No differences in the area below the curve was found. Both 
curves overlapped (data not shown). The VT values of the ROI (whole brain) were 
calculated with both the Logan analysis and the ‘single tissue compartment model’, in 
order to verify that the VT effect measured in the Logan method was concordant with 
another method. Pearson’s correlation coefficient (r) was very good, 1.000 (p =0.000). 
The Logan curve gave an excellent fit in all cases. The VT in ROI whole brain in the 
group of patients (n=13) with depression was lower at a nearly significant level (Z = -
2.008; p=0.055). K1 (whole brain ROI) showed no significant difference between the 
groups.  (0.48 ± 0.15 (controls) vs. 0.41 ± 0.10 (patients); p = 0.15). Neither did the k2 
values (0.71 ± 0.10 (controls) vs. 0.75 ± 0.15 (patients); p=0.46). In the ANCOVA none 
of the cofactors (age, length of present episode, number of previous episodes, severity 
of symptoms) showed a significant effect on the results. Both groups were compared 
with a Student’s t-test for the selected ROIs (prefrontal cortex, anterior cingulate 
cortex, temporal lobes, hippocampi, amygdala). Here we found a significantly lower VT 
in the patient group for the prefrontal cortex (0.64 ± 0.20 (controls) vs. 0.44 ± 0.15 
(patients); p=0.009), the temporal lobes (0.66 ± 0.21 (controls) vs. 0.44 ± 0.19 (patients); 
p=0.01), the anterior cingulate cortex (0.53 ± 0.20 (controls) vs. 0.34 ±0.18 (patients); 
p=0.016), and for amygdala (0.72 ± 0.30 (controls) vs. 0.49 ± 0.24 (patients); p=0.045) 
but not for hippocampus ( 0.55 ± 0.32 (controls) vs. 0.41 ± 0.13 (patients); p= 0.146). VT 




Characteristics of subjects with major depressive episode 
AO: Age of onset; LPE: length of present episode; O=outpatient; DT = day treatment; PC = psychiatric 
clinic; M = male; F = female; HAMD = Hamilton Depression Rating Scale; BP-I = Bipolar disorder type I; 
D = (current phase) depressive; MDD = Major Depressive Disorder, P = psychotic features; PTSD Post 

















1 PC M 47 22 20 BP-I, 
D,P 
22 valproic acid 2000 mg/d (level 
79 mg/l); venlafaxine 225 
mg/d, risperidone 2 mg/d 
2 O F 72 67 12 MDD 20 mirtazapine 30 mg/d, 
temazepam 20 mg 1 dd 1; 
cetirizine 10 mg/d 
3 PC F 71 45 104 MDD 25 imipramine 100mg/d; 
lactulose 30 ml/d; 
esomeprazol 20 mg/d; 
quetiapine 200 mg/d 
4 DT F 51 27 26 BP-I,D 22 lithium carbonate 900 mg/d 
(level 0·88 mg/l); diclofenac 
150 mg/d 
5 PC F 
 
52 33 26 MDD,P 37 tranylcypromine 60 mg/d; 
olanzapine 15 mg/d 
6 PC M 
 
60 60 8 MDD, P 26 citalopram 20 mg/d 
7 PC M 
 
56 51 52 MDD 
PTSD 
31 lithiumcarbonate 1000 mg/d 
(level 0·90 mg/L); nortriptyline 
100 mg/d 
8 PC M 
 
55 23 26 MDD, 
PD 
25 nortriptyline 100 mg/d 
9 PC F 
 
56 31 104 MDD 27 tolderodine 4 mg/d; 
temazepam 20 mg/d; 
cisordinol 2 mg/d; mirtazapine 
30 mg/d 
10 O M 41 39 6 MDD 24 citalopram 40 mg/d; 
mirtazapine 30 mg/d; 
oxazepam 50 mg/d 
11 PC F 52 38 12 BP-I 29 valproic acid 1500 mg/d; 
temazepam 20 mg/d; asacol; 
thyrax 75 µg/d 
12 PC M 46 46 20 MDD 24 venlafaxine 150 mg/d 
13 PC M 52 44 6 MDD 30 venlafaxine 150 mg/d 
14 O F 57 56 12 MDD 19 mirtazapine 30 mg/d; 
citalopram 20 mg/d 
  
  
correction for multiple tests. The mean ± S.D. of VT for each group are shown for each 
ROI in  figure 1. 
 
A pixel-by pixel t test (without scaling) comparing both groups (13 vs. 13) in SPM2, 
showed several clusters, mainly located in temporal and frontal regions, in which the 
tracer uptake (VT) was lower in the patient group, Pfdr = 0.028 (see table 4.2). The 
largest cluster measured 52 cm3, including predominantly temporal lobes, reaching 
from the precentral gyrus to cerebellum and to the parietal lobes. The other large 
cluster (36 cm3) included the prefrontal cortex (see fig. 2). The clusters that reached 
statistical significance overlapped to a great extent with the area’s found in the ROI-
analysis. Length of present episode (in weeks), HAMD scores, number of previous 
episodes, allelic variation of MDR-1 polymorphisms 3435C>T and 2677G>T, diagnosis 
and administered verapamil activity as covariates in ANCOVA had no significant effect 
as confounder on the results.  
 











52.8 0.028 3.66 -38  -2 -10 left temporal lobe, gray matter 
 0.028 3.62 -12  -6   8  left thalamus, ventral anterior nc.  
 0.028 3.40  28  12 -24  right temporal lobe,  superior temporal gyrus 
35.6 0.028 3.64  44  26  22 right frontal lobe middle frontal gyrus 
  3.37 -20  46  22 left frontal lobe, superior frontal gyrus 
8.0 0.028 3.37 -42 -52 -18 left cerebellum 
1.5 0.028 2.83  -4 -62  4 left occipital lobe, lingual gyrus 
4.3 0.028 2.81  -6 -26  48 left frontal lobe, paracentral lobule 
 
characteristics of significant clusters in SPM2  




A subanalysis of the 10 patients with major depressive disorder (MDD) was also done. 
The subset was compared to a matched subset of our control group both at ROI level 
and in a voxelwise analysis in SPM2. The results in the voxelbased approach indicated a 
somewhat stronger decrease in VT compared to the control group. A large cluster (240 
cm3, PFDR=0.016, T max=4.83) was found, comprising mainly temporal lobes and frontal 
cortex (data not shown). The VT in ROI whole brain was also significantly lower than 
in the matched control group (0.75 ± 0.25 (controls) vs. 0.55 ±0.08 (MDD);  p=0.030). 
The results on ROI level for selected are shown in figure 4.1.  
 
Finally, we compared the subgroup of patients with a treatment resistant depressive 
episode (n=7) to a matched subset of our control group. This comparison gave 
comparable results in both the voxelbased and pixelbased approach to the analysis of 
the whole group (n=13), yielding a significant decrease in VT both on ROI level and on 





T-test comparison of the two groups at selected regions of interest.  Distribution 
Volume (VT) (mean  (○) and standard deviation (I) are shown in regions relevant for 
depression. amyg = amygdalae; hipp = hippocampus; cing = anterior cingulate cortex; pfc = prefrontal 
cortex; temp = temporal lobes; c = control group; d = patient group with a depressive episode (n=13); MD 
= subgroup (n=10) of patients with a major depressive disorder. Both patient groups showed a significant 




This study shows a significantly lowered [11C]-verapamil uptake (distribution volume) 
in prefrontal cortex and temporal lobes in patients with a major depressive episode. The 
results of different methods of analysis were all in accordance with each other. In 
functional imaging studies the prefrontal cortex and temporal lobes have often been 
associated with MDD.30,31 To our knowledge this is the first study showing involvement 
of P-glycoprotein in medicated patients with major depressive disorder. Seven of  the 
13 patients studied were considered to be treatment resistant, most patients were 
admitted to a psychiatric hospital, indicating either a severe depressive episode or a 
chronic course of the illness. Although clinical parameters indicating treatment 
resistance or chronicity were not significant cofactors in ANCOVA, a significant 
decrease in VT (in temporal and frontal areas) was found in in a subset of patients with 
a treatment resistant depressive disorder (compared to a matched control group). 
 
Treatment resistance in depression may in fact be associated with increased P-gp 
function. Increased P-gp function may cause low uptake of antidepressants. Similar to 
treatment resistant epilepsy where increased expression of P-gp is associated with 
resistance to antiepileptics and poor prognosis,32,33 treatment resistance may also have 
influenced our results.  
Regional differences in VT may reflect localized regions of higher P-gp function, which 
may be under the influence of a functional polymorphism of MDR1. The SNP C3435T 
has been associated with altered P-gp function, albeit in an intestinal cell line,18 which 
does not necessarily reflect the P-gp expression in brain cells. However, the impact of 
genetic variations in the MDR1- gene on the course of major depressive disorder or the 
response on antidepressants is considered to be moderate or absent, and results are 
conflicting.34-38 The frequencies of the determined polymorphism in our study group 
did not differ from the frequencies seen in the general population.29,38 
Our results may also be explained by a neuroinflammatory process. There is increasing 
evidence for the role of cytokines in the pathogenesis of depression. Inflammation 
results in the release of proinflammatory cytokines, acting as neuromodulator and 
accounting for most of the symptoms in depression.39,40 Experimental animal models of 
inflammation show that inflammation can influence P-gp expression and activity in 
different ways.14,15,41 Although a decrease in function and expression of P-gp seems to 
be the case in acute inflammatory models, the study by Tan and colleagues shows that 
P-gp function was increased after the acute inflammatory phase.42 The course of a 
depressive episode may be similar in such a way that in the chronic phase P-gp is 
upregulated.43 Post mortem studies are warranted to confirm these hypotheses. It is 
desirable that further (neuro-imaging) studies are conducted to shed light on the 
neuro-inflammatory events in major depressive disorder. 
  
 
Regional differences in VT might be explained by an increase in atrophy in cortical 
brain areas in major depression. However, the most consistent findings in studies using 
structural MRI is reduction in hippocampal volume44 and basal ganglia, whereas 
atrophy in frontal regions has been found less consistently. In contrast the most robust 
reduction in VT, in our study was seen in the temporal lobes for which atrophy has not 
been reported. The fact that no differences in VT were found in the hippocampus at 
ROI level may be due to spill-in of radioactivity of the adjacent choroid plexus, since is 
has been reported that there is a high accumulation of radioactivity in the choroids 
plexus.45  
 
A possible limitation of the present study is the fact that patients were treated with 
antidepressant medication. The increase in P-gp function in our study could be caused 
by the use of medication. Drugs or substances that are known to enhance the P-gp 
expression were all excluded in our study (see table 4.1). Many of the antidepressant 
and antipsychotic drugs used are substrates for P-gp, but their effect on P-gp activity is 
probably not clinically relevant.46-49  
Of several antidepressants and anticonvulsants it is known that they inhibit the P-gp 
pump in a concentration dependent manner in porcine brain cells.48-51  In in-vitro 
studies of antupsychotics inhibition of P-gp was only seen in concentrations above 
therapeutically relevant plasma levels, thus suggesting that the inhibitory effect of 
antipsychotics may not play a role in clinical practice.46,48  Recently, it was found that 
venlafaxine (used by three patients) can induce P-gp in human caco-2 cells.52 
Nevertheless, the implication of chronic use of antidepressant and/or antipsychotic 
drugs is however not known. It cannot be excluded that antidepressant and/or 
antipsychotic agents given for a sustained period lead to an up-regulation of the P-gp 
pump.  To rule out this possibility, future studies in medication-naive patients are 
needed.  
 
In addition to a possible effect on P-gp function, medication may also have influenced 
the metabolism of [11C]-verapamil. It is known that anticonvulsants influence [11C]-
verapamil metabolism, probably through induction of cytochrome P450.53 Two of our 
patients were on valproic acid. Leaving these 2 patients out of the analysis of difference 
to the results. Medication may also have influenced the free fraction of [11C]-verapamil, 
leading to a lower VT effect in the patient group. The influx parameter (K1) suggested 
no difference between the two groups, due to a large variance. The fact that only 
certain areas (i.e. temporal lobes and prefrontal cortex) showed a significant decrease in 
VT cannot be explained in this way.   
    
  
In the present study no analysis of metabolites was performed. Although this can be 
seen as another limitation of the study, we assume that the total contribution of 
metabolites, that contribute to the PET- signal, but have no affinity for the P-gp pump, 
is small. Only the N-demethylated fraction (so called polar fraction) has no affinity for 
P-gp.54,55 As Lubberink et al. have shown the “one tissue compartment” model gives an 
excellent fit of the data, irrespective of metabolite input.54 Their data indicate that the 
contribution of the polar fraction to the brain signal is small. It can however not be 
excluded that chronic use of antipsychotic and antidepressant agents may have 
influenced the metabolism of [11C]-verapamil, thereby reducing brain uptake of the 
radiotracer in patients. However, the fact that a decrease in VT is only seen in specific 
areas can probably not be attributed to the metabolites of [11C]-verapamil.  
 
In summary, in our PET study using [11C]-verapamil as a tracer, we have found 
evidence for an increased function of P-gp in patients with a major depressive episode 
under long term treatment conditions, which for the first time may provide an 
explanation for treatment resistance in patients suffering from major depressive 
disorder. 
 
Figure 4.2  
 
T-map showing a diminished Distribution Volume of [11C]-verapamil in 13 patients 
with a depressive episode compared to the healthy control group (n = 13). The clusters 
that reached statistical significance in a voxel-wise t- test (pFDR < 005) (in SPM2) are 
shown. (A) significant projections on a glass brain. (B) MRI-overlay: a large cluster 
located in frontal cortex, left and right temporal lobes, as well as subcortical nuclei is 
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Abstract 
P-glycoprotein (P-gp), a major efflux pump in the Blood-Brain Barrier (BBB) has a 
profound effect on entry of drugs, peptides and other substances into the central 
nervous system (CNS). The brain permeability can be negatively influenced by 
modulation of the transport function of P-gp. Inflammatory mediators play a role in 
schizophrenia, and may be able to influence the integrity of the BBB, via P-gp 
modulation. 
We hypothesized that P-gp function in the BBB is changed in patients with 
schizophrenia. Positron-emission tomography was used to measure brain uptake of 
[11C]-verapamil, which is normally extruded from the brain by P-gp. We found that 
patients with chronic schizophrenia using antipsychotic drugs compared to healthy 
controls showed a significant decrease in [11C]-verapamil uptake in temporal cortex, 
basal ganglia and amygdalae, and a trend towards a significant decrease was seen 
throughout the brain. The decrease of [11C]-verapamil-uptake correlates with an 
increased activity of the P-gp pump. Increased P-gp activity may be a factor in drug 







 In schizophrenia, the pathological mechanism, leading to an illness affecting all 
domains of behavior, remains unknown. Several authors have tried to correlate the 
structural and functional brain abnormalities in schizophrenia with alterations in the 
blood-brain barrier (BBB).1-3 
In normal circumstances, the BBB is an important factor in the protection of the brain 
against harmful environmental influences. The endothelial tissue forming the BBB 
exhibits very low permeability and expresses enzymes and efflux pumps, further 
limiting the passage of drugs, peptides and proteins.  
There are strong indications for an impaired integrity of the BBB in schizophrenia,3 
such as increased intracerebral concentrations of the soluble intercellular adhesion 
molecule-1 (sICAM-1) and Very Late Antigen-4 (VLA-4) in schizophrenia have been 
reported.2 Furthermore, the content of immunoglobulin and albumin is raised in 
cerebrospinal fluid in 30% of patients with schizophrenia. The increased permeability 
facilitates the penetration of inflammatory cells or the invasion of infectious pathogens, 
thus causing damage to the brain.1,4  
 
An important element of the BBB that is increasingly recognised as a gate keeper of the 
brain, P-glycoprotein (P-gp), which is an efflux pump, limiting the entrance of many 
structurally divergent lipophilic molecules, such as peptides and many of the drugs 
used in psychiatry and neurology.5,6 P-gp is encoded by the ABCB1 gene (ATP-binding 
cassette, sub-family B, (previously MDR-1, or Multi Drug Resistance gene). Genetic 
variants of ABCB1 have been proposed as potential susceptibility factors for 
schizophrenia and several brain diseases and as determinants of treatment response to 
antipsychotic drugs.7-9 Furthermore, the protective role of the BBB may be 
compromised in schizophrenia due to a inflammatory or to a neurodegenerative 
process.10 The activity of P-gp may be influenced bidirectionally by inflammatory 
reponses.11 Moreover, P-gp function is reported to be decreased in the progression of 
neurodegenerative diseases.12 However, no direct evidence is available for a 
dysfunction of P-gp in schizophrenia.  
The activity of P-gp at the BBB can be studied in vivo by neuroimaging techniques 
such as PET with [11C]-verapamil as PET-tracer.13 It appears to be a suitable 
methodology for the in vivo assessment of P-gp functionality in humans, and allows 
the quantification of BBB-P-gp function in neurodegenerative diseases.14-16 In this 
preliminary study we performed positron emission tomography (PET) brain imaging of 
P-gp with [11C]-verapamil as radiotracer in schizophrenic patients and healthy controls.  
We hypothesized that P-glycoprotein function would be altered in dorsolateral 
prefrontal cortex, amygdala, thalamic nuclei, temporal areas as well basal ganglia since 
these areas are known to play a role in schizophrenia.17-20 We further hypothesized that 
  




Materials and methods 
  
Subjects 
Ten patients suffering from schizophrenia, paranoid type, were recruited and 
participated in the study. All underwent a Mini International Neuropsychiatric 
Interview (M.I.N.I. plus 5.0.0., Dutch Version, 2000) for DSM-IV and fulfilled the 
criteria for schizophrenia, paranoid type.21 Inclusion criteria for subjects with 
schizophrenia were 1) age 18-65 years; 2) fulfilment of the DSM-IV criteria for 
schizophrenia; and 3) capacity to give informed consent. Exclusion criteria were 1) use 
of known P-gp modulating agents (cardiovascular drugs, antimalarial drugs, 
cyclosporine A, phenothiazines, hormones (eg. tamoxifen), certain antibiotics such as 
cefoperazone, ceftriaxone, erythromycine);22 2) any somatic disease of kidney, liver, 
heart or brain; 3) history of traumatic brain damage; 4) electroconvulsive treatment in 
the past three months; 5) abnormalities at clinical (incl. neurological) and laboratory 
examination; 6) pregnancy. This research was approved by the Ethics Committee of the 
University Medical Centre Groningen, and all subjects gave written informed consent 
according to the Declaration of Helsinki. 
For all patients a PANSS (Positive And Negative Symptom Scale) was done at the time 
of the PET study.23 All were in good physical health and none had meaningful 
laboratory abnormalities. The inclusion and exclusion criteria for healthy controls were 
similar. In addition, the healthy controls as well as their first degree relatives were 
required to have no history of any psychiatric disease, nor in their first degree relatives.  
Before the scan, blood was drawn from the venous canula for genotyping. Three 
common ABCB1 single nucleotide polymorphisms (T129C, G2677T/A and C3435T) 
were detected using a PCR-RFLP-method (polymeric chain reaction - restriction 
fragment length polymorphism). 
 
Radiochemistry 
Racemic [11C]verapamil was produced as previously described.24 The injected 
radioactivity of [11C]-verapamil did not differ between control subjects (mean = 382 
MBq; SD = 20) and subjects with schizophrenia (mean 385 MBq; SD = 76). In all cases, 
specific activity was at least 16 Gbq/µmol. 
 
PET procedure  
We used an ECAT EXACT HR+ position camera (Siemens/CTI, Knoxville, TN). After 
the radiotracer injection of [11C]-verapamil serial dynamic PET scanning was 
  
performed at escalating time frames over a period of 60 minutes. Continuous arterial 
blood sampling to measure the activity of the radiotracer took place during the scan in 
order to define the input function. Manual samples (collected at intervals of 10 
minutes) were collected to calibrate the plasma and blood time-activity data. No 
metabolite analysis was done. Images were reconstructed in brain mode using an 
iterative reconstruction (Ordered Subsets - Expectation Maximization) with 4 iterations 
and 16 subsets and a Gaussian filter of 4 mm. The scans were performed in 3D mode. 
Regions of interest were traced using an computerized brain atlas (Talairach Daemon) 
(The Research Image Center UTHSCSA, University of Texas Laboratory, USA).  
  
Data analysis  
Image visualization and region of interest (ROI) analyses were performed using Clinical 
Applications Programming Package software (CAPP; CTI/Siemens PET Systems, 
Knoxville, TN). First, all images were transformed into a stereotaxic standard space. 
This normalizing spatial transformation matches each scan to the [11C]-verapamil 
template that was available from an earlier study of our group.15 Stereotaxic 
normalization of PET images allows comparison of scan data in identical pixels across 
different subjects and scans.  
The data were analyzed in three ways. First the data for the whole brain were 
compared between patients and controls. Then a-priori defined brain regions were 
tested with SPM2 and appropriate small volume correction. Finally, a hypothesis 
generating test was performed on all voxels using SPM2 and FDR correction. In all 
cases the Volume of Distribution (VT) was used as a measure for P-gp function.  
The multilinear implementation approach (MA1)25 of the Logan plot26 was used to 
determine VT with minimal bias. For the whole brain ROI analyses we additionally 
verified VT in a kinetic analysis (i.e. one-tissue compartment model).  Finally, using the 
one-tissue compartment model, the whole brain influx (K1) was calculated also. VT was 
calculated and its difference between patient group and control group was compared 
with t-tests and ANCOVA (analysis of covariance) with age as cofactor. Parameters in 
the patient group (different scores on PANSS scale, antipsychotic dose in Haloperidol 
equivalents (mg), number of previous episodes) were also considered as predictors in a 
regression analysis, or their correlation with VT was calculated.  
 
To test the a-priori defined brain regions, the VT images (based on the whole brain 
time-activity curve) were then analyzed with SPM2 (Statistical Parametric Mapping, 
2002). Based on the literature as cited above, we selected the following regions: 
prefrontal cortex, basal ganglia, temporal cortex, amygdalae and thalamic nuclei. These 
regions were defined using a single mask image encompassing all selected brain 
regions. Then small volume correction was applied to correct for the multiple 
comparison in the selected volume only. No scaling or global normalisation was 
  
performed to test absolute differences in VT. To adjust for differences in individual 
neuroanatomy and to improve the signal-to-noise ratio, a 12-mm full-width at half-
maximum Gaussian smoothing filter was applied to all images. The group comparison 
was made after age correction (ANCOVA). Using the PET model option ‘single 
subjects, covariates only’, measurement of a potential confound (number of previous 
episodes, antipsychotic dose (Haldol equivalents), PANSS score could also be 
determined.  
  
Finally, hypothesis generating tests were performed in SPM2. The same contrasts as 
mentioned above tested the main effect between the patient group and the healthy 





The patient group (10 males, mean age 43.9 years ± 16.9) was compared to a sex and age 
matched comparison group (mean age 43.0 ± 17.6 years). On the PANSS patients had a 
mean score of 12.9 (± 2.6) for positive symptoms 16.4 (±7.9) for negative symptoms and 
24 (± 6.2) for general symptoms. All subjects had suffered three or more psychotic 
episodes, the last episode within 6 months prior to the PET-scan. None had a comorbid 
psychiatric or somatic disorder. All subjects used antipsychotic medication at the time 
of scanning. Table 5.1 shows the demographic characteristics and medication use of the 
patient group. 
The mean brain time activity curves (TAC) (after correction for weight and injected 
dose) at brain ROI level of both groups were almost equal, the mean area under the 
curve (AUC) was not significantly lower for schizophrenia than for  the control group. 
The Logan curves of all subjects gave an excellent fit of the observed data. Correlation 
of calculated VT between the Logan method and the one tissue compartment model was 
excellent: Pearson’s coefficient was 0.906 (p<0.01).  The VT over the whole brain was 
lower in the patient group (0.47 ± 0.15) than in the control group (0.67 ± 0.26), 
although not significantly (t = 2.095; df = 18; p = 0.051); K1 was equal between the 
groups (controls: 0.046 ± 0.014; patients: 0.052 ± 0.023; p = 0.47). K2 showed large 
variation in the patient group (0.17 ± 0.23) (vs. controls: 0.07 ± 0.0071) and appeared 
not to be equally distributed (Levene’s test: F = 5.82; p = 0.027). In a nonparametric test 
k2 was significantly higher in the patient group (Kolmogorov-Smirnov Z = 1.565; p = 
0.015). None of  the parameters (i.e. Haldol equivalents, number of previous episodes, 
PANSS scores) correlated with VT or K1 in the patient group, neither a significant effect 
in a linear regression model (ANOVA) was found. Additionally, we corrected the data 
for age (with ANCOVA), since the age variation in the sample was large. In the age 
  
corrected model, with VT as dependent variable, the significant trend was lost (F=2.25; 
p=0.136), age explained 21% of the variance in the sample. No correlation between age 
and controls (Pearson ρ=0.05; p=0.89) or patient group (ρ=-0.35; p=0.32) was found, 
however. 
 
In SPM2 the a priori hypothesis was performed with ANCOVA (with age as cofactor) 
for the selected areas (temporal cortex, prefrontal cortex, amygdala, basal ganglia and 
thalami). Significant clusters, showing a lower VT in the patient group,  were found in 
the temporal cortex (PFDR = 0.032), basal ganglia (PFDR = 0.019), amygdala (PFDR = 0.028), 
but not in thalamus (PFDR = 0.108), and prefrontal cortex (PFDR = 0.076). More details are 
shown in table 5.2. No significant effect of the cofactors (PANSS, number of previous 
episodes, antipsychotic dose) were found in SPM2 (option ‘single subject, covariates 
only’). A hypothesis generating analysis (ANCOVA, age as cofactor) comparing both 
groups showed  1 large cluster and two clusters of modest size, with a significant trend 
at voxel level (PFDR = 0.094), clusters involving many areas throughout the brain, in 
particular the temporal lobes, limbic lobes (right temporal lobe, 25.3 cm3 and left 
temporal lobe 17.2 cm3), the left parietal lobe (10.2 cm3) basal ganglia, and to less extent 
smaller areas in the frontal lobes (see figures 1a and 1b). The areas represent a (trend to 





T-map showing a diminished a trend towards a decreased Distribution Volume of 
[11C]-verapamil in 10 patients with schizophrenia, a depressive episode compared to 
the healthy control group (n = 13). compared to 10 healthy controls in sagital, coronal 
and axial directions. The clusters of voxels at PFDR  = 0.09 (in SPM2)  are shown. 
(A): projections on a glass brain 
(B) MRI-overlay:  clusters located in (fronto)temporal and parietal lobes, as well as 




Characteristics of subjects with schizophrenia 
NE = Number of previous Episodes; Rem. (months): number of months in remission since last psychotic 
episode; PANSS = Positive and Negative Symptoms Scale (Sheehan et al., 1998); P,N,G = scores on  
symptom scales for Positive, Negative, General symptoms; Medication: oral dosis in mg per day. Cloz = 
Clozapine; Hal = Haloperidole; Ris = Risperidone; Parox = Paroxetine; Cital = Citalopram; Tem = 











T-value (max) PFDR 
Temporal cortex 40.7 2.76 0.032 
Thalamus 12.5 2.59 0.108 
Basal ganglia 4.6 2.72 0.019 
amygdalae 1.4 2.38 0.028 
PFC 32.1 3.04 0.076 
characteristics of most significant clusters of the selected volumes of interest in  SPM2  
PFC =  prefrontal cortex; PFDR= (false discovery rate) corrected p-value 
Subject 
No 











1 44 19 >5 3 14,20,38 Ris IM 50,Cloz 200, 
Parox 20 
2 45 23 >5 12 16,9,24 Ris 2 
3 40 21 >5 4 11,21,20 Cloz 300, Tem 20 
4 35 24 5 6 10,6,19 Ris 6 
5 40 25 >5 10 12,13,20 Cloz 300 
6 23 18 4 8 13,13,21 Olanz 20 
7 31 22 >5 3 16,28,22 Olanz 10 Cital 20 
8 34 19 5 9 15,27,30 Ris 4, Parox 20 
9 34 30 3 6 9,11,21 Olanz 20 Zuclo 20 
  
Genetic Polymorphisms 
Three common ABCB1 single nucleotide polymorphisms (SNP) (-129 T >C (exon 1), 
2677 G> T/A (exon 21) and 3435 C> T (exon 26)) were determined in the patient group. 
For the SNP 3435 on exon 26 the allele frequencies in the patient group were CC 33%; 
CT  44% and TT 22%. For the SNP 2677 allele frequencies were 33% GT, 44% GG, 22 
% TT. The frequencies of the combination of 2677GG/3435CC was 33%. The allele 
frequencies of the SNPs 3435 and 2677 in our subjects were not different from the 
frequency in the population.27,28 Of  SNP 129T>C the allele frequency was found to be 





This study shows regionally decreased [11C]-verapamil uptake in temporal cortex, 
amygdalae and basal ganglia in patients with schizophrenia compared to healthy 
controls. Our study group consisted of 10 patients with chronic paranoid 
schizophrenia, all having suffered at least three psychotic episodes with residual 
symptoms. All used antipsychotic drugs. The results of different methods of analysis 
were in accordance with each other, showing a trend towards a significant decrease in 
VT in patients with schizophrenia, which is interpreted as an increase in P-gp function, 
since differences in influx were not found. Moreover, a higher efflux was found at 
whole brain ROI level. To date, this is the first time evidence has been obtained 
explaining a relationship between a functional change of the efflux pump in medicated 
patients with schizophrenia. 
 
Our findings may be of great value since an increase in P-gp function may be relevant 
for the clinical course in schizophrenia. Increased P-gp function causes low uptake of 
antipsychotic agents and may thus be associated with poor treatment outcome. In 
oncology P-gp upregulation is coupled to tumor resistance to chemotherapy and poor 
prognosis.29 An increase of P-gp function in the BBB may be correlated with a more 
chronic course of schizophrenia. Our results may at least partially explain why often 
lower antipsychotic doses suffice in first episode patients.  Abnormalities in the 
amygdala, basal ganglia and temporal cortex are consistent with available evidence, 
that suggests that the pathological process in schizophrenia affects many areas.18 An 
open question is how and why P-gp function is regionally increased in schizophrenia, 
and what the treatment consequences can be of a regionally increased P-gp function.   
A possible association with an increased expression or activity of (cerebral) P-gp in 
schizophrenic patients may be a functional polymorphism of ABCB1. The frequencies 
of the determined polymorphisms in our study group did however not differ from the 
frequencies seen in the general population,28 although no definitive conclusions can be 
  
drawn due to the small sample size. There are reports of great variation in the 
expression of P-gp,30,31 but P-gp expression does not necessarily reflect activity.32 The 
best studied SNP is C3435T and although it has been associated with altered P-gp 
function,33 the results of different studies have been discordant.34 It has been suggested 
that ABCB1 haplotypes should be analyzed in stead of SNPs.8,34 However, the impact of 
genetic variations in the ABCB1 gene on pharmacokinetics and pharmacodynamics of 
P-gp substrates is considered to be moderate.8,35  
 
The local P-gp increase found in our study may also be explained by a 
neuroinflammatory or a neurodegenerative process. Studies that focus on cytokine 
production in schizophrenia patients show that pro-inflammatory cytokines are 
actively involved,36,37 and models of acute neuro-inflammation in cell lines show that 
several pro-inflammatory cytokines can reversibly inhibit P-gp function and its 
expression.32,38,39 However, P-gp-activity and expression appears to be increased after 
the acute phase.11,40 TNF appears to exert both an acute pro-inflammatory as well as a 
neuroprotective effect through different receptor subtypes.41,42 A functional change in 
P-gp activity may also fit in a neurodegenerative hypothesis of schizophrenia, with 
long-term alterations in blood–brain barrier permeability after inflammatory events in 
early life.10 Tan et al. demonstrated an up-regulation of P-gp in a human BBB model 
following exposure to activated T-lymphocytes.43  
 
Another explanation for the increase in P-gp function in our study could be the use of 
medication that induces P-gp-function. All medication known to induce P-gp activity 
was excluded in our study.22 All of the patients used antipsychotic agents and three 
used an antidepressant as well (see table 5.1). Most of the psychotropic drugs used are 
known substrates for the P-gp pump.44-47 On the short term these drugs have shown to 
possess weak inhibitory effect on P-gp activity, which is probably clinically 
irrelevant.44,46 Although not used by any of the patients, in a [11C]-verapamil PET study 
we recently showed that P-gp function at the BBB is increased by chronic 
administration of venlafaxine.48  The use of medication is a limitation of the study. 
Besides a possible effect on P-gp function, medication may also have influenced the 
metabolism of [11C]-verapamil. Anticonvulsives for example are known to influence 
[11C]-verapamil metabolism, probably through induction of p450 cytochromes.49 Of 
antipsychotic agents this effect is however not known. Medication might also have 
influenced the free fraction of [11C]-verapamil, consequently leading to a lower effect 
in the patient group. On the other hand, the influx parameter K1 was not different 
between the two groups, indicating a comparable influx between the groups. Besides, 
the fact that only certain areas show a decrease in radio tracer uptake cannot be 
explained in this way. 
 
  
In our study no analysis of metabolites was done. We assume that the contribution of 
radioactive metabolites of [11C]-verapamil to the PET-signal, that has no affinity for the 
P-gp pump is small.  Only the N-demethylated fraction (so called polar fraction) has no 
affinity for P-gp.50,51  The data of Lubberink c.s. indicate that the contribution of the 
polar fraction to the brain signal is small. It is however possible that chronic use of 
antipsychotic and antidepressant agents has had influence on metabolism of [11C]-
verapamil, thereby reducing brain uptake of the radiotracer in patients. The fact that K1 
showed no differences between the groups and the fact that differences are only seen in 
specific areas militate against the role of metabolites on the PET data.   
 
In summary, in this [11C]-verapamil-PET study evidence was found for local increase in 
P-gp activity in medicated schizophrenia patients. Our results shed new light on the 
pharmacokinetics of antipsychotic drugs in schizophrenia and offers an explanation for 
the occurrence of drug resistance in schizophrenia. The small study group may limit 
the evidential value of our findings. Future studies that focus on the role of P-gp in 
different phases of the disease in a larger study group without the confounding 
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Background: P-glycoprotein, an ATP-driven efflux pump in the blood-brain barrier, 
has a major impact on the delivery of antidepressant drugs in the brain. Genetic 
variants in the gene ABCB1 encoding for P-glycoprotein have inconsistently been 
associated with adverse effects. In order to resolve these inconsistencies, we conducted 
a study in a large cohort of patients with major depressive disorder with the aim to 
unravel the association of ABCB1 variants with adverse effects of antidepressants and 
in particular with SSRIs, which display affinity as substrate for P-glycoprotein. 
Method: The Netherlands Study of Depression and Anxiety (NESDA) study was used as 
a clinical sample. For 424 patients data were available on drug use, side effects. We 
selected six ABCB1 gene variants (1236T>C, 2677G>T/A, 3435T>C, rs2032583, 
rs2235040, rs2235015) and analyzed them for association with adverse drug effects 
using multinomial regression analysis  for both single variants and haplotypes.  
Results: Number of SSRI-related adverse drug effects was significantly associated with 
rs2032583C (p=0.002) and rs2235040A (p=0.001) and a haplotype containing the six 
variants (p=0.002). Moreover, both anticholinergic (e.g dry mouth, constipation, 
restlessness) and serotonergic effects (sleeplessness, gastrointestinal complaints, sexual 
effects, twitching) were significantly predicted by these variants and haplotype 
(p=0.002 to 0.011).  
Conclusion: Adverse drug effects with SSRI treatment, in particular anticholinergic and 




One of the major problems with pharmacotherapy of major depressive disorder (MDD) 
is the lack of predictive clinical variables in the occurrence of unpredictable adverse 
drug reactions, often leading to a prolonged treatment course. An important aspect in 
this regard is the ability of a drug to pass the blood-brain barrier.   
P-glycoprotein (P-gp) is an ATP-driven efflux pump, predominantly located at the 
luminal side of the brain capillaries.1 P-gp has an unusually broad capacity to recognize 
and expel hundreds of molecules from the brain, including many antidepressant drugs.2 
The processes involved often exhibit considerable interindividual variability, which 
may be genetically determined. P-gp is a member of the ATP-binding cassette (ABC) 
superfamily and is encoded by the ABCB1 gene, formerly denoted as MDR1 (multi-
drug resistance gene 1).  
 
Animal studies have shown that penetration of several antidepressants depends on the 
functionality of P-gp at the blood-brain barrier.3-6 By affecting plasma levels and 
intracerebral concentration, altered P-glycoprotein function or expression may cause 
adverse drug effects and ultimately influence therapeutic response.   
Most studies that analyzed the relation of ABCB1 gene variants with antidepressants 
have focused on treatment response, with contradictory results.7-13  Analysis of 
antidepressants related adverse drug effects in relation to ABCB1 polymorphisms has 
not been studied extensively so far. Of the three studies to date, one study focused on a 
single drug effect (postural hypotension in nortriptyline use (n= 8) in a relatively small 
sample (n = 78).14 In another small sample study (n=55) antidepressant-induced switch 
to mania was studied in 26 users of various antidepressants, without taking account of 
the differential affinity of antidepressants for the P-gp pump.15 Peters et al. used a large 
sample (STAR*D, n=565) of MDD patients using citalopram and found no association 
between 3 single nucleotide polymorphisms (SNPs) (3435C>T, 2677G>T or 1236C>T) 
and ‘tolerance’ to citalopram. ‘Tolerance’ was considered when subjects continued with 
citalopram until the end of study period while patients who left the study at any time 
due to side effects, were defined as ‘intolerant’.   
 
Conflicting results may result from small sample sizes and thus limited statistical 
power. The present study uses data from a Dutch cohort of 424 depressed patients using 
selective serotonin reuptake inhibitor (SSRI), and examines whether related adverse 









NESDA is a longitudinal, naturalistic cohort study examining the course and 
consequences of depressive and anxiety disorders. The collection and genotyping of the 
NESDA sample has been described elsewhere.16 In brief, 2981 participants were 
recruited through mental health care organizations (n=807), the community setting 
(n=564) and  primary care (n=1610). They were assessed using the Composite Interview 
Diagnostic Instrument (CIDI) to diagnose depressive and anxiety disorders according to 
the Diagnostic and Statistical Manual of Mental Disorders – Fourth Edition (DSM-IV-
TR). The interview also provided information on age of onset, number of MDD 
episodes, and specific symptoms of depression. At baseline, detailed assessment was 
made of psychopathology using different inventories and scales. Many other data were 
collected including sociodemographic data and health indicators.  
At the two-year follow up assessment phenotypic data concerning course of the current 
or previous depressive episodes were gathered. Medication use was assessed based on 
drug container inspection of drugs used and coded using the Anatomical Therapeutic 
Chemical (ATC) classiﬁcation.17  Use of antidepressants was considered when taken at 
least 50% of the time and included selective serotonin reuptake inhibitors (ATC-code 
N06AB). Antidepressants were categorized into SSRIs with known substrate affinity for 
P-glycoprotein (i.e. citalopram, paroxetine, venlafaxine, fluvoxamine, sertrailine). All 
other non-SSRI antidepressants were left out of the analysis (i.e. tricyclic 
antidepressants, St. John’s Wort, lithium, MAO inhibitors) as well as SSRIs without 
affinity for P-gp, or without compelling evidence for the opposite (i.e. fluoxetine, 
bupropion, nefazodone, trazodone, mirtazapine, duloxetine,).2,4-6,18-20 Subjects using co-
medication with a strong modulatory effect on P-gp function, such as calcium blocking 
agents, protease inhibitors, cardiac glycosides, ketoconazole, methotrexate, 
quinidine,21,22 were excluded from the analysis. 
 
Adverse drug effects 
The questionnaire on “side effect of psychotropic medication” provided a self-reported 
inventory of psychotropic medication (type, frequency, dosage, duration), treatment 
response and adverse side effects data.  Adverse drug reactions (ADRs) were measured 
at the 1-year and 2-year follow-up. ADRs were reported as ‘present’ or ‘absent’. The 
ASEC-12 self report questionnaire, a short version of the Antidepressant Side Effect 
Checklist, was constructed for NESDA. Recently, the ASEC-21 has been validated 
against the UKU Side Effect Rating Scale, a semi-structured interview by a health 
professional.23,24 The ASEC-12 specifically asks for the presence of 12 ADRs, which 
have been related to antidepressants: sleeplessness, sleepiness during day time, 
restlessness, twitching/muscle cramps, dry mouth, transpiration, sexual side effects, 
  
nausea, constipation, diarrhea, weight gain and dizziness). In addition, participants 
were asked to add other side effects, not covered in the inventory. Side effects were 
also grouped and defined as either ‘anticholinergic’ (i.e. restlessness, constipation, dry 
mouth), ‘serotonergic’ (i.e. diarrhea, sexual side effects, twitching, nausea, 
sleeplessness) or ‘histaminergic’ (sleepiness during the day, weight gain). 
Antidepressants were categorized into SSRIs with known substrate affinity for P-
glycoprotein (i.e. citalopram, paroxetine, venlafaxine, fluvoxamine, sertraline). All 
other non-SSRI antidepressants were left out of the analysis (i.e. tricyclic 
antidepressants, St. John’s Wort, lithium, MAO inhibitors) as well as SSRI’s without 
affinity for P-gp, or without compelling evidence for the opposite (i.e. fluoxetine, 
bupropion, nefazodone, trazodone, mirtazapine, duloxetine).2,4-6,18-20 Sertraline was 
categorized as a SSRI with P-gp affinity based on high in vitro affinity.20  
 
SNP selection and genotyping  
A selection of six single nucleotide polymorphisms (SNPs) was made on the basis of  
positive reports in the existing literature8,10,25,26.  This included the three common 
coding SNPs 3435C>T (rs1045642), 2677G>T/A (rs2032582) and 1236T>C (rs1128503) 
and three non-coding SNPs (rs2235015, rs2032583 and rs2235040) that were associated 
with treatment response to antidepressants.11,12 The genotypic data were obtained from 
the genome-wide association study.27 These data were subjected to rigorous quality 
control criteria.28 None of the six SNPs was directly genotyped, but estimated genotype 
probabilities were obtained through imputation.29 The quality of imputation was good 
(p=0.93) for 3435C>T and excellent (p=0.99-1.00) for the other SNPs. More details are 
presented in table 6.1.  ‘ 
 
Table 6.1 
Major characteristics of all single nucleotide polymorphisms 
* Position from NCBI Genome build 36, release 22 
 
Covariates and exclusion criteria 
We excluded 16 participants who used medication with a strong inhibitory effect on P-















3435 rs1045642 86976581 C/T 0.444 0.93 coding exon 27 
2677 rs2032582 86998554 G/T 0.577 0.99 coding exon 22 
1236 rs1128503 87017537 C/T 0.579 1.00 coding exon 13 
 rs2235015 87037500 G/T 0.793 0.99 Intron 5 
 rs2235040 87003686 A/G 0.134 0.99 intron boundary 
exon 21 
 rs2032583 86998497 C/T 0.134 1.00 intron 22 
  
ketoconazole, methotrexate, quinidine)21,22 were excluded from the analysis. The group 
of subjects using statin drugs (e.g. simvastatin, ATC codes: C10AA01-C10BA02)) (n=42) 
was considered large enough to include statin use in all analyses as a covariate. The 
variables ‘age’ and ‘gender’ were also included in each analysis as covariates, since these 
variables have an impact on the side effect profile of antidepressants.30,31   
 
Statistical analysis 
Hardy–Weinberg equilibrium was evaluated by χ2 statistics. No SNPs were found to 
violate Hardy-Weinberg equilibrium using a Bonferroni-corrected threshold. 
Multinomial logistic regression analysis was conducted for SSRI-related adverse effects 
divided in three groups, namely 0, 1-3 and 4-12 adverse effects, with allele dosages of 
the SNPs as independent variable.  
A multinomial analysis was also done for aggregated groups of adverse drug effects (i.e. 
serotonergic, anticholinergic, histaminergic (see above)). Likewise, these variables were 
recoded into multinomial variables (0, 1, or 2 or more adverse effects). Furthermore, all 
adverse drug effects were tested as dichotomous variable (absent or present) in a 
logistic regression analysis, on possible associations with the polymorphisms that had 
shown an effect in the multinomial analysis. The analyses were carried out for the 
group of SSRI users (SSRIs with affinity for P-gp), as well as for paroxetine and 
citalopram separately, since these groups were large enough for analysis. Follow-up 
analysis with only the two SNPs that had shown an association in the multinomial 
analysis, were carried out for the three aggregated groups (i.e. anticholinergic, 
serotonergic and histaminergic) and 12 separate adverse drug effects. The 
(multinomial) regression analyses for the variables ‘histaminergic’ and ‘serotonergic’ 
was done with dichotomous variables, because too few cases (4 and 6) remained in the 
2+ group, making the validity of the model uncertain.  
 
Frequencies of the haplotypes containing the six SNPs were estimated using the 
following randomization procedure. For each individual and each SNP a genotype was 
assigned randomly five times from its imputed genotype probability distribution. Next 
for each randomized set the software package PHASE was used to estimate haplotype 
probabilities for each individual.32,33 The haplotype probabilities were aggregated and 
frequencies of the 64 possible haplotypes were calculated.32,33 For each of the four 
haplotypes with a frequency of >10%, haplotype dosage (i.e. the estimated number of 
haplotypes in an individual) was determined for every individual using the estimated 
haplotype probabilities like is done for Haplotype Trend Regression analysis.34 
Haplotype analysis was performed using multinomial or logistic regression analysis 
similar to the single SNP analyses described earlier. In addition, we used these 
frequencies to estimate linkage disequilibrium (LD) of each pair of SNPs. Given the 
  
strong LD for two SNP pairs (2677G>T/A-1236T>C: r2 = 0.88 and rs2235040-rs2032583: 
r2 = 0.98), the significance threshold was set at 0.0125 as a result of a Bonferroni 
correction for multiple testing. Statistical analyses were conducted using SPSS software 
version 16.0 (SPSS Inc., Chicago, Illinois, USA) and Microsoft Excel® 2003 (Microsoft 





The sample consisted of 504 SSRI users, of which 347 were current users and 157 had 
used an SSRI before. 16 were excluded because of use of comedication with a strong 
inhibitory effect on P-gp function. For 64 cases genotype or interview data were 
incomplete, and these were also excluded from the analysis. The remaining 424 cases 
were used for analysis. Details of the study sample are given in table 6.2. 
 
Adverse side effects 
For SSRI use, the most reported side effects were sexual dysfunction (19.0%), dry 
mouth (18.8%), sleepiness during the day (18.8%), weight gain (17.7%) and profuse 
sweating (14.5%). Gastrointestinal side effects were relatively infrequent: diarrhoea 
(3.8%), nausea (10.1%) and constipation (8.9%). Other reported side effects in the 
inventory were dizziness (14.1%), sleeplessness (7.5%), restlessness (6.5%) and muscle 
spasms or twitching (8.7%). For the SSRI users (n = 424), two SNPs were significantly 
associated with the number of side effects (rs2235040A: p = 0.002; OR= 2.32; and 
rs2032583C: p = 0.001, OR = 2.41), see table 6.3. Sex and age had no significant effect as 
covariate in these analyses. Statin use had no significant effect in any of the analyses.  
 
Of the three groups of aggregated side effects, ‘anticholinergic’ ‘serotonergic’  and 
‘histaminergic’, the two SNPs were also significantly associated with both  ‘multiple’ 
anticholinergic effects: rs2235040A (p = 0.010; OR = 1.92), rs2032583C (p = 0.010; OR  
= 1.92) and ‘few’ serotonergic effects: rs2235040A (p = 0.005; OR = 1.85), rs2032583C (p 
= 0.002; OR  = 1.96). Male gender was strongly associated (OR = 1.96; p = 0.004) with 
more ‘serotonergic’ effects (containing the variable ‘sexual effects’), but not with  
anticholinergic (p = 0.053). No association was found with ‘multiple’ serotonergic 
effects, due to the fact that this group contained only 16 subjects. No associations were 
found with ‘histaminergic’ effects.  
 
The two SNPs were also evaluated as predictors of each single side effect in adjusted 
logistic regression analyses. The variable ‘sleepless’ was strongly associated with 
  
rs2235040A (p = 0.0003; OR = 2.93) and rs2032583C (p = 0.0003; OR = 2.95). The two 
SNPs were (after correction for multiple tests) not significantly associated with the 
occurrence of ‘constipation’ (rs2235040A: p = 0.047; OR = 1.85 and rs2032583C: p = 
0.049: OR= 1.84). Male gender was significantly associated with the occurrence of 
SSRI-related sexual side effects (p = 0.0003; OR = 2.63). There was a non significant 
association for use of statins (p = 0.064) for the variable ‘weight gain’. 
 
The two mostly used SSRIs in this study, paroxetine (n=151) and citalopram (n = 106), 
were separately tested for possible gene related side effects. For paroxetine, we found 
nominal significant associations between the two SNPs and ‘multiple’ anticholinergic 
effects (for rs2235040A: OR= 3.22; p = 0.034 and for rs2032583: OR = 3.28; p = 0.031), 
but these did not withstand multiple testing correction. No effects were found for 










Basic characteristics of the study sample 
 
Haplotype analysis  
Of the 64 haplotypes, covering the six SNPs used in the analysis (3435C>T-2677G>T/A-
1236T>C-rs2235015-rs2032583-rs2235040), we analyzed the four with a frequency higher 
than 10%: T-T-T-G-T-G (39%), T-G-C-G-T-G 14%, C-G-C-T-C-A, 13%, and C-G-C-G-
T-G, 22%. The haplotype C-G-C-T-C-A showed similar p-values for all the significant 
associations that we observed earlier for the two SNPs (see table 6.3). 
 
 
Subjects using  an SSRI (with P-gp 
affinity) (n) 
424 
sex (M:F) 133:291 
age (mean ± SD) 41.0 ±11.8 
citalopram (n) 106 
average dose (mg ± SD) 20.3 ± 8.53 
paroxetine (n) 151 
average dose (mg ± SD)  20.2 ± 5.17 
venlafaxine (n) 87 
average dose (mg ± SD)  107.0 ± 63.7 
fluvoxamine (n) 42 
average dose (mg ± SD) 69.7 ± 24.8 
sertraline (n) 38 
average dose (mg ± SD) 64.3 ± 23.0 
  
Table 6.3 
Single locus and haplotype results from multinomial and logistic regression analyses 
on   SSRI-related side effects Significance was assessed using multinomial and logistic 
regression analysis adjusted for sex, age and statin use, and odds ratio’s  including p-
values, are shown for minor allele carrier versus non-carrier. Bold values indicate 
significant results.  n.a. = not analysed because of too low numbers; P-gp = P-





Our results suggest that some ABCB1 polymorphisms might predict adverse side effects 
related to the SSRIs that have affinity for P-glycoprotein. Of the six SNPs tested, two 
intronic SNPs (rs2235040A and rs2032583C) and the haplotype C-G-C-T-C-A were 
 SSRI N  rs2235040A rs2032583C C-G-C-T-C-A 
 adverse effects (0 vs 1+) 1.61 (p = 0.051) 1.73 (p = 0.028) 1.63 (0.052) 
adverse effects (0 vs 2+) 2.32 (p = 0.002) 2.41 (p = 0.001) 2.35 (p = 0.002) 
anticholinergic (0 vs 1+) 0.781 (p = 0.41) 0.782 (p = 0.41) 0.813 (p = 0.41) 
anticholinergic (0 vs 2+) 1.92 (p = 0.011) 1.92 (p = 0.010) 1.92 (p = 0.011) 
serotonergic (0 vs 1+)*  1.85 (p = 0.005)* 1.96 (p = 0.002)* 1.93 (p = 0.005)* 
serotonergic (0 vs 2+) 1.88 (p = 0.16) 2.07 (p = 0.12) 2.08 (p = 0.12) 
histaminergic (0 vs 1+) 0.855 (p = 0.51) 0.85 (p = 0.50) 0.84 (p = 0.48) 
histaminergic (0 vs 2+) 1.88 (p = 0.089) 1.87(p = 0.094) 1.97 (p = 0.075) 
constipation 1.54 (p = 0.072) 1.55 (p = 0.66) 1.79 (p = 0.064) 
dry mouth 1.62 (0.046) 1.63 (p = 0.042) 1.69 (p = 0.052) 
sweating 1.34 (p = 0.27) 1.36 (p = 0.26) 1.33 (p = 0.31) 
restlessness 1.34 (p = 0.44) 1.35 (p = 0.43) 1.34 (p = 0.45) 
sleepless 2.93 (p = 0.0003) 2.95 (p = 0.0003) 3.12 (p = 0.0003) 
sleepiness 1.45(p = 0.12) 1.46 (p = 0.11) 1.53 (p = 0.083) 
weight gain 1.01 (p = 0.99) 1.00 (p = 0.99) 1.02 (p = 0.96) 
diarrhea 1.18 (p = 0.74) 1.21 (p = 0.71) 1.22 (p = 0.70)  
nausea 1.26 (p = 0.48) 1.41 (p = 0.29) 1.41 (p = 0.30) 
sexual 1.20 (p = 0.48)* 1.20 (p = 0.46)* 1.19 (p = 0.50)* 









dizziness 1.13 (p = 0.65) 1.23 (p = 0.44) 1.25 (p = 0.42 
 adverse effects (0 vs 1+) 1.45 (p = 0.36) 1.60 (p = 0.25) 1.45 (p = 0.36) 
adverse effects (0 vs 2+) 1.63 (p = 0.34) 1.76 (p = 0.23) 1.66 (p = 0.28) 
anticholinergic (0 vs 1+)  0.99 (p = 0.95) 0.98 (p = 0.96) 0.95 (p = 0.95) 
anticholinergic (0 vs 2+) 3.22(p = 0.034) 3.28 (p = 0.031) 3.27 (p = 0.033) 
serotonergic (0 vs 1+)  1.28 (p = 0.47) 1.36 (p = 0.38) 1.37 (p = 0.45) 
serotonergic (0 vs 2+) n.a. n.a.  n.a. 
histaminergic (0 vs 1+) 0.73 (p = 0.40) 0.76 (p = 0.46) 0.77 (p = 0.43) 
paroxetine 151 
histaminergic (0 vs 2+) n.a. n.a.  n.a. 
  
significant predictors  for the number of adverse side effects, and were in particular 
associated with serotonergic (especially sleeplessness) and anticholinergic effects. 
To date, this is the first study demonstrating a relation between the pharmacokinetic 
gene ABCB1 and adverse drug effects in SSRIs. The associations between the SNPs 
rs2235040 and rs2032583 and phenotype or clinical response, seem promising. In our 
study, the two SNPs were in near complete LD, thus representing the same 
information. Both SNPs have been associated with higher treatment response on 
antidepressants, that are transported by P-gp, in contrast to mirtazapine, which is not a 
substrate for P-gp.11,12 In these studies, the T-carriers of  rs2032583 were associated 
with poor treatment response, which may correspond with a higher level of adverse 
effects, as we found for the rs2032583 C-allele.   
Neither our study nor previous ones,11,12,35 found an effect of the SNPs 1236C>T, 
2677G>T/A and 3435C>T. These three SNPs have been the focus of many 
pharmacokinetic and disease related studies, with contradictory results, since these are 
common SNPs in the coding region of the ABCB1 gene.36 However, genetic associations 
of these SNPs with clinical phenotypes have largely been inconsistent.9,37 The 1236C-
2677G-3435C haplotype is one of the most frequently observed in most populations.37  
In fact, the C-G-C haplotype has been connected to altered P-gp functionality in 
several studies, but ABCB1 haplotype association studies have also been inconclusive so 
far.9,36 In our study the haplotype containing 1236C-2677G-3435C links to the 
rs2032583C and rs2235040A allele and both these single SNPs and the total haplotype 
of SNPs were associated with adverse drug effects. This implies that the haplotype 
association that was observed previously might be caused by the association of the two 
single SNPs rs2032583 and rs2235040, which are in almost complete LD with each 
other. The intronic SNPs rs2032583 and rs2235040 are non-coding SNPs, but might be 
linked to another functional variant. However, in the absence of replication of the 
findings in this report, and in the light of the many controversies on ABCB1 related 
gene effects so far, the conclusions need to be interpreted with care. 
 
One of the limitations of this study is the fact we have not controlled for all co-
medication. Many drugs have shown to posses some inhibitory or inductory properties 
in vitro, such as statins,38 antipsychotics or antidepressants,6 but their impact on P-gp 
function in vivo may be clinically irrelevant.5,6 Therefore, we only excluded co-
medication, for which clear evidence was available, with respect to P-gp inhibitory or 
inductory properties of a drug, e.g. antiretroviral or other immunosuppressive agents.39 
We controlled for statin use because this group was considered large enough to include 
in the analyses as a covariate. In none of the analyses, however, any interaction was 
seen. Interaction with other co-medication can however not be excluded. The gene 
  
effect that we found for the SSRIs with affinity for P-gp may not be valid for each SSRI 
to the same degree. The selected SSRIs have shown to have comparable substrate 
properties2,4-6 and moreover, substrate specific in vivo data on P-gp function is lacking.  
 
We found an association between SNPs in ABCB1 and serotonergic and anticholinergic 
activity. With respect to both receptor systems, there is no obvious relation (at least not 
for antidepressants) between serotonergic or anticholinergic activity and substrate 
affinity for P-gp or P-gp function. An explanation for the association with 
anticholinergic activity could be the overrepresentation of paroxetine (>35%) in the 
sample. Paroxetine exhibits higher anticholinergic activity than all other SSRIs.40 The 
fact that we did not find an association in the subgroup of paroxetine users may be due 
to the sample size.  
 
In conclusion, our results suggest that the number of adverse effects related to SSRIs, 
transported by P-glycoprotein, in particular serotonergic (especially sleeplessness) and 
anticholinergic effects, is associated with two intronic SNPs of the ABCB1 gene 
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Background: P-glycoprotein, an ATP-driven efflux in the blood-brain barrier, has a 
major impact on the disposition of antidepressant drugs in the brain. Gene variants of 
the encoding gene ABCB1 have inconsistently been associated with both treatment 
response, side effects and have been suggested as vulnerability factor for depressive 
disorders.  
Method: Data were from 1601 depressed patients of the  Netherlands Study of 
Depression and Anxiety (NESDA). We explored  a possible role of 6 ABCB1 gene 
variants (1236T>C, 2677G>T/A, 3435T>C, rs2032583, rs2235040, rs2235015) as 
susceptibility factors in the course of MDD. Susceptibility indicators of MDD (young 
age of onset, recurrent episodes, familial aggregation) were tested for their association 
with the 6 polymorphisms and haplotypes.  
Results: Of the possible susceptibility factors of MDD, ‘young age of onset’ was 
negatively associated with three SNPs rs2032583 (p = 0.005), rs2235040 p = 0.005), 
rs1045642 (p = 0.0015) and a haplotype (p = 0.006), indicating that the minor allele of 
these gene variants protected against early onset depression. Two haplotypes 
containing 1236T-2677T-3435T were significantly (p = 0.0065 and p = 0.010) 
associated with recurrent episodes. 
Conclusion: Some ABCB1 gene variants may indicate susceptibility for early onset and 
recurrent MDD.   
 
     




P-glycoprotein (P-gp) is an ATP-driven efflux pump, a product of the ABCB1 gene, and 
is located at the luminal side of the brain capillaries. Among efflux transporters at the 
blood-brain barrier, P-gp plays a dominating role, since it transports hundreds of 
chemically diverse molecules. The physiological role of P-gp at the blood-brain barrier 
involves the protection of the brain from blood borne xenobiotics. In major depressive 
disorder (MDD), P-gp has a tentative role in the disposition and pharmacokinetics of 
antidepressant treatment, as many antidepressants have affinity for this pump.1  
A protective role for P-gp in MDD may be less obvious, but its activity appears to 
decrease in specific brain regions with age, possibly indicating a role in 
neuroprotection.2 Besides, genetic variation may influence the vulnerability for a 
disease. For example, ABCB1 gene variants have recently been associated with higher 
risk of drug addiction.3 
The evidence for the involvement of the ABCB1 gene in MDD as a susceptibility factor 
is sparse. To date, two small studies have been published. In the first, a weak 
association (not corrected for multiple testing) between the 2677A allele and mood 
disorders has been described in a Japanese study of 62 subjects4 and secondly, two 
single nucleotide polymorphisms (SNPs) (rs1202184 and rs1922242) were related to 
severity of MDD in a Taiwanese study.5  
 
The relative risk for MDD is increased higher for first degree relatives of probands with 
MDD,6 but is further increased in probands with an age at onset below 30 years or with 
recurrent episodes.6-8 The subgroup with recurrent episodes and early onset is often 
considered as a narrow phenotype of MDD, with a higher relative risk for MDD, which  
may be 4-5 times higher than non recurrent, late onset MDD.9  The higher relative risk 
in probands with a recurrent early onset MDD increases the power to map 
susceptibility genes. 
 
With the availability of the NESDA data (Netherlands Study of Depression and 
Anxiety), a large study cohort with 1601 participants with a diagnosis of MDD, who 
had been selected for genome-wide genotyping, it is possible to examine SNP profiles 
within the ABCB1 gene that characterize  susceptibility factors in MDD.  
 
 
     





The NESDA is a longitudinal, naturalistic cohort study examining the course and 
consequences of depressive and anxiety disorders in 2981 participants. The collection 
and genotyping of the NESDA sample has been described elsewhere.10    
 
SNP selection and genotyping  
A selection of six single nucleotide polymorphisms (SNPs) was made based on positive 
reports in the available literature.4,5,11 This includes the three common coding SNPs 
3435C>T (rs1045642), 2677G>T/A (rs2032582) and 1236T>C (rs1128503)12 and three 
noncoding SNPs (rs2235015, rs2032583 and rs2235040) that were associated with 
treatment response on antidepressants.13,14 The genotype data were obtained from the 
original genome-wide association study.15  These data were subjected to a rigorous 
quality control criteria.16 None of the six SNPs was genotyped, estimated genotype 
probabilities and allele dosages were obtained through imputation.17 The quality of 
imputation was good (p=0.93) for 3435C>T and excellent (p=0.99-1.00) for the other 
















3435 rs1045642 86976581 C/T 0.444 0.22 0.93 coding exon 27 
2677 rs2032582 86998554 G/T 0.577 0.61 0.99 coding exon 22 
1236 rs1128503 87017537 C/T 0.579 0.71 1.00 coding exon 13 
 rs2235015 87037500 G/T 0.793 0.79 0.99 Intron 5 
 rs2032583 86998497 C/T 0.134 0.82 1.00 intron 22 
 rs2235040 87003686 A/G 0.134 0.82 0.99 intron boundary 
exon 21 
Major characteristics of all single nucleotide polymorphisms 
*Position from NCBI Genome build 36, release 22; c/o = coded allele versus other allele; 
HWE = Hardy-Weinberg equilibrium (p value) 
 
Baseline  and 2-year follow up data, collected between September 2004 and February 
2007, were used. 1601 cases with a lifetime MDD were included. Of those, 786 had 
experienced one episode and 815 had had more than one episode. For all cases 
genotype information was available.   
 
Three presumed indicators of susceptibility in MDD were examined in relation to the 
SNPs: ‘age of onset’ (defined as MDD starting before the age of 30)6 and ‘recurrence’, 
‘familial risk’ and ‘treatment course’. The variable ‘age of onset’ was analyzed as 
     
   
 
dichotomous variable (‘MDD starting before 30 years’ versus ‘starting after 30 years’ 
and as continuous variable. The variables ‘recurrence’ were (highly) skewed and 
therefore a multinomial variable was constructed. ‘Recurrence’ had four values (i.e. 0 (= 
first episode), 1, 2 and 3 (three or more recurrences). This classification was chosen, 
because three or more depressive episodes is often regarded as chronic depression, 
resulting in other treatment algorithms.18 The variable ‘familial risk’ indicated the 
number of first degree family members and had three values (0, 1 (1 or 2 family 
members) and 2 (≥ 3 family members). We did not construct a multinomial variable 
‘age of onset’, because this variable was normally distributed and besides, 
differentiation between ‘starting before 30 years’ and ‘starting after 30 years’ seemed 
most discriminant.6 Age and sex were used as covariate.  
 
Statistical analysis 
For the continuous variable ‘age of onset’ linear regression was used, and the other 
variables (dichotomous variable ‘age of onset’, ‘familial risk’ and ‘recurrences’ were 
analyzed with multinomial regression analysis with SNPs as independent variables. 
Frequencies of the haplotypes containing the all 6 SNPs were estimated using the 
following randomization procedure. For each individual and each SNP a genotype was 
assigned randomly five times from its imputed genotype probability distribution. Next 
for each randomized set the software package PHASE was used to estimate haplotype 
probabilities for each individual.19 Finally the haplotype probabilities were aggregated 
and dosages of the eight possible haplotypes were calculated (i.e. yielding eight 
variables). Haplotype analysis was performed for the three most common haplotypes 
with a frequency of >10% using linear or multinomial regression analysis, similar to the 
single SNP analyses described earlier. We also determined the haplotype frequencies of 
all 6 SNPs20 and used these frequencies to estimate linkage disequilibrium (LD) of each 
pair of SNPs. 
 
Given the complete LD for one SNP pair (see results), an adapted approach for multiple 
testing was applied,21 and the significance threshold was set at 0.0127. Statistical 
analyses were conducted using SPSS software version 16.0 (SPSS Inc., Chicago, Illinois, 




     




At baseline, 786 subjects had a first depressive episode and 815 had undergone one or 
more recurrences. The sample consisted of 1099 females and 502 males. Mean age of 
onset was 27.5 ± 12.3, the average age at the  time of the interview was 42.0 ± 12.5. Of 
the 1601, 366 had a negative (first degree) family history for MDD, 868 had 1 or 2 
affected family members, and 367 had more than 2 family members with MDD.  
 
Susceptibility factors of MDD 
‘Age of onset’ was significantly associated with rs2235040A (p = 0.005, beta = -0.070) 
and rs2032583C (p = 0.007, beta = -0.067), indicating that these carriers had a higher on 
onset of MDD at younger age. The subjects with MDD, who were carrier of 3435C or 
rs2235040A had a higher change on onset of MDD starting before 30 years (n = 889). 
The Odds ratio (OR) for 3435C carriers was 1.27 (p =0.0015) and for rs2235040A OR: 
1.31 (p = 0.01). In both analyses male sex was significantly associated with lower 
change on early onset (OR = 0.60; p = 0.00004). For none of the SNPs an association 
was found with either ‘recurrences’ or ‘family risk’. Results are presented in table 7.2.  
 
Haplotype analysis  
The r2 values between the different SNPs were high for 2677-1236 (r2 = 0.88), 
suggesting strong LD. rs2235040 and rs2032583 (r2 = 0.98) demonstrated nearly 
complete dependency. The other r2 values ranged from 0.10 to 0.56.  Five haplotypes 
containing the three most common coding SNPs (1236C>T-2677G>T/A-3435C>T-
rs2235015-rs2032583-rs2235040) and capturing a large proportion of the observed 
haplotypes12 had an observed frequency of >5 % and were examined in relation to the 
examined variables. The frequencies of the different haplotypes were: C-G-C-G-T-G 
(22%), T-T-T-G-T-G (39%), T-G-C-G-T-G (14%), C-G-C-T-T-G (6.4%) and C-G-C-T-
C-A (13%), which (pertaining to the 1236-2677-3435 haplotype) were comparable to 
the frequencies reported in the literature.12 The C-G-C-G-T-G and C-G-C-T-T-G 
haplotypes appeared significantly associated with ‘recurrence’ (p = 0.010 and p = 
0.0065).  
No association was found with 2 or more recurrences, which was not related to power, 
the numbers of subjects with 1,2 of 3 and more episodes were comparable (1 
recurrence: 257; 2 recurrences: 227 and ≥3 recurrences: 328 subjects). Age had a 
negligible effect (OR = 1.02; p = 0.002) and sex had no effect.  The haplotype C-G-C-T-
C-A was significantly (negatively) associated with continuous age of  onset of 
depression (beta = -0.068; p = 0.006), as well as with ‘MDD starting before 30 years’ 
(OR = 1.31; p = 0.012), with lower risk for male gender (OR = 0.60; p = 0.00004). The 
haplotypes T-T-T-G-T-G and C-G-C-G-T-G showed a non significant association with 
     
   
 
intermediate family risk (p = 0.027) and low familiy risk (p = 0.049), respectively (see 




In the present study we found significant associations between several polymorphisms 
of the ABCB1 gene and onset of MDD before 30 years (rs2235040A: OR= 1.3, p = 0.01; 
3435C: OR = 1.3, p = 0.0015) or onset of MDD at younger age (rs2032583C; beta = -
0.07, p = 0.007; rs2235040A: beta = -0.067, p = 0.007). For the haplotype C-G-C-T-C-A 
comparable associations with age of onset were found. Furthermore, the haplotypes C-
G-C-T-T-G (OR = 1.7, p = 0.0065) and C-G-C-G-T-G (OR = 0.71; p = 0.01) were 
associated with recurrent  MDD. These results suggest that several polymorphisms and 
a haplotype of the ABCB1 gene may either predict onset of MDD at younger age (or 
before 30 years) and recurrence of MDD.  
 
The differences we found in ABCB1 gene variation between the group with first 
episode MDD and those with one recurrence, as well as between those with an early 
onset may indicate a relation between the ABCB1 gene and an unfavourable course of 
the disorder or severity. It is unknown whether the studied ABCB1 polymorphisms are 
also connected to increasing the risk for MDD, since we did not compare between 
MDD phenotypes and control cases. In respect to recurrent MDD it is unclear why no 
gene effect is seen for the groups with two or more recurrences, but is conceivable that 
other (gene) effects interfere with a possible adverse effect of ABCB1 gene variants.   
 
Higher remission percentages for rs2235040A and 2232583C carriers were found for 
MDD patients treated with an antidepressant with P-gp substrate properties.13,14 In a 
recent study (de Klerk et al., unpublished observations) we found an association 
between these SNPs and SSRI-related adverse effects. No effect on treatment response 
for these genes was found for duloxetine,22 which is probably not a P-gp substrate. The 
results for SNP 3435C>T as predictor of treatment response have been discordant, only 
one study describes a higher remission rate in treatment with either paroxetine, 
venlafaxine, or (es)citalopram for C-carriers (haplotype including 3435CC).5,11,13,14,23,24   
A possible link between early onset of depression, higher level of adverse drug 
reactions on SSRIs with P-gp affinity, and higher remission rates on SSRIs could imply 
that the SNPs rs2235040 and rs2032583 are associated with decreased function of P-gp 
at the blood-brain barrier. A decreased P-gp function may lead to higher net influx of 
an antidepressant, thus attributing to higher remission rate, and also to higher (central) 
     
   
 
adverse drug reactions. Besides, there are theories suggesting a relation between 





Single locus and haplotype results for regression analyses on susceptibility factors in  
MDD Significance was assessed using multinomial regression analysis, and odds ratio’s  including p-
values, are shown for minor allele carrier versus non-carrier. Bold values indicate significant results. 
*logistic regression (MDD starting before 30 years versus starting after 30 years) ** linear regression 
analysis was used for the continuous variable ‘age of onset’ 
 
Furthermore, the suggested gene effect are limited, because the odds ratios are rather 
small. Due to the small effects, these polymorphisms are likely not useful as single 
indicator in clinical practice. Nevertheless, the uncovering of associations in ABCB1 























































































































































     
   
 
and other genes,  each conferring a small effect on the MDD phenotype may help to 
point out susceptibility factors in the disorder.   
In conclusion, our results suggest that the polymorphisms  rs2235040, 2232583 and 
3435CC and the haplotypes 1236-2677-3435 T-T-T and T-T-C may be related to altered 
susceptibility for MDD.    
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Background: The multidrug efflux transporter P-glycoprotein (P-gp) is expressed in 
high concentrations at the blood-brain barrier (BBB) and has a major function in the 
transport of drugs. In a recent PET-study evidence was found for an increased function 
of P-gp at the BBB in medicated patients suffering from major depressive disorder.  We 
used small-animal PET and [11C]-verapamil to study P-gp function at the BBB of rats, 
either being administered venlafaxine, an antidepressant, or subjected to chronic stress, 
a factor contributing to the development of depression.  
Methods: In a first experiment, male Wistar rats underwent a 3–week footshock 
procedure as a model of human depression. In a second experiment,  rats were 
chronically treated with the antidepressant venlafaxine (25 mg/kg/d via an implanted 
osmotic minipump). In both experiments. Thereafter, a [11C]-verapamil PET scan was 
performed. Results: In the chronically stressed rats, the distribution volume (VT) of 
[11C]-verapamil was significantly increased, whereas treatment with venlafaxine had 
the opposite effect and caused a significant reduction in VT. The changes in VT could 
not be attributed to the influx rate constant (K1). 
Conclusion: Our data suggest that P-gp function at the BBB is inhibited by chronic 




In normal circumstances the blood-brain barrier (BBB) contributes to brain 
homeostasis by protecting the brain from potentially harmful endogenous and 
exogenous substances.1 This restricted entrance to the brain is mainly established by 
active efflux mechanisms at the BBB.2 One of the major efflux transporters is P-
glycoprotein (P-gp), acting as a gate keeper protein for toxic substances at the luminal 
side of the brain capillary.3 Due to its localization, potency and broad multispecificity 
P-gp is a key determinant of drug entry to the brain.4 
P-gp function can be modulated by a wide variety of endogenous and environmental 
stimuli,5 including proinflammatory cytokines.6,7 In vitro, the P-gp function at the BBB 
is downregulated after short term exposure to inflammation whereas its function is 
upregulated following more prolonged exposure.8-10 
 
Depressive disorders have been linked to neuroinflammatory events, wherein 
proinflammatory cytokines, acute phase proteins and possible endotoxic substances 
easily cross the BBB due to an increased permeability.11,12 Other indications for a loss of 
integrity of the BBB in depressive disorders come from studies of the cerebrospinal 
fluid (CSF) in depressed patients.13-15  
 
In a PET study with [11C]-verapamil, recently performed by our group,16 we found an 
increased function of P-gp at the BBB in a group of medicated patients with a major 
depressive disorder (MDD). The interpretation of this finding was complicated by the 
heterogeneity in the patient group and the use of antidepressants and other 
psychotropic drugs. There are in fact two explanations that could account for the 
change in P-gp function we found. First, the increase in P-gp function might be a result 
of the depressive disorder itself or a result of some sort of neuronal or physiological 
correlate of depression, e.g., chronic neuroinflammation or stress. Second, and opposite 
to the first explanation, the increase in P-gp function might be a result of 
antidepressant treatment.  
Most antidepressants are substrates of the P-gp pump and generally they have a weak 
inhibitory effect.17,18 However, so far this effect is only found in vitro with 
concentrations that are far above therapeutically relevant levels.19-21  
In the present study we aimed to differentiate between the two explanations for the 
increase in P-gp function in depressed patients. With laboratory rats as a model species, 
we used an experimental approach in a strictly controlled setting to examine changes in 
P-gp function in response to: 1) chronic antidepressant treatment, and 2) chronic, 
uncontrollable stress, as a potential contributing factor to the development of 
depression. We hypothesised that chronic stress would lead to inhibition of P-gp 
function and that chronic antidepressant treatment at a therapeutic level would lead to 
  
increased P-gp function. [11C]-verapamil positron emission tomography (PET) has been 
found to be a suitable methodology for the in vivo assessment of P-gp function.22,23 
[11C]-verapamil is a well characterized PET ligand for evaluating P-gp function at the 
BBB; it is a poor  substrate for other transporters such as Multi Resistance Protein 
(MRP1).23-25 
To assess these hypothesized changes in P-gp function, PET brain imaging with [11C]-
verapamil as radiotracer was performed in two study groups, i.e. a chronic stress model 
and a continuously administered antidepressant model, and two control groups of male 







48 Male Wistar rats (Harlan, Groningen, the Netherlands) weighing 275-300 g at the 
time of arrival, were individually housed in cages with food and water ad libitum. The 
room was maintained at a temperature of 21 ± 1 °C and on a 12:12 dark/light cycle. 
Housing conditions were the same for all rats. Animal experiments were conducted 
according to the European Council Directive of November 24, 1986 (86/609/ECC) and 
were approved by the Committee on the Ethics of Animal Experiments of Groningen 
University. 
 
Induction of stress  
The footshock stress procedure was done using a footshock box containing an animal 
space placed on a grid floor connected to a shock generator and scrambler. This stress 
model was adapted from Trentani et al.26 Stress group rats (n=16) were subjected to a 
daily session of footshock stress for 21 consecutive days. During the session in the 
footshock box rats received 5 uncontrollable and inescapable footshocks (0.8 mA in 
intensity and 8 s in duration). All footshock sessions took place during the light phase. 
In order to increase unpredictability and minimize habituation, both duration of 
footshock sessions and intervals between shocks within a session varied randomly 
(session duration: 15-80 min; shock interval: 1-15 min). Control rats stayed undisturbed 
in their home cages throughout the experiment. In the beginning of the light phase, 
before the start of daily footshock session, all rats were weighed and the difference in 
body weight gain between the groups was used as a read-out of stress effect on animals’ 
physiology. 
 
Administration of venlafaxine  
  
To study the effects of chronic antidepressant treatment on P-gp function, rats were 
subjected to a 3-week treatment on venlafaxine. After 14 days of acclimatization a 
group of 8 rats were anesthetized with Isoflurane (2-2.5%). Osmotic minipumps (Alzet 
Model 2004, purchased from Charles River) containing 250 mg venlafaxine (kindly 
provided by Dr. F.J. Bosker) dissolved in 2 ml saline (0.9 % NaCl) were subcutaneously 
implanted. This pump model continuously releases its content at approximately 2.5 
μl/hr for 4 weeks. Assuming that the average body weight of the rat is around 360 g 
during the procedure, the mean administered dose of venlafaxine is 25 mg/kg/day. We 
estimated that this dose would approach the human therapeutical serum level.27,28 
Before implantation, all pumps had been placed in a sterile 37°C saline bath for 2 days. 
The control group (8 rats) underwent the same procedure, the osmotic minipump 
containing saline without an active drug. The active drug or the vehicle was 
administered for 21 days.  
 
Radiochemistry 
Racemic [11C]-verapamil was produced as previously described.29 The injected 
radioactivity of [11C]-verapamil varied between 50-100 MBq with a specific activity of 
at least 40 GBq/nmol.  
 
PET procedure 
On the day of the PET scan the rats were transported in their home cage to the PET 
facility. The transport was at least 4 hours prior to the scan procedure, so that the 
animals could habituate to their new environment. Before the PET procedure, the rats 
were anesthetized with 2-2.5% isoflurane, whereupon a canula for arterial blood 
sampling was inserted into the right femoral artery. All scans were performed with a 
Focus 220 microPET camera (Siemens/Concorde Microsystems, Knoxville, USA). After 
injection of [11C]-verapamil in the penile vein serial dynamic PET scanning was 
performed at escalating time frames and serial arterial blood sampling for [11C]-
verapamil took place during the scan in order to define the input function. Of each 
animal 14 samples were manually drawn at t = 15, 30, 45, 60, 75, 90, 120, 180, 300, 450, 
600, 900, 1800 and 3600 s. The blood volume of each sample taken, around 0.1 ml, was 
partially replaced by saline/heparine, to prevent clotting of the canula.  
 These samples were further processed to measure the radioactivity in plasma. In this 
way the contribution of the injected activity to the PET-signal could be calculated. 
Metabolite analysis could not be realized since this would lead to hypovolemia in the 
rat during scanning. In each PET scan session two animals were scanned, the first rat 
starting at t=0, the second starting at t = 960 s (one control and one experimental rat, in 
random order to prevent a scan order effect). The injected dose of [11C]-verapamil at 
the moment of injection was similar for both animals to ensure similar counting 
statistics. All data were corrected for physical decay to the moment of injection.  
  
Metabolite correction 
Determination of metabolites in the rats used in the study was not feasible, because of 
the risk of hypovolemia during scanning. Instead, we used metabolite data performed 
in three control rats (provided by Dr. G. Luurtsema). Mean percentages of metabolites 
and parent compound  at four time points were used to construct a standard metabolite 
curve, using SigmaPlot (Systat Software Inc., San Jose, USA) (option ‘exponential rise to 
max’). This regression curve was used as standard metabolite correction for the plasma 
input function in the modelling. Subsequently we manipulated this curve and 
constructed a regression curve, reflecting a hypothetical situation  of a ‘slow’ 
metabolism, corresponding to a 5-10% diminution of metabolites formed after 60 
minutes of scanning. By using this curve as input in the venlafaxine arm of the study 
(the normal metabolite curve as input for the control group), we could make an 
estimation of the VT difference across the two groups in case metabolism would be 
substantially slowed down through the administration of venlafaxine. 
 
List mode data were reframed into a dynamic sequence of 4 x 60 s, 3 x 120 s, 4 x 300 s, 3 
x 600 s frames. Images were reconstructed per time frame employing an interactive 
reconstruction algorithm (OSEM2D). The final datasets consisted of 95 slices with a 
slice thickness of 0.8 mm, and an in-plane image matrix of 128 x 128 pixels of size 1 x 1 
mm2. Data sets were fully corrected for random coincidences, scatter and attenuation. 
A separate transmission scan was acquired for attenuation correction. This scan was 
performed right before the emission scan. A study-specific template was constructed 
onto which the realigned images were spatially normalized.  
 
Data analysis 
After conversion to an ECAT7 image file format the microPET images were analyzed 
with a ROI-based approach (regions of interest). A whole brain ROI was manually 
drawn using Clinical Applications Programming Package software (CAPP5; 
CTI/Siemens PET Systems, Knoxville, TN). A graphical analysis according to Logan for 
quantification of the dynamic PET data was done with plasma data as input.30 The 
Logan plot was started at 5 minutes and the parameter for cerebral blood volume was 
fixed at 0.0. With this method the distribution volume (VT) was estimated. Because the 
slope (i.e.VT effect) obtained in the graphical approach may be biased in the presence of 
noisy data,31 we verified the VT in a kinetic analysis (i.e. single tissue compartment 
model). The influx rate constant (K1) and efflux k2 were derived from this model and on 
all parameters (i.e. VT, K1 and k2) the group means (experimental group vs. control 
group) were compared with each other, using t-tests. Analysis of variance was done to 
test for the influence of K1, k2 and body weight gain (or venlafaxine concentration) as a 





Effects of chronic stress 
The stress procedure was started with 16 rats (35 days, 448.1 g ± 26.3) and 16 rats (416.3 
± 32.1) were used as control. Statistics were performed using analysis of variance 
(repeated measures) for the body weight gain during the stress procedure. The 
chronically stressed rats gained less weight than the control rats; 30.1 ± 14.4 (stress) vs. 
60.1 ± 25.2 g (controls); p = 0.004 (t-test), (see figure 8.1). Also, a significant effect of 
time was seen (F=93.46; p<0.001).  
11 of the controls and 10 stressed rats could be used for the final analysis. The Logan 
gave a good fit in all cases. A significant increase in VT was found in the stress group 
(VT (stress): 1.40 ± 0.54 versus VT (controls): 1.00 ± 0.30; t= 2.14; p = 0.047) (see figure 
8.2). K1 and k2 did not differ across the two groups; K1 was 0.28 ± 0.24 (controls) vs. 
0.13 ± 0.06 (stress); p = 0.11 and k2 was 0.21 ± 0.14 (controls) vs. 0.16 ± 0.11 (stress); p = 
0.42. A comparison was made between the VT obtained from the Logan method with 
the VT from a kinetic analysis (one tissue model). The Pearson’s correlation coefficient 
was 0.990 and a nearly equal level of significance was reached when comparing the two 
groups in a t-test (p = 0.051). In an analysis of variance, body weight or weight gain had 







Effect of stress on body weight gain. Chronically stressed rats (n=12) gained less 
weight than control rats (n=12). The animals were weighed every day starting 4 days 







Distribution volumes of [11C]-verapamil (VT) for the stress and venlafaxine 
experiments, showing increased VT in chronically stressed rats, and a significant 
decrease of VT in rats receiving venlafaxine.  
 
Venlafaxine administration 
Eight rats of both groups had an osmotic minipump implanted either venlafaxine or 
saline. In one scanned pair a failure in computer software made the results 
questionable. The production of [11C]-verapamil failed twice, leaving 5 rats per groups 
for analysis, of which 3 ‘venlafaxine rats’ were scanned first. The average plasma 
concentration of venlafaxine was 77.6 ± 19.6 μg/l. The Logan fit was good in all cases. 
The VT in the venlafaxine group (0.80 ± 0.14) was significantly lower than the VT in the 
control group (1.00 ± 0.13),  (t-test, p = 0.047) which was comparable to the control 
group of the stress experiment (see figure 8.2). The VT in Logan showed a good 
correlation with VT measured in a ‘one tissue model’ (Pearson’s = 0.994, p = 0.000-). In 
the kinetic model the VT in the venlafaxine group showed a comparable significant 
decrease in the t-test compared to the controls (t=-2.55; p = 0.039). K1 and k2 were not 
significantly lower in the venlafaxine group, although K1 showed a trend towards 
significance: K1 (controls) 0.14 ± 0.08 vs. K1 (venlafaxine) 0.057 ± 0.01; p = 0.085; k2 
(controls) 0.17 ± 0.13 vs. k2 (venlafaxine) 0.07 ± 0.02; p = 0.15. The measured 
venlafaxine concentration (after scanning) had no predictive value for VT in an analysis 
of variance.  
Subsequently we tested the differences in VT between the groups. With the 
venlafaxine arm with a signicantly slower metabolism (i.e.  5-10% decrease in  
metabolites formed after 60 minutes). The  VT in the venlafaxine group was still 
significantly lower (0.76 ± 0.13) than the control group (1.00 ± 0.13) which was 






The present study shows that chronic stress in rats significantly increases the VT of 
[11C]-verapamil in the brain, whereas a sustained 3-week treatment with the 
antidepressant venlafaxine in a ‘therapeutical’ concentration decreases the VT of the 
tracer. The increased VT in chronic stress can be interpreted as a decrease in P-gp 
function at the BBB, since no differences in influx (K1) were seen between the groups. 
For the venlafaxine treated rats the decreased VT may either be explained by an 
increase in P-gp activity and/or an increased influx, since K1 showed a nearly 
significant decrease in the treatment group.   
 
The chronic footshock stress model used in this study has been previously shown to 
induce HPA axis hyperactivity as well as impairments in the mechanisms governing 
neuroplasticity in the adult brain.26,32,33 A highly significant difference in body weight 
gain between stress and control rats observed in our study has been described 
previously and demonstrates a strong stress effect on animals’ physiology. Our results 
suggest that chronic stress leads to reduced P-gp function, which in the long run might 
leave the brain more vulnerable to the influx of potentially harmful substances. This 
reduction in BBB function might be one of the pathways via which stress contributes to 
central nervous system malfunction and disease. Our results may thus give new insight 
in the pathophysiology of depression 
 
Increased P-gp function in response to venlafaxine administration should result in 
enhanced neuroprotection. However, increased pump function also implies reduced 
access of venlafaxine to the sites of action within the central nervous system. Chronic 
administration of venlafaxine may be related with a decreased pharmacological effect 
in the face of therapeutic doses, and consequently contribute to treatment resistance. 
The effects of venlafaxine treatment and chronic stress on P-gp are in the opposite 
direction. It is a plausible assumption that venlafaxine reduces the effect that chronic 
stress has on P-gp. The results suggest that our previous [11C]-verapamil PET-study 
showing an increased P-gp function in medicated patients with chronic depression may 
thus be ascribed to the use of antidepressants.34  
 
Several authors have demonstrated that antidepressants, can exert an inhibitory effect 
on P-gp function, although this has only been shown in vitro, at concentrations in the 
range above therapeutic conditions.20,21 Venlafaxine has been shown to have a weak 
effect op P-gp, both inhibitory21 and inductive.35 The average serum level of 
venlafaxine in the rat was 69 μg/l, which is considered to be within the therapeutic 
range in humans.28  
 
  
Moreover, chronic stress dysregulates the HPA-axis and leads to an increased 
glucocorticoid serum level.36 Cortisol is a substrate of P-gp and in case of inhibition of 
P-gp its access to the brain is increased.37,38  
Elevated levels of intracerebral cortisol are associated with compromised brain function 
and with neurochemical and anatomical changes in different brain areas.39,40 An 
increased cortisol level also leads to an increased activation of brain glucocorticoid 
receptor function and an increased negative feedback on the HPA axis.38 Although this 
feedback mechanism is altered in depression, antidepressants decrease HPA-activity in 
depression.41 Cortisol may be regulated by P-gp through the inhibiting effect of 
antidepressants on P-gp. However, cortisol entry to the brain is probably not regulated 
by P-gp only, as Mason et al. found in mice.42  
  
Metabolite measurement in the same animals was not feasible. In the absence of 
individually metabolite-corrected plasma input data our data are not entirely reliable, 
because a pharmacokinetic effect on verapamil metabolism through e.g. inhibition of 
P450 enzymes or an alteration of plasma free fraction cannot be excluded. However, 
significant changes in metabolism due to venlafaxine administration are not reasonable 
on the basis of the available literature. An effect of venlafaxine on the free fraction of 
[11C]-verapamil is theoretically conceivable, although in verapamil metabolism the 
fraction is low (around 10%). Usually, the free fraction is not accounted for in 
modelling, because it can be assumed that there is an equilibrium is between the 
compartments. To date, no reliable method for determination of the free fraction of 
[11C]-verapamil has been described.  
 
Venlafaxine is a substrate of cyp2D6 and has a weak inhibitory effect on 2D6, whereas 
this iso-enzyme does not play an appreciable role in verapamil metabolism, which is 
mainly dependent on cyp3A4 metabolism.43,44 Venlafaxine has no effect on 3A4 
metabolism.43,45,46 
 
Thus, although we had no reasons to suspect significant changes in [11C]-verapamil 
metabolism through venlafaxine, we have compared the VT between the group in a 
hypothetical situation of a significant slower metabolism in the venlafaxine group 
 We still found a decrease of VT in the venlafaxine group, which was significant in the 
Logan analysis (p = 0.036), although this could not be confirmed in the  kinetic analysis 
(p = 0.15).  
 
In conclusion, our results suggest that chronic stress in rats leads to a loss of integrity of 
the blood-brain barrier due to a decreased function of P-glycoprotein. The implication 
of this might be an increased brain vulnerability and increased sensitivity to central 
nervous system malfunction and disease. This finding supports the hypothesis that 
  
reduced BBB-function might contribute to the pathophysiology of stress related 
disorders such as depression. Furthermore, our results suggest that antidepressants may 
in part exert their therapeutic effect by normalization of P-gp activity and BBB-
function. Further studies using other antidepressants form different pharmacological 
classes are warranted to confirm our findings.  
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The blood-brain barrier (BBB) plays an important role in maintaining the internal 
milieu of the brain. One important function of the BBB is to restrict the entry of 
xenobiotics. P-glycoprotein (P-gp) is a multispecific efflux pump, highly expressed at 
the BBB and with the ability to extrude a wide array of unrelated compounds. In 
particular, lipophilic molecules, such as antineoplastic agents, immunosuppressants, 
cardiac glycosides, but also antidepressants and antipsychotics are substrates for P-gp.1  
In humans, P-gp is encoded by a single gene, ABCB1, formerly denoted as MDR1. It 
belongs to the superfamily of ATP binding Cassette (ABC) transporters. Rats have two 
P-gp genes at the BBB, called mdr1a (or mdr3 or ABCB1a) and mdr1b (or ABCB1b). 
Together, these two genes have a comparable tissue distribution as human ABCB1. 
ABCB1a knockout mice have no detectable P-glycoprotein in the brain, indicating that 
this is the only gene responsible for drug efflux at the BBB.2 ABCB1a encodes two 
isoforms of P-gp, both present in the BBB. The 140kDa protein appears to be the main 
isoform, it seems to be the immature form, which is not finally processed within the 
cell (also called called mdr3) (Potschka, personal communication). The 174 kDa protein 
is the functional mature form, which is integrated into the membrane, formerly named 
mdr1a.3   
There is still some controversy regarding the exact localization of P-gp in the brain. 
The majority of studies have shown that its predominant location is at the luminal side 
of the endothelial cell,4 but P-gp might also be involved in the regulation of drug 
transport at the subcellular level.5  
P-gp is present in all BBB-protected regions, which excludes the choroid plexus, 
selected circumventricular organs and the posterior pituitary,6 which have leaky 
capillaries. Under normal circumstances, P-gp is probably equally distributed 
throughout the brain, although the evidence so far is limited. In two recent PET studies 
in healthy controls, using R-[11C]-verapamil as probe for P-gp function, regional 
differences in tracer uptake were neither seen at baseline nor following P-gp 
inhibition.7,8  
Assessment of regional differences in P-gp expression and activity is of great interest, 
because a regional change in activity might contribute to the pathology of various 
neuropsychiatric disorders, but it could also be an indicator of local(ized) pathology. In 
PET studies indications were found for regional changes in P-glycoprotein activity 
with both psychiatric and neurological disorders.9-11 Although not confirmed in PET 
studies, epilepsy and Alzheimer dementia might also be characterized by regional 
alterations in P-gp expression or function. Regional decline of P-gp function may also 
be related to ageing.12,13  
It is now well established that many cortical and subcortical structures are involved in 
the psychopathology of major depressive disorder (MDD).14,15 Brain activation studies 
  
show hypoactivity in the frontal and temporal cortex as well as in the insula and 
cerebellum with patients suffering from MDD, whereas activity in these regions is 
increased during antidepressant treatment. The area and level of brain activation may 
depend on the drug of choice.16,17 Cortical and subcortical areas have also been 
implicated in schizophrenia, in particular, the dorsolateral prefrontal cortex18 and the 
basal ganglia.19  
 
In this study we assessed the P-gp expression and the cerebral distribution patterns in 
three different models in male Wistar rats: 1) a depression model (chronic stress 
paradigm)20 2) a schizophrenia model (neuroinflammation paradigm)21 and 3) an 
antidepressant treatment model20 (3 week chronic administration of venlafaxine). Each 
condition might reflect physiological processes or localized pathology. Both P-gp 
function in vivo (using [11C]-verapamil PET) and P-gp expression (using western 
blotting and immunohistochemistry) were used for comparisons.  We have used the 
PET data on chronic stress and on chronic administration of venlafaxine and the rat 
brain tissue from a previously published animal PET study.20  
 
Materials and methods  
 
Animals 
All experiments were performed on male Wistar rats (Harlan, Groningen, the 
Netherlands) weighing 275-300 g at the time of arrival. Animals were individually 
housed in cages with food and water ad libitum. The room was maintained at a 
temperature of 21 ± 1 °C and on a 12:12 dark/light cycle. Housing conditions were the 
same for all rats. Animal experiments were conducted according to the European 
Council Directive of November 24, 1986 (86/609/ECC) and were approved by the 
Committee on the Ethics of Animal Experiments of Groningen University.  
 
Chronic stress procedure  
This has been described in our previous publication.20 Briefly, a group of rats ( n=16) 
was subjected to a daily session of foot shock stress for 21 consecutive days. During the 
session in the foot shock box rats received 5 uncontrollable and inescapable foot 
shocks. Control rats (n=16) stayed undisturbed in their home cages throughout the 
experiment.  
 
Chronic administration of venlafaxine 
This has also been described in the previous study.20 In short, osmotic mini-pumps 
were subcutaneously implanted in rats (n=16). These pumps continuously released 
either venlafaxine (25 mg/kg/day) (n=8) or saline (n=8) in the control group. The active 
drug or the vehicle was administered for 21 days.  
 
  
Neuroinflammation model (Herpes encephalitis) 
On the first day a group of 8 rats was intranasally inoculated with 1x107 PFU of Herpes 
Simplex Virus-1, leading to an clinical encephalitis. A control group (n= 8) was 
inoculated with PBS. On day 6 both groups underwent a PET scan.   
 
PET procedure and data analysis 
The PET procedure has been described elsewhere.20 In brief, before the scan the rats 
were habituated to the PET facility. After being anaesthesized the tracer [11C]-
verapamil was injected into the penile vein. 14 arterial samples and metabolite data 
were used as input function. A study-specific template was constructed onto which the 
realigned images were spatially normalized.  
 
The reconstructed images were analyzed with a ROI-based approach (region of 
interest) with the use of a microPET program expanded with addition of Siemens 
Inveon Research Workplace (Siemens AG, Erlangen, Germany). This system is a 
multimodality image review, fusion, supporting CT and PET formats and it allows 
quantitative analysis of the data, using semi-automated region of interest techniques. 16 
ROIs were predefined on a template. A graphical analysis according to Logan for 
quantification of the dynamic PET data was done with plasma data as input. The Logan 
plot was started at 5 minutes and the parameter for cerebral blood volume was fixed at 
0.03. With this method the distribution volume (VT) was estimated. Because the slope 
(i.e.VT effect) obtained in the graphical approach may be biased in the presence of 
noisy data, we verified the VT in a kinetic analysis (i.e. single tissue compartment 
model). The influx rate constant (K1) and efflux k2 were derived from this model and on 
all parameters (i.e. VT, K1 and k2) the group means (experimental group vs. control 
group) were compared with each other, using t-tests. 
 
Brain collection, western blotting and immunohistochemistry  
At the end of the PET experiments, rats were still anaesthesized. Brains were dissected 
and divided into two hemispheres. The left hemisphere was dissected in three parts, 
which were hippoacampus, prefrontal cortex and parietal cortex, and  was snap frozen 
in liquid nitrogen and conserved at -80˚C.  The right hemisphere was fixed in 4% 
paraformaldehyde solution and was also cryopreserved.  
 
For western blotting (WB) analysis whole brain tissue was homogenized, and a lysis 
buffer (50mM HEPES (pH 7.4), 150mM NaCl, 10mM EDTA, 4 mM EGTA (pH 7.4), 
0.2% NP-40, 5 mM b-glycerophosphate, 100 mM sodium fluoride, 5 mM 
orthovanadate, 1 mM DTT, 1 mM PMSF and a protease inhibitor) was employed for 
cell lysis and protein solubilisation. After centrifugation the pellet and supernatant 
were split and both samples were sonificated, Protein concentration was 
  
determined using a Bradford assay, samples were diluted if necessary and stored as 
aliquot samples in a sample buffer at -80˚C. The solubilised membrane proteins 
were separated by sodium dodecyl sulphate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred by electroblotting to a Polyvinlidene Difluoride 
membrane using Tris-glycine buffer for 2 hr at 25 Volt. Immunoblots were blocked 
30 hr with I-block (Tropix) at room temperature. After blocking the blots were 
incubated withP-glycoprotein monoclonal antibody (MAb) C219 (Alexis, Enzo life 
sciences 1:1000) overnight at 4˚C, a MAb against P-gp. Horseradish peroxidase-
conjugated goat anti mouse gG (1:5000 Santa Cruz) was used as secondary antibody . 
Detection was carried out with enhanced chemiluminiscence (ECL Pierce) 
according to the manufacturers instructions. and a  digital image was analyzed by 
quantification of optical density.  
 
For immunohistochemistry (ICH) serial sections of the right hemisphere were cut 
using a cryostat into 30μm slices and stored in 0.01M PBS (pH 7.4) with 0.01% 
Sodium Azide. The immunostainings were performed on free-floating sections 
under continuous mild agitation. Brain sections were washed in 0.01 PBS pH 7.4 and 
endogenous peroxidase activity was reduced with 0.3% H2O2  in 0.01M PBS (pH 7.4) for 
30 min at room temperature.The brain sections were washed in 0.01M PBS (pH 7.4) 
and Preincubated with 5% normal goat serum and 0.1% TritonX-100 in 0.01M PBS (pH 
7.4) for 30 min at room temperature, and then incubated with the MAb P-glycoprotein 
C219 (1:1000, Alexis, Enzo Life Sciences) overnight at 4˚C. Subsequently, sections were 
rinsed in 0.01 M PBS (pH 7.4) and incubated for 2 h at room temperature with the 
secondary antibody horseradish peroxidase-conjugated goat anti-mouse (1:400) in 
0.01M PBS (pH 7.4) with 0.1% Triton-X 100 and 1% NGS. Then, avidin-biotin 
complex (1:500 Vector ABC kit, Vector Laboratories, Burlingame, Ca, USA) was added 
for 1.5 hr at room teperature and washed in 0.01M PBS (pH 7.4), after which the 
staining was visualized with 1 mg/ml diaminobenzidine and 0.001% H202. Thereafte, 
sections were rinsed in 0.01M PBS (pH 7.4), mounted on slides (Superfrost) with 1% 
Gelatine and 100 mg potassium chromium III sulfate, dehydrated by the ethanol-xylol 





Venlafaxine (PET study) 
 The image files of 5 venlafaxine treated rats and 5 sham were available for analysis 
with both a kinetic model (one compartment model) and a graphical approach (logan 
analysis) (see figure 9.1). There was good overlap between the two methods, pearson’s ρ 
was 0.99 for the controls and 0.88 for the venlafaxine group. ROIs lining extracerebral 
  
structures (i.e. bulbus, frontopolar lobe, pons and medulla) had much higher VT’s than 
deeper brain structures, which is due to spill-in activity.  The mean VT of controls in all 
ROIs was higher than in the venlafaxine group, significantly in 6 ROIs and a significant 
trend was seen in 7 ROIs (see table 9.1). When corrected for multiple testing, VT was 





A: Mean distribution volumes (VT) of venlafaxine vs. controls for each ROI.  




The pituitary lies outside the blood-brain barrier and the VT is 2.5 larger than the mean 




Stress (PET study) 
 11 controls and 9 rats from the stress procedure were available for the analyses. Logan 
analysis and one compartment kinetic analysis were carried out. The correlation 
coefficient ρ for both groups was 1.00. In the kinetic analysis, the VT in 9 ROIs was 
significantly higher in the stress group, and in the remaining 8 ROIs a significant trend 
was seen (see table 9.1, figure 9.1B). The pituitary, with little or no Pgp expression, was 
the only area showing no difference at all between groups (p = 0.47). Again, areas 
lining the extracellular structures had a higher VT, caused by spill-in. In none of the 
ROIs a significant difference was seen after Bonferroni correction.  
 
Table 9.1 

















ROI: region of interest; p = p-values, none is significant after correction for multiple testing 
   
 
Western immunoblots of hippocampus 
We utilized MAb C219 and performed Western immunoblot analysis of extracts of 
hippocampus. Three different animal models were compared with control rats: 1) 
neuroinflammation model (Herpes Simplex Virus Encephalitis), 2) chronic stress model 
and 3) model for chronic administration of an antidepressant. In homogenates from rat 
hippocampus two immunoreactive bands were detected , a major band at 140 kDa and 
a very weak one at 174 kDa. Both bands represent isoforms of P-gp, the 140 kDa being 
the main isoform of P-glycoprotein in the rodent brain,3 The 174 kDa was too weak to 
be analyzed with densitometry (figure 9.2A). Therefore comparisons were made on the 
ROI venlafaxine stress 
 p p 
bulbus 0,011 0,064 
frontopolar 0,086 0,036 
frontal cortex R 0,060 0,035 
frontal cortex L 0,039 0,079 
frontal cortex (L + R) 0,048 0,039 
striatum 0,086 0,023 
right cortex 0,058 0,019 
left cortex 0,15 0,023 
total cortex 0,091 0,013 
amygdala 0,031 0,079 
hippocampus 0,55 0,019 
hypothalamus 0,16 0,050 
thalamus 0,047 0,028 
midbrain 0,25 0,058 
pons 0,073 0,096 
medulla 0,091 0,053 
cerebellum 0,030 0,077 
pituitary 0,129 0,47 
  
basis of the 140 kDa band (figure 9.2B. It is to note that no actin band was included in 
the blots, which is necessary as reference value for comparison. Nevertheless P-gp 
expression seems increased with neuroinflammation, and decreased with chronic stress. 
The venlafaxine treated rats did not show differences in P-gp expression, however the 
bands were of low quality. It is obvious that our preliminary results must be replicated 






Western blot analysis of P-glycoprotein using C219 antibody. 
 
Figure 9.2A showing two bands (stress (S) versus control (C)) that represent the two 
isoforms of P-gp, found in the BBB. The 174kDa band is the full-length (mature) form. 
The ‘immature’ form is the main isoform in rodents, and dominates in situations 
where P-gp is upregulated. The 140 kDa band represents P-gp (mdr3),  
 
 
Figure 9.2B showing three conditions compared to controls (C): 
A= neuroinflammation versus controls 
B = stress versus controls 





In a previous PET study with rats it was demonstrated that sustained venlafaxine 
administration led to an increased P-gp activity at the BBB,20 whereas chronic stress led 
  
to a decreased activity of P-gp.20 This study shows that P-gp is globally affected in both 
situations. Immunochemical studies in rats and PET studies in man suggest that P-gp 
expression develops synchronously with other BBB components and that P-gp is 
present in nearly every region (see introduction) of the brain.7,8,22 The uniform 
distribution of P-gp in the brain is a logic explanation for the global changes in P-gp 
activity. In depressive disorders and schizophrenia, both stress related disorders, 
regional changes in P-gp activity have been reported,10,11 which seem to be in contrast 
with the results of regional analysis of the animal PET study.  However, only 5 areas in 
the PET study on depressive disorders were analyzed, compared to 18 areas in the 
animal study. Besides, the methodology in both studies differed. If the same (small 
number of) areas had been chosen in the animal study, there would be a trend towards 
a significant decrease in P-gp activity in the hippocampus and (total) cortex. A regional 
change in P-gp activity in chronic stress can therefore not be excluded on the basis of 
these results.  
  
The changes in P-gp activity may reflect changes in protein regulation at various levels. 
Although preliminary, the first results of the western blots support the PET results. The 
P-gp expression in neuroinflammation seems increased compared to controls, which is 
in line with the PET results21 showing an increased P-gp activity throughout the brain 
(except in cerebellum and brain stem) in an acute neuroinflammation. In contrast, P-gp 
expression might be lower at the BBB, after exposure to chronic stress, which is 
contingent with decreased P-gp activity. However, comparison of different samples is 
not reliable without an actin band, which serves as reference measure for the amount 
of protein in a sample. The quality of the venlafaxine blots was too poor to be 
analyzable.  
 
Thus, the preliminary results of this study suggest that changes in P-gp activity due to 
chronic antidepressant treatment (venlafaxine) and chronic stress are not confined to 
specific regions in the brain, which is in line with the uniform distribution of P-gp in 
the brain. Moreover, the changes in P-gp activity may be connected to regulatory 
changes in protein level, even after 4 days.   
 
To underpin these preliminary results, the western blot analysis of all samples, 
including frontal cortex samples must be finished, and these results must be correlated 
to the individual PET measurements. Immunohistochemistry may support the idea of 
global downregulation of P-gp in chronic stress in rats, but was not yet performed at 
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Both MDD and schizophrenia are severe psychiatric disorders, both tending to 
chronicity and affecting many people throughout the world.  Schizophrenia is often a 
debilitating disease, characterized by several relapses with psychotic features, decreased 
skills during the life cycle, often leading to elimination of major social activities and 
relations. Neurodevelopmental events and genetic factors may contribute in the 
pathophysiology.  
 
MDD is considered a heterogeneous condition in which different biologic 
abnormalities play a role in the symptomatology. The life time prevalence of MDD in 
the Netherlands is around 15%, the one year prevalence was 5.8% in 1998.1 Today, 
MDD is worldwide the third leading cause of disease burden.2 Despite intensive 
research during the past decades, the neurobiological basis and the pathophysiology of 
MDD remain largely unknown, although genetic factors and childhood trauma’s are 
known to play a role. 
 
The aim of the present thesis was to investigate the possible role of P-glycoprotein (P-
gp) at the blood-brain barrier (BBB) in major depressive disorder (MDD) and 
schizophrenia. 
 
Pertaining to the pathophysiology of both disorders, neuroinflammatory events appear 
to play a central role. For instance, it is now known that stressful events paving the 
way to stress related disorders, lead to changes in neuroplasticity, impair neurogenesis 
and may lead to a neuroinflammatory response in the brain.3 As such, it has been 
suggested that neurotoxic processes may contribute to the pathophysiology of 
neurodegenerative diseases. An increase or accumulation of toxic substances in the 
brain can alter neurotransmission or may damage neurons.4,5Accumulation of toxic 
substances can occur as a result of a diminished blood-brain barrier (BBB) function. 
Likewise a defective BBB function may cause a hampered outward transport of toxic 
waste products, leading to malfunctioning neuronal tissue. the A PET study in 
Parkinson’s Disease supported this theory.6 In this study it was found that the function 
of P-gp, an important efflux pump in the BBB, was diminished in the midbrain. 
 
The BBB is formed by the brain capillary non-fenestrated polarized endothelial cells 
that have high-resistance tight junctions. Besides low passive permeability, the brain is 
protected from potentially harmful endogenous and exogenous substances by efflux 
transporter proteins, located in the brain capillary wall. P-glycoprotein is a product of 
the ABCB1 gene and is most principal drug efflux transporter, involved in the outward 
transport of a wide variety of lipophilic drugs and endogenous substances.7 Attenuation 
of P-gp function, for example through use of pharmacologic inhibitors, results in 
  
substantial changes in the pharmacokinetics and pharmacodynamics of various 
substrates. 8,9  
 
We hypothesized that P-gp function was altered at the BBB by the effects of 
neuroinflammation, which appear to play a role in MDD and schizophrenia. In the first 
study (chapter 4), P-gp function at the BBB was investigated in 13 patients with MDD, 
all using antidepressants, compared to a sex and age matched control group, using [11C]-
verapamil as PET tracer. Cerebral distribution volume (VT) was used as measure for P-
gp function. In addition, three (common) polymorphisms were determined with rt-
PCR and analyzed as covariate of VT. Both region-of-interest (ROI) and voxel analysis 
using statistical parametric mapping (SPM2) were performed to assess regional brain P-
gp function. We found a significantly decreased VT (i.e.[11C]-verapamil uptake) in 
patients with MDD, with both methods, representing an increased P-gp function, 
mainly in prefrontal and temporal regions. A genotype effect was not seen in this small 
sized group. In a post hoc analysis it appeared that 7 out of 13 patients were considered 
to have a treatment resistant depression (TRD). Comparison between the subgroups 
(TRD vs. non-TRD), was not eligible since these groups were not matched. The 
question of biased results (increased activity of P-gp) related to TRD could not be 
excluded. The study had several limitations. Probably the most serious limitation 
concerned the missing of a metabolite analysis. Without this input function it can not 
be excluded that the difference between the groups is not related to P-gp function but 
to a different rate in metabolism of the tracer. In chapter 4  we have discussed why we 
assume metabolism has no major influence on P-gp functionality. Other drawbacks 
were the use of several antidepressants and other psychotropics, some of them with an 
inconclusive effect on P-gp. In chapter 5 the same protocol is used to assess the in vivo 
function of P-gp in 10 schizophrenic patients, compared to a matched control group. 
The results were very much comparable to the results in the MDD study, although the 
results of the voxel-wise analysis were only significant when small volume correction 
was applied. Nevertheless, the results in both studies  suggested a regional increase in 
P-gp function, which might denote a general disease characteristic (eg. inflammation), 
or be related to medication. Although we excluded the use of inhibitors of P-gp at 
recruitment, both antidepressants and antipsychotics have shown (low) affinity 
(principally in in vitro studies) to P-gp. In addition, some appear to exhibit inhibition 
of P-gp activity in vitro.10-13 The in vivo inhibitory effect on P-gp in human is 
unknown, and presumed to be negligible, because supratherapeutical doses were 
needed to inhibit P-gp in BBB models.12 In a mouse model Grauer and Uhr showed that 
long term administration of a weak to moderate P-gp substrate (amitriptyline) does 
admittedly not lead to significant differences between Pgp knock-out and wild type 
mice, but led to large differences in brain accumulation of its metabolites.14  
 
  
The effects on P-gp activity of both medication, MDD, schizophrenia and stress we 
found (chapters 4,5, and 8) could have been influenced by gene variation as well. 
Although we determined three polymorphism in the human PET studies, the sample 
was expectedly not adequate to detect small gene effects. The literature on ABCB1 
polymorphisms relating gene variation to phenotype is far from conclusive. In the 
following chapters 6 and 7 we present the results of the NESDA study, a large 
multicenter cohort, investigating the long term outcome of depression (and anxiety) as 
it presents in the general population. Based on our previous results (chapters 4,5 and 8), 
a decline of P-gp functionality in chronic stress, we hypothesized that ABCB1 might be 
a susceptibility factor in depression. Furthermore, we were interested in the relation 
between antidepressant related side effects and ABCB1 polymorphisms. Data on dose-
to-plasma concentrations were not available. We examined the possible association of 6 
SNPs (single nucleotide polymorphism) (i,e, three common SNPs and 3 SNPs having 
shown a positive association on treatment response15,16) with possible susceptibility 
factors for depression. Data from meta analyses suggested that familial aggregation in 
MDD was particularly related to ‘early onset’ (often defined as ‘beginning before the 
age of 30’) and recurrent episodes (i.e. more than 1 episode).17 For two of SNPs that had 
shown to be related to faster response to an antidepressant (with affinity for P-gp)15,16 a 
negative association was found for the age of onset, amounting to a smaller change on 
MDD starting at young age, for those with the mutation (rs2235040, rs2232583, 
rs1045642). Furthermore, an association was found between the haplotype 1236T-
2677T-3435C and recurrent episodes. The Odds ratios were small (0.735-0.785), and 
the fact that they were found in a large sample (n=1826), indicate that these 
polymorphisms will not be not useful as single indicator in clinical practice. 
Nevertheless, the uncovering of associations in ABCB1 and other genes, each 
conferring a small effect on the MDD phenotype may help to point out susceptibility 
factors in the disorder. Another important finding in the NESDA study was the 
association of two ABCB1 polymorphisms rs2235040 and rs2032583 with the incidence 
and severity of side effects related to SSRI’s (that are P-gp substrates). Also, a 
haplotype, containing the three most common coding SNPs (i.e. 1236C>T, 2677G>T, 
3435C>T) and the two SNPs rs2235040 and rs2032583 (1236T-2677T-3435T-
rs2235015G-rs2032583T-2235040G) was found to be associated with occurrence of 
adverse effects. Occurrence of anticholinergic and serotonergic adverse effects was also 
predicted by these SNPs and haplotype. In particular, these SNPs and haplotype were 
associated with sleeplessness. Our results suggest that these polymorphisms may predict 
the occurrence of (anticholinergic and serotonergic) side effects  in patients who use a 
SSRI with affinity for P-gp. The linkage of SNP rs2032583 to the haplotype 1236T-
2677T-3435T may act as  a marker of a functional haplotype of ABCB1. Of course, 
caution must be exercised with the interpretation of these results, as there are many 
controversies on ABCB1 related gene effects.  
  
 
In chapter 8, which is a sequel to the studies described in chapters 4 and 5, a 
comparison was made between two of the presumed explanations of increased cerebral 
P-gp activity. In male Wistar rats, we compared the effect of chronic stress and the 
effect of chronic administration of venlafaxine to control rats. A 3-week foot shock 
procedure was used as a model for human depression. [11C]-verapamil-PET was used to 
assess P-gp function in vivo. Venlafaxine exhibits weak to moderate affinity as a P-gp 
substrate18,19 and does not modulate cyp3A4, the enzyme involved in [11C]-verapamil 
metabolism. Although is was not feasible to perform metabolite analysis in the animals 
in this study, we corrected for metabolism by using data on [11C]-verapamil metabolism 
from another experiment. To test whether the outcome variable (VT) was influenced 
significantly by changes in metabolism, we constructed metabolite curves, either 
representing slower or faster metabolism and used these as input for the analysis. Only 
slight changes were seen, which made an effect due to metabolite changes less 
probable. Both groups differed significantly from their control group: chronic 
administration of venlafaxine had led an increased activity of P-gp, the whole brain 
being the region-of-interest, while chronic stress gave the opposite effect: cerebral P-gp 
activity was significantly decreased. Thus, on the one hand, the findings implicate that 
chronic stress (as a model for human depression) cause diminished activity of P-gp, 
which is in line with the cytokine hypothesis of depression. In such a model depression 
is seen as a neuro-inflammatory event, in which proinflammatory cytokines cause 
damage to the BBB and elicit P-gp inhibition,20-22 In case of chronic stress, however, a 
few (in vitro) studies suggest that P-gp is increased.23,24 To date, there are no in vivo 
studies to confirm any modulatory effect by chronic stress. On the other hand, the 
results implicate that chronic administration of a P-gp substrate (venlafaxine) causes an 
increase in P-gp function. The effects of both venlafaxine and chronic stress on P-gp 
may indicate an up-and downregulatory phenomenon respectively. The studies of Uhr 
et al. and Grauer and Uhr may support the idea of upregulation of P-gp after chronic 
administration of a P-gp substrate, since they registered (in two different studies) a 
significantly decreased brain uptake in wild type mice compared to knock-out mice 
(acute effect), that was no longer present in mice after long term administration of 
amitriptyline (see figure 10.1).14,25  
 
In chapter 9  the results of chapter 8 are further elaborated. We hypothesized that the 
difference in VT due to chronic administration of [11C]-venlafaxine, would be global in 
stead of regional, which was the case. P-gp activity was equally distributed throughout 
the brain, reflecting a homogenous distribution of cerebral P-gp. P-gp was significantly 
higher in the pituitary, both in the control group and venlafaxine treated group, which 
fits in the supposition that the pituitary lies outside the BBB.26 The effect of spill-in in 
regions adjacent to extracerebral structures caused higher VT’s in both groups. When 
  
these regions (i.e. bulbus, frontopolar lobes, cerebellum, pons, medulla) and pituitary 
were excluded from the comparison, VT’s, were comparable with the previous study.   
We also examined the regional distribution of [11C]-venlafaxine in rats that underwent 
chronic stress and compared this to the control group. As we had found a regional 
increase in P-gp activity in patients with a depressive episode, using antidepressants, 
we hypothesized to find this in the stress experiment too. The decrease in the stress 
group was globally, and again, for both groups higher VT’s were seen in regions 
neighbouring non cerebral tissue, and in the pituitary. A comparison between the 
human study (chapter 4) and these results may be halted for several reasons. Firstly, the 
experiment in rats is only a model for human depression, and secondly, there are many 
methodological differences between the two experiments. Besides, in the human  
study, only 5 regions, related to the pathophysiology of depression, were chosen for 
multiple comparisons, in stead of 18 regions in the rats. If we had chosen these regions 
for multiple comparison in the rat experiment, a trend towards a significant decrease 
would be seen in hippocampus (p = 0.094) and cortex (p = 0.064). On the basis of these 
results, it can not be excluded that P-gp activity is regionally changed (decreased).         
Chapter 9 also includes the description of western blot and immunohistochemistry 
techniques. The rat brains of the experiments described in chapter 8 were collected 
after the PET experiment. The hemispheres were divided, the left hemisphere was snap 
frozen, the right was fixed in paraformaldehyde and also cryopreserved. Rat brains 
from a neuroinflammation experiment were provided (by Janine Doorduin) for 
comparison with the other pathological conditions and controls. Western blot is used 
to determine the amount of protein (P-glycoprotein) in brain tissue, and the results can 
be correlated with the PET results, reflecting the activity of P-gp in vivo.  In this way a 
differentiation can be made between increased/decreased pump activity due to  up- or 
downregulation (i.e. increased or decreased amount of protein) or altered pump activity 
without a change in the amount of protein. Immunohistochemistry enables 
determination of the amount of protein in specific regions.  Accordingly, a comparison 
between regional P-gp activity and regional amount of P-gp can be made. At this stage, 
the in vitro experiments are in full progress, and results are not available yet. 
 
Concluding remarks and future directions 
The protection of the brain by the blood-brain barrier has been regarded as a sanctuary 
for many decades. Intensive research in the past several decades has contributed to a 
better understanding of the way molecules are transported into the CNS. It has become 
clear that the transporter P-glycoprotein is involved in the outward transport of many 
molecules that play a role in depressive disorders, although its role for certain 
compounds (eg. cortisol) is still debated. Besides, it has been shown that P-gpfunction 
can be modulated by many factors, which may also play a role in depressive and 
psychotic disorders. Our results suggest that P-gp activity at the BBB is decreased when 
  
exposed to chronic stress (as model for MDD), and that administration of an 
antidepressant (a P-gp substrate) increases its function. It is however not clear whether 
modulation of P-gp is detrimental or has consequences for drug dosing. P-gp function 
may be decreased as a required step in the acute stress response, necessary to allow the 
passage of proinflammatory proteins. In the recovery period of a depression the activity 
of P-gp may then be at another rate. This hypothetical role in different phases during 
the course of a depressive episode may tested with new PET studies. In this case it 
would be necessary is to perform PET scans, using different radioligands, aimed at 
mapping P-gp activity and inflammation. Maybe a more important development in 
PET research in respect to P-gp imaging is the development of a tracer or a method to 
study the effect of drug interactions with P-gp. New strategies that could be worked 
out are, such as radiolabeling of a new drug candidate after administration of an inhibitor, 
or a double PET scan to evaluate the effect of a P-gp modulator. 
Another finding presented in this thesis, is the fact that the gene encoding for P-gp 
may be related to phenotype. In the first place polymorphisms appeared to be 
associated with severe side effects on the SSRIs (venlafaxine, citalopram, paroxetine, 
fluvoxamine) that have shown affinity to P-gp. If these findings are replicated, it shall 
be a further step towards so called personalized medicine, which involves the 
avoidance of unnecessary drug trials. Future goals in this regard are the optimalization 
of a predicted drug response for each individual.  
Secondly, three ABCB1 polymorphisms were associated with a lower change on early 
onset MDD. This finding – if replicated - may contribute in the uncovering of a genetic 
profile conferring susceptibility for MDD. More large scale genetic studies may help to 






Concentration of amitriptyline and its metabolites in various organs in abcb1ab-/- 
mice (black bars) versus wild type mice (grey bars). At the right, Amitriptyline is once 
administered 3 hours prior to decapitation, resulting in significantly higher 
intracerebral concentrations for amitriptyline and its metabolites25 
At the left, amitriptyline has been administered for 10 consecutive days, resulting in 
equal intracerebral concentrations for the parent drug, whereas the intracerebral 
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Het doel van dit proefschrift is het onderzoek van de mogelijke rol van de eiwitpomp 
P-glycoproteïne (P-gp), dat aanwezig is in de bloed-hersenbarrière (BHB) in depressie 
en schizofrenie.  
 
Zowel depressie (MDD, Major Depressive Disorder) als schizofrenie zijn ernstige 
psychiatrische stoornissen, die wereldwijd voorkomen en gekenmerkt worden door een 
chronisch beloop. 
Schizofrenie is vaak een invaliderende ziekte, die gekenmerkt wordt door terugkerende 
psychotische episoden en afname van cognitieve en sociale vaardigheden. Vaak treedt 
er verlies van zowel sociale als maatschappelijke rollen. Afwijkingen in de normale 
ontwikkeling van het zenuwstelsel en ook genetische factoren kunnen een rol spelen in 
het ontstaan van deze ziekte.  
 
Depressie wordt beschouwd als een heterogene stoornis, waarbij verscheidene 
biologische afwijkingen een rol kunnen spelen in het symptomencomplex. De ‘life 
time’ prevalentie van depressie in Nederland is ongeveer 15%, terwijl de 
eenjaarsprevalentie in 1998 5.8% was.1 Volgens een WHO rapport staat depressie qua 
omvang en leed tegenwoordig wereldwijd op de derde plaats.2 Ondanks intensief 
wetenschappelijk onderzoek sinds de laatste decennia, zijn kennis over het ontstaan en  
oorzaken van de ziekte grotendeels nog onopgehelderd. Wel is bekend dat genetische 
factoren en psychotrauma’s in de kinderleeftijd een rol kunnen spelen.  
 
Wat betreft de onderliggende ziekteverschijnselen, geldt voor beide stoornissen dat 
sprake is van ontstekingsreacties in het centrale zenuwstelsel. Stressvolle 
gebeurtenissen kunnen leiden tot aan stress gerelateerde stoornissen (zoals depressie). 
Ook bij schizofrenie speelt stress een belangrijke rol. Ten gevolge van stressreacties 
kunnen allerlei veranderingen optreden in het brein, zoals veranderingen in de 
plasticiteit van zenuwcellen, afname van nieuwvorming van zenuwweefsel en 
ontstekingsverschijnselen in het brein.3 Een mogelijke verklaring voor het ontstaan van 
beide ziekten wordt gevormd door de hypothese dat ontstekingsreacties in het brein 
ontstaan door schadelijke stoffen die (onder invloed van stress) het brein 
binnendringen. Deze kunnen vervolgens bijdragen aan het ontstaan van 
neurodegeneratie (stoornissen waarbij sprake is van verlies of achteruitgang van 
mentale functies, waartoe zowel depressie als schizofrenie soms worden gerekend). 
Ophoping van schadelijke stoffen in het brein kan optreden als gevolg van een 
verminderde functie van de BHB.4,5 Een PET-studie (positron emission tomography, dit 
is functioneel beeldvormend onderzoek) bij mensen met de ziekte van Parkinson 
ondersteunt deze theorie.6 In deze studie vond men een afgenomen pompfunctie van 
P-gp, een belangrijke pomp in de BHB, die vanuit het hersenweefsel moleculen 
  
terugpompt in de bloedbaan. Deze verminderde pompfunctie was gelokaliseerd in 
hetzelfde hersengebied gelokaliseerd als de ziekte van Parkinson.  
 
De BHB is aanwezig in de kleinste bloedvaatjes van de hersenen (capillairen). Deze 
capillairen zijn zo gebouwd dat vrijwel geen enkel molecuul doorgelaten wordt. De 
vaatwandcellen hebben nauwelijks openingen en zitten tegen elkaar aangekit door 
speciale strengen "tight junctions”). Kleinere moleculen kunnen door diffusie het brein 
binnenkomen. Mogelijk schadelijke stoffen, zowel lichaamseigen als lichaamsvreemde, 
worden door naar buiten gerichte pompen (effluxpompen) teruggepompt in de 
bloedbaan. P-glycoproteïne is de belangrijkste effluxpomp in de BHB. P-gp wordt door 
het ABCB1-gen gecodeerd. Deze pomp heeft een enorme capaciteit, maar het meest 
opmerkelijke aan deze pomp is dat het talloze geheel verschillende moleculen kan 
transporteren.7 Een afgenomen (P-gp)pompfunctie, bijvoorbeeld door een 
farmacologische remmer, kan leiden tot een sterk toegenomen hersenopname van 
moleculen die door P-gp getransporteerd worden (‘substraten’).8,9 
  
Wij veronderstelden dat de functie van P-gp veranderd zou zijn bij mensen met een 
depressie en schizofrenie, mogelijk ten gevolge van de ontstekingsreactie in het brein.  
In de eerste studie (hoofdstuk 4) werd de functie van P-gp onderzocht in 13 mensen 
met een depressie. Allen gebruikten een antidepressivum. De groep werd vergeleken 
met een qua leeftijd en sexe gematchte controlegroep. [11C]-verapamil werd gebruikt 
als tracer. Het distributievolume (VT) werd gebruikt als maat voor de activiteit van P-
gp. Er werd bloed afgenomen voor genetisch onderzoek. Eventuele genvariatie van drie 
veel voorkomende polymorfismen (van ABCB1) werden als covariaat van het 
distributievolume geanalyseerd. Zowel een statische (region-of-interest) als 
dynamische analyse (voxelwise analysis) werd gedaan, deze laatste met behulp van het 
programma SPM2  (“statistical parametric mapping”), om de regionale P-gp functie te 
bepalen. We vonden een significante verlaging van het distributievolume, hetgeen 
correspondeert met een toegenomen functie van P-gp. Deze bevinding werd gedaan 
met beide methoden, en was met name gelokaliseerd in de prefrontale schors en 
temporale kwabben, gebieden die beiden geassocieerd zijn met depressie.  We vonden 
geen relatie met variatie in genotype, hetgeen ook niet te verwachten was in zo’n 
kleine groep. In een posthoc analyse bleek dat 7 patiënten een therapie resistente 
depressie (TRD) hadden. Een vergelijking tussen de zo ontstane subgroepen (TRD 
versus non-TRD) liet geen verschillen zien, maar was formeel ook niet mogelijk omdat 
de groepen niet gematcht waren. Daarmee kon de mogelijkheid van bias van de 
resultaten door therapieresistentie niet weerlegd worden. Het was dus mogelijk dat de 
toegenomen P-gp activiteit gerelateerd was aan therapieresistentie, hetgeen zeer 
belangwekkend zou zijn, aangezien hiermee een verklaring voor therapieresistente 
depressie gegeven kon worden: doordat P-gp activiteit toegenomen was, kon het 
  
antidepressivum onvoldoende werkzaam kunnen zijn in de hersenen, omdat het in 
versterkte mate uitgepompt werd door P-gp. De studie kende verschillende 
tekortkomingen. In de eerste plaats was geen metabolietanalyse verricht, hetgeen de 
interpretatie van de resultaten bemoeilijkt. Zonder deze inputfunctie kan niet worden 
uitgesloten dat de verschillen tussen de groepen veroorzaakt worden door verschillen 
in metabolisme van de tracer. In hoofdstuk 4 beargumenteren we waarom we 
aannemen dat metabolisme geen belangrijke invloed heeft gehad op de activiteit van P-
gp. Een andere belangrijke beperking van de studie betrof het gebruik van 
verschillende antidepressiva en andere farmaca bij de onderzoeksgroep. Van sommige 
farmaca kon niet worden uitgesloten worden dat ze de P-gp activiteit beïnvloedden. In 
hoofdstuk 5 werd hetzelfde protocol gebruikt om de in vivo functie van P-gp in 
schizofrenie te bepalen. Dit is gedaan in 10 patienten en 10 gematchte 
controlepersonen. De resultaten kwamen in sterke mate overeen met de resultaten van 
de depressiestudie, al was het resultaat van de dynamische analyse alleen significant 
wanneer de analyse alleen de gebieden van potentieel belang betrof (“small volume 
corrrection”). De resultaten uit beide studies suggereerden dat sprake was van een 
regionale toename van P-gp activiteit, hetgeen theoretisch zou kunnen passen bij de 
ziekte, m.a.w. de lokaal verhoogde activiteit van de pomp zou een ziektekenmerk (bijv. 
een ontstekingsreactie) kunnen zijn. Ook zou de verhoogde activiteit te verklaren 
kunnen zijn door het gebruik van medicatie. We hadden weliswaar het gebruik van 
medicatie met een duidelijk remmende werking op P-gp uitgesloten voor deelnemers 
aan de studie, zowel antidepressiva als antipsychotica blijken echter in celstudies lage 
tot matige activiteit te hebben voor P-gp. Bovendien blijken sommige middelen ook 
nog een remmend effect op P-gp te kunnen hebben in zulke celstudies.10-13 Het is niet 
bekend of dit effect ook in de mens zal kunnen optreden, en waarschijnlijk is het effect 
te verwaarlozen, omdat het remmende effect in deze cellijnen (modellen voor de BHB) 
pas optrad bij concentraties  die ver boven het therapeutische niveau lagen.12 Toch is 
het niet geheel uit te sluiten dat medicatie de verschillen in P-gp activiteit 
veroorzaakte. In een diermodel (muizen) toonden Grauer en Uhr aan dat langdurige 
toediening van amitriptyline ( een antidepressivum met een zwak tot matige affiniteit 
voor P-gp) geen verschil in concentratie gaf in de hersenen bij muizen zonder P-gp in 
de hersenen (“knock out” model) ten opzichte van genetisch normale muizen (“wild 
type”), terwijl de metabolieten van amitriptyline juist in sterke mate waren opgehoopt 
in de hersenen bij het knock out model.14   
 
De gevonden effecten op de activiteit van P-gp door zowel medicatie als depressie, 
stress en  psychose (zie hoofdstuk 4,5, en 8) kunnen ook beïnvloed zijn door genetische 
variatie. Alhoewel we in de humane PET studies geen aanwijzingen vonden voor 
genveranderingen in drie polymorfismen (3435T>C, 2677G>T/A, -129T>C), is daarmee 
nog geen uitspraak te doen over een relatie tussen de gevonden P-gp veranderingen in 
  
functie en genvariatie, omdat de getoetste sample veel te klein was. De literatuur 
betreffende de relatie tussen het ABCB1 gen en fenotype is alles behalve eensluidend. 
In de hoofdstukken 6 en 7 presenteren we de resultaten van de NESDA studie 
(NEtherlands Study on Depression and Anxiety). DE NESDA studie is een groot 
multicenter cohort onderzoek, dat de lange termijn uitkomsten van depressie ( en 
angststoornissen) onderzoekt, zoals deze stoornissen zich in de algemene populatie 
voordoen. Op basis van de resultaten, gepresenteerd in hoofstuk 4,5 en 8, namelijk dat 
sprake is van een verlaagde activiteit van P-gp in depressie, was onze hypothese dat 
genetische variatie van het ABCB1 gen geassocieerd zou kunnen zijn met een 
verhoogde kwetsbaarhied voor het ontstaan van depressie, ofwel het beloop van 
depressie. Verder waren we geïnteresseerd in de mogelijke relatie tussen  ABCB1 
polymorfismen en bijwerkingen op antidepressiva (P-gp substraten). We onderzochten 
de mogelijke associatie van 6 SNPs (single nucleotide polymorphisms) met mogelijke 
kwetsbaarheidsfactoren voor depressie. Drie veel voorkomende SNPs en drie 
polymorfismen, voor welk een relatie was aangetoond met respons op antidepressieve 
behandeling bij depressie25,26 werden geanalyseerd. Data uit meta-analyses hebben laten 
zien dat familiair voorkomen van depressie met name voorspeld kan worden door het 
voorkomen van recidiverende depressieve episoden (het voorkomen van meer dan een 
episode) en een vroeg ontstaan van de ziekte (beginleeftijd voor het 30e jaar).27 Voor 2 
van de onderzochte SNPs (rs2235040 en rs 2032583) vonden we een negatieve 
associatie met het vroeg ontstaan van depressie, hetgeen impliceert dat een persoon 
met het recessieve allel van een van deze SNPs beschermd is tegen het vroeg optreden 
van depressie. Voor 3435CC vonden we een zelfde verband, dat niet significant was na 
correctie voor het aantal tests. Er werd ook een significant verband gevonden tussen 
het haplotype 1236T-2677T-3435C en het aantal recidief depressies. De Odds ratio’s 
waren klein (0.735 – 0.785), hetgeen aangeeft dat deze polymorfismen niet bruikbaar 
zijn als enkele indicator voor het bepalen van kwetsbaarheid in een individu. De 
gevonden verbanden hebben elk afzonderlijk een kleine invloed op het fenotype. 
Niettemin is het vinden van dergelijke associaties van groot belang voor het verder in 
kaart brengen van kwetsbaarheidsfactoren van de depressieve stoornis. 
Een andere belangrijke bevinding in de studie met de NESDA, beschreven in hoofdstuk 
7, was de associatie tussen twee ABCB1 polymorfismen (rs2235040 en rs2032583) en 
het optreden (incidentie) en de ernst van bijwerkingen gelateerd aan SSRIs (selectieve 
serotonine heropnameremmers), die affiniteit hebben voor P-gp. De twee SNPs 
voorspelden ook significant de ernst van anticholinerge en serotonerge bijwerkingen. 
De relatieve overrepresentatie van paroxetine (>35%) in de sample kan verklaren 
waarom een relatie gevonden werd met anticholinerge bijwerkingen. Een 
verklaringsmechanisme  kon ook voorspeld worden in paroxetine (n=110), een SSRI 
met meer anticholinerge bijwerkingen dan andere SSRI’s, hetgeen mede kan verklaren 
dat juist op dit middel een verband gevonden wordt. Voor venlafaxine, dat minder 
  
anticholinerge werking heeft dan paroxetine, vonden we een significante trend naar 
een verband tussen anticholinerge bijwerkingen en rs2235040 en rs2032583. Voor 
citalopram, dat vrijwel geen anticholinerge bijwerkingen heeft, werd geen effect 
gevonden.  Onze resultaten suggereren een verband tussen het optreden en ernst van 
(anticholinerge) bijwerkingen op SSRI’s (indien P-gp substraat) en ABCB1 
genpolymorfismen. De vele tegenstrijdige resultaten tot op heden manen tot 
voorzichtigheid in de interepretatie van onze bevindingen.  
 
In hoofdstuk 8 wordt een dierstudie beschreven, waarin we zoeken naar de verklaring 
van de resultaten beschreven in hoofdstuk 4 en 5. De regionale verhoging van P-gp 
activiteit zou verklaard kunnen worden door de stoornis (i.e. stress als 
pathofysiologisch mechanisme) of door het gebruik van medicatie. In verschillende 
groepen ratten vergeleken we (ten opzichte van een controlegroep) het effect van 
chronische stress en het effect van langdurig gebruik van het antidepressivum 
venlafaxine. Met een procedure, waarbij ratten gedurende 3 weken werden 
blootgesteld aan elektrische schokken, werd een depressie nagebootst. [11C]-verapamil-
PET werd gebruikt om de activiteit van P-gp in vivo te bepalen. Venlafaxine heeft 
zwakke tot matige affiniteit voor P-gp15,16 en heeft geen modulerende invloed op 
cyp3A4, het enzym dat grotendeels [11C]-verapamil metaboliseert. Alhoewel het niet 
mogelijk was in de proefdieren een metabolietanalyse te verrichten, werd in deze 
studie gecorrigeerd voor het metabolisme door [11C]-verapamil metabolisme data te 
gebruiken van een andere studie. We hebben hierbij gekeken naar eventuele gevolgen 
van veranderingen in het metabolisme door de metabolietcurve te manipuleren. Het 
bleek dat een iets langzamer of iets sneller metabolisme geen grote veranderingen op 
de uitkomstmaat (VT) had, hetgeen het onwaarschijnlijk maakte dat de verschillen 
tussen de groepen ratten zouden berusten op verschillen in metabolisme. In beide 
experimenten waren significante verschillen tussen de groepen te zien. In de groep 
ratten die venlafaxine ontvingen, werd een significante toename van P-gp gezien, 
terwijl chronische stress juist leidde tot een significante verlaging van P-gp. De 
verschillen werden gezien op ‘whole brain’ niveau. De betekenis van deze bevindingen 
is dat chronische stress (als model voor depressie) leidt tot een verminderde 
pompfunctie van P-gp, hetgeen ondersteund wordt door de ‘cytokine hypothese’ in 
depressie. Hierin wordt depressie gezien als resultante van een ontstekingsreactie in het 
centrale zenuwstelsel. Ontstekingsbevorderende eiwitten veroorzaken hierbij schade 
aan de BHB en zorgen voor remming van P-gp.17-19 In enkele in vitro studies zijn 
aanwijzingen gevonden voor een toename van de P-gp activiteit door chronische 
stress.20,21 Er zijn echter geen in vivo studies die deze hypothese kunnen bevestigen. 
Onze studie is de eerste in dit opzicht, waarin een verband gezien wordt tussen 
chronische stress en verandering van de P-gp activiteit.  Aan de veranderde activiteit in 
zowel chronische stress en na chronische toediening van venlafaxine kan 
  
respectievelijk een af- of toename van de hoeveelheid P-glycoproteïne ten grondslag 
liggen, zgn. down- of upregulatie. De studies van Uhr et al. en Grauer en Uhr 
ondersteunen deze gedachte. In twee studies toonden zij aan dat een enkele gift 
amitriptyline (een P-gp substraat) in muizen leidde tot een significant verlaagde 
hersenopname in genetisch normale muizen (wild type) ten opzichte van muizen die 
P-gp misten (‘ABCB1a -/- knock out’ muizen).  Wanneer echter gedurende 10 dagen 
amitriptyline toegediend werd, werd geen verandering meer gezien tussen beide 
groepen in de concentratie amitriptyline in de hersenen (zie figuur 10.1).14,22  
 
In hoofdstuk 9 worden de resultaten van hoofdstuk 8 verder uitgewerkt. We 
veronderstelden dat chronische toediening van [11C]-venlafaxine niet zou leiden tot 
regionale verschillen in distributievolume (VT) (als maat voor P-gp activiteit, het VT is 
omgekeerd evenredig met de P-gp activiteit), maar dat de verschillen alleen globaal 
zouden zijn, hetgeen inderdaad het geval was: in alle regio’s werd een vergelijkbare 
afname van VT gevonden. Het VT was in de hypofyse veel hoger in beide groepen, 
hetgeen een bevestiging is van de veronderstelling dat de hypofyse ‘buiten’ de bloed-
hersen barrière ligt.23 Daarnaast was sprake van toegenomen VT waarden in de 
gebieden grenzend aan niet-hersenweefsel, dat niet door verlaagde P-gp activiteit 
verklaard werd, maar als gevolg van ‘overstraling’ uit deze gebieden gezien werd. 
Wanneer deze  perifere gebieden (i.e. bulbus, frontopolaire kwabben, cerebellum, pons, 
medulla)  niet in de analyse werden meegenomen, waren de distributievolumes 
vergelijkbaar met de resultaten zoals in hoofdstuk 8 beschreven.  
We onderzochten ook de regionale verdeling van [11C]-venlafaxine in ratten, die 
blootsgesteld waren aan chronische stress en vergeleken dit met de controlegroep. Een 
regionaal verschil in distributievolume zoals in de depressiestudie werd niet gevonden, 
er was sprake van een algemene verhoging van VT (passend bij een verlaging van P-gp 
functie) en net als bij de venlafaxinestudie werd er verhoogde activiteit gemeten in de 
perifere gebieden en in de hypofyse, die geen P-gp in haar capillairen heeft. Een 
vergelijking met de humane (depressie)studie gaat echter op verschillende fronten 
mank: ten eerste, is het stressexperiment bij ratten een model voor humane depressie, 
en zodoende nooit geheel vergelijkbaar. In de humane studie werden bovendien slechts 
5 gebieden (gerelateerd aan psychopathologie) geselecteerd voor vergelijking, in plaats 
van de 18 gebieden bij de rat. Als we deze gebieden ook in het rattenexperiment 
gekozen hadden voor multipele vergelijking, zou sprake zijn van een trend naar 
significante verhoging van VT in hippocampus (p = 0.094) en cortex (p = 0.064). Op 
basis van deze studie kan daarom niet uitgesloten worden dat sprake is van een 
regionale veranderingen (verlaging) in P-gp activiteit t.g.v. stress.  
 
Hoofdstuk 9  bevat ook een beschrijving van experimenten met het hersenweefsel van 
ratten, die na de studie (hoofdstuk 8) getermineerd werden. Het betreft de ‘Western 
  
Blot’, een techniek, waarbij de hoeveelheid eiwit (in dit geval P-glycoproteïne) bepaald 
kan worden. Met deze techniek is het mogelijk te onderzoeken of verschil in 
pompactiviteit berust op een verschil in het aantal pompjes (up- of downregulatie). Een 
andere nog toe te passen techniek is ‘immunohistochemie’, die ook regionale 
verschillen in eiwithoeveelheid kan aantonen. In dit stadium zijn de analyses niet 
afgerond, en is definitieve bespreking van de resultaten nog voorbarig. Wel kan gezegd 
worden dat de voorlopige resultaten de resultaten van de PET analyses ondersteunen: 
de veranderde functie van P-gp gaat samen met een veranderde expressie van het eiwit 
in het brein.  
 
Concluderende opmerkingen en richting voor verder onderzoek  
De bloed-hersen-barrière (BHB) is lange tijd beschouwd als een rigide structuur om het 
brein, die passage van vele stoffen onmogelijk maakte. Intensief onderzoek in de laatste 
decennia heeft bijgedragen aan een beter inzicht in de manier waarop het transport van 
moleculen via de BHB verloopt. 
Duidelijk is dat P-glycoproteïne als transporteiwit betrokken is bij het terugwaartse 
transport (van brein naar bloedbaan) van vele moleculen, die ook bij depressie een rol 
spelen. In sommige gevallen is niet geheel opgehelderd welke rol P-glycoproteïne 
speelt bij het transport van een bepaald substraat  speelt, zoals bij cortisol bij voorbeeld. 
Verder is aangetoond dat de P-gp functie gemoduleerd kan worden door vele factoren, 
zoals ook factoren die een rol spelen bij psychotische en depressieve stoornissen. Onze 
resultaten wijzen op een verlaging van P-gp activiteit in de BHB bij blootstelling aan 
chronische stress in ratten, (als model voor depressie) en toediening van een 
antidepressivum ( een P-gp substraat) doet de functie van P-gp toenemen. Het is niet 
bekend of zulk een verandering pompfunctie op een of andere manier nadelig is, of dat 
het consequenties heeft voor de dosis van een antidepressivum. Het is mogelijk dat 
verlaging van de activiteit van P-gp in de acute fase van de stressreactie, zoals bij de 
depressieve stoornis, nodig is om passage van pro-inflammatoire eiwitten mogelijk te 
maken. In de chronische fase of in de herstelfase van een depressieve episode kan de 
activiteit van P-gp anders zijn. Deze hypothetische functie van P-gp in verschillende 
fasen van een ziekteproces kan onderzocht worden in nieuwe PET studies, door 
gebruik te maken van verschillende liganden, die zowel inflammatie als P-gp activiteit 
in kaart kunnen brengen. Nieuwe strategieën kunnen worden uitgewerkt, zoals het 
labelen van nieuwe potentiële medicijnen, na toediening van een P-gp remmer, of 
dubbele PET scans, voor en na toediening van een modulator. 
Een andere belangrijke bevinding die in dit proefschrift wordt gepresenteerd, is de 
relatie tussen het depressiefenotype en het gen dat codeert voor P-gp. Ten eerste 
bleken ABCB1 polymorfismen geassocieerd te zijn met het optreden en de ernst van 
bijwerkingen op SSRIs (venlafaxine, citalopram, paroxetine, fluvoxamine), die 
getransporteerd worden door P-gp. Als deze bevindingen gerepliceerd worden, is het 
  
een stapje vooruit in de richting van de zogenaamde gepersonaliseerde geneeskunde, 
hetgeen impliceert dat onnodige medicatie trials worden vermeden, en een 
medicatiekeuze zoveel mogelijk gebaseerd is op het genetische profiel van de patient.  
Toekomstige doelen in dit opzicht zijn optmalisatie van het voorspelde effect van 
medicatie voor iedere gebruiker. Ook dienen mogelijke epigenetische veranderingen  
in het P-gp molecuul bestudeerd te worden.   
Ten tweede, drie ABCB1 polymorfismen waren geassocieerd met een lagere kans op 
een vroeg begin van de depressieve stoornis. Een haplotype was geassocieerd met 
recidief depressie. Deze bevindingen - mits gerepliceerd -  kunnen bijdragen aan 
blootleggen van het genetisch profiel dat kwetsbaarheid voor depressie beschrijft. Om 
hier meer inzicht in te krijgen, zijn meer grootschalige studies nodig, die licht kunnen 
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Drenthe. Door jullie is de mogelijkheid van promotieonderzoek gecreëerd. In het 
bijzonder wil ik Nelie Schouten noemen. Nelie, je draagt onderzoek een warm hart toe. Je 
bent steeds vol lof en vertrouwen geweest. Dank daarvoor. Het is een zeer genereus 
aanbod geweest, dat gezien de noodzakelijke bezuinigen in de GGZ in de toekomst helaas 
(waarschijnlijk) niet meer door collega’s benut kan worden. Dat is te betreuren, omdat 
juist binnen de klinische setting onderzoek zo belangrijk is. Ik hoop hier in de toekomst in 
GGZ Drenthe hier ook een bijdrage aan te kunnen leveren. De plannen liggen al klaar! 
 
In de humane studies was Meyke Roosink de wegbereider. Dankzij jou had ik een 
vliegende start. Ook veel steun heb ik gehad van Anna Bartels, die ervarener was en mij 
steeds kon uitleggen hoe ik praktisch te werk moest gaan. De dierstudie was niet mogelijk 
  
geweest zonder de samenwerking met de faculteit biologie. De samenwerking tussen Peter 
Meerlo en Aren van Waarde is hierin cruciaal geweest. Anniek Visser en Tim de Jager 
hebben het uitvoerende werk gedaan in Haren en bij NGMB. Ook de ondersteuning van 
Janine Doorduin en Jurgen Sijbesma op NGMB en van Girste Dagyte en Folkert Postema 
in Haren is van groot belang geweest. De inzet en behulpzaamheid van secretaresses en de 
MNW-ers, die niet altijd de meest makkelijke patiënten kregen, heb ik steeds 
gewaardeerd. Een conclusie van dit proefschrift is ook dat mensen met een depressie 
moeilijker te scannen zijn dan mensen schizofrenie. Bij de in vitro studie heeft Wanda 
Douwenga de Western Blots voor en met me gedaan. Anniek, nu in de rol van AIO, hielp 
me opnieuw met de analyses van Inveon.  
 
Ik heb het vaak lastig gevonden om zo in deeltijd te promoveren, ik kwam te weinig op 
het NGMB om er echt te integreren. Ondanks mijn geringe aanwezigheid heb ik me er 
altijd heel welkom gevoeld. Als afdeling maken jullie er samen een fantastische sfeer van. 
Heel bijzonder te ervaren hoe zo veel mensen van verschillende nationaliteit opgenomen 
worden en zich thuis voelen op NGMB. Ik heb door het ‘promoveren in deeltijd’ wel de 
verbinding met vakgenoten gemist. De schaarse momenten die er wel waren, zoals een 
congresweek met Janine en Anna, zijn me dan ook dierbaar geweest. 
 
Het was een voorrecht gebruik te mogen maken van de grote NESDA dataset voor de 
laatste twee studies. Ik heb veel gebruik gemaakt van de kennis en kundigheid van Ilja 
Nolte. Brenda heeft haar rol als laatste auteur meer dan waard gemaakt. De NESDA 
studies hebben mede dankzij jullie bijdragen twee mooie artikelen opgeleverd. Ik ben 
benieuwd waar ze geplaatst zullen gaan worden.  
 
Ook zonder de waarnemers van de kliniek tijdens de onderzoeksdagen was er weinig 
terecht gekomen van dit proefschrift. Van maart tot half mei ben ik vrijgesteld van 
klinische werkzaamheden en hebben Jalmar de Vries en Claar Mooij mij waargenomen. 
Mijn directe collega Hans Kamphuis nam mij iedere onderzoeksdag waar.  
 
De betrokkenheid en interesse van vele vrienden, collega’s en familie heb ik erg 
gewaardeerd. Chris en Pieter, fijn dat jullie paranimf zijn. Ik kon bij jullie vaak terecht 
voor praktische vragen en tips.   
 
Allen heel veel dank! 
 
Gijs, Sietze en Fransien, ik vind het bijzonder dat jullie op de promotie zullen zijn. Anita, 
je hebt me hebt me enorm veel ruimte gegeven en je bent een grote steun voor me 
geweest. Laten we onze dromen blijven volgen, samen met onze mooie kinderen. Let’s  go 
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ABC: ATP binding cassette 
ADR: adverse drug reaction 
ANCOVA: analysis of covariance  
ASEC: antidepressant side effect checklist 
ATC: Anatomical Therapeutical Classification 
ATP: Adenosine TriPhosphate 
BBB: blood-brain barrier 
BCRP: breast cancer resistance protein 
CAPP: Clinical Applications Programming Package 
CIDI: Composite International Diagnostic Interview 
CNS: central nervous system 
CSF: cerebrospinal fluid 
Cyp: Cytochrome P450 
DNA: deoxyribonucleic acid 
DSM-IV: Diagnostic Statistical Manual, 4th edition 
EC: endothelial cell 
EC50: Median Effective Concentration (required to induce a 50% effect) 
ET-1: endotheline-1 
GWAS: genome wide association study 
HAMD: Hamilton depression (rating scale) 
HPA axis: hypotuitary-pituary-adrenal (axis) 
HSVE: Herpes Simplex Virus Encephalitis 
IL: interleukine 
kD: kilodalton 
KO: knock out 
LAT1: large neutral amino-acid transporter 
LD: linkage desequilibrium 
L-DOPA: L-3,4-dihydroxyphenylalanine 
MAO: mono amine oxidase 
MBq: megabecquerel 
MDR1: multi drug resistance-1 
MINI: Mini Neuropsychiatric Interview 
MRI: magnetic resonance imaging 
MRP: Multi Resistance Protein 
NCBI: National Center for Biotechnology Information 
NMDA:  N-methyl-aspartic acid 
OAT: organic anion transporting 
OATP: organic anion transporting polypeptide family 
OSEM:  ordered subsets expectation maximum 
PET: positron emission tomography  
P-gp: P-glycoprotein 
PTSD: posttraumatic Stress disorder 
RNA: Ribonucleic acid 
ROI: region of interest 
  
SD: standard deviation 
sICAM-1: serum Inter-Cellular Adhesion Molecule-1 
SNP: single nucleotide polymorphism 
SPM2: statistical parametric mapping 
SPSS: Statistical Package for the Social Sciences 
SSRI: Selective Serotonin Reuptake Inhibitor 
TEER: trans endothelial electric resistance 
TNFα: tumor necrosis factor α 
UKU: Udvalg for Kliniske Undersøgelser (side effects rating scale) 
VLA-4:  Very Late Antigen-4 
VPM-PET: [11C]-verapamil - positron emission tomography 
VT: volume of distribution 
WB: Western Blot 
WT: wild type 
 
 
